[
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a053523.html",
    "subject": "Cell Transplantation (Mesencephalic, Adrenal-Brain and Fetal Xenograft)",
    "document_number": "TRANS.00004",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Transplantation of adrenal, fetal mesencephalic and xenograft fetal tissues to the brain is considered <strong>investigational and not medically necessary</strong> for the treatment of Parkinson\u2019s disease and for all other indications.</p>",
    "content": "Investigational and Not Medically Necessary:\nTransplantation of adrenal, fetal mesencephalic and xenograft fetal tissues to the brain is considered investigational and not medically necessary for the treatment of Parkinson\u2019s disease and for all other indications.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Transplantation of adrenal, fetal mesencephalic and xenograft fetal tissues to the brain",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Transplantation of adrenal, fetal mesencephalic and xenograft fetal tissues to the brain is considered investigational and not medically necessary for the treatment of Parkinson\u2019s disease and for all other indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 971,
          "prompt_tokens": 862,
          "completion_tokens": 109,
          "total_cost": 0.005945000000000001,
          "processing_time": 1.6762399673461914
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a045960.html",
    "subject": "Umbilical Cord Blood Progenitor Cell Collection, Storage and Transplantation",
    "document_number": "TRANS.00016",
    "publish_date": "04/10/2024",
    "status": "Revised",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<li>The use of umbilical cord blood progenitor cell transplantation is considered <strong>medically necessary</strong> for selected individuals when <strong><em>all</em></strong> of the following criteria are met:\t<ol>\t\t<li>One or two donor cord unit(s) is used for a single recipient; <strong>and</strong></li>\t\t<li>The <em>total</em> nucleated cell (TNC) count is equal to or greater than 2.3 x 10<sup>7 </sup>per kg; <strong>and</strong></li>\t\t<li>The umbilical cord blood stem cell unit(s) is used for an allogeneic stem cell transplant for an approved indication and the appropriate stem cell transplant criteria are met.</li>\t</ol>\t</li>\n<li>One or two donor cord unit(s) is used for a single recipient; <strong>and</strong></li>\n<li>The <em>total</em> nucleated cell (TNC) count is equal to or greater than 2.3 x 10<sup>7 </sup>per kg; <strong>and</strong></li>\n<li>The umbilical cord blood stem cell unit(s) is used for an allogeneic stem cell transplant for an approved indication and the appropriate stem cell transplant criteria are met.</li>\n<li>Collection and storage of cord blood is considered <strong>medically necessary</strong> only when an allogeneic transplant is imminent for an identified recipient and the above criteria are met. Storage will only be authorized at centers approved by <strong>one</strong> of the following:\t<ol>\t\t<li>Foundation for the Accreditation of Cellular Therapy (FACT); <strong>or</strong></li>\t\t<li>NetCord-FACT; <strong>or</strong></li>\t\t<li>National Cancer Institute (NCI); <strong>or</strong></li>\t\t<li>National Marrow Donor Program (NMDP); <strong>or</strong></li>\t\t<li>AABB (formerly known as American Association of Blood Banks); <strong>or</strong></li>\t\t<li>California Department of Public Health.</li>\t</ol>\t</li>\n<li>Foundation for the Accreditation of Cellular Therapy (FACT); <strong>or</strong></li>\n<li>NetCord-FACT; <strong>or</strong></li>\n<li>National Cancer Institute (NCI); <strong>or</strong></li>\n<li>National Marrow Donor Program (NMDP); <strong>or</strong></li>\n<li>AABB (formerly known as American Association of Blood Banks); <strong>or</strong></li>\n<li>California Department of Public Health.</li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>The use of umbilical cord blood progenitor cell transplantation is considered <strong>investigational and not</strong> <strong>medically necessary</strong> when criterion A is not met.</p>\n<p>Prophylactic collection and storage of umbilical cord blood is considered <strong>investigational and not medically necessary</strong> when proposed for an unspecified future use for an autologous stem cell transplant in the original donor or for an unspecified future use as an allogeneic stem cell transplant in a related or unrelated donor.</p>",
    "content": "Medically Necessary:\n<li>The use of umbilical cord blood progenitor cell transplantation is considered medically necessary for selected individuals when all of the following criteria are met:\t<ol> <li>One or two donor cord unit(s) is used for a single recipient; and</li> <li>The total nucleated cell (TNC) count is equal to or greater than 2.3 x 10<sup>7 </sup>per kg; and</li> <li>The umbilical cord blood stem cell unit(s) is used for an allogeneic stem cell transplant for an approved indication and the appropriate stem cell transplant criteria are met.</li> </ol> </li>\n<li>One or two donor cord unit(s) is used for a single recipient; and</li>\n<li>The total nucleated cell (TNC) count is equal to or greater than 2.3 x 10<sup>7 </sup>per kg; and</li>\n<li>The umbilical cord blood stem cell unit(s) is used for an allogeneic stem cell transplant for an approved indication and the appropriate stem cell transplant criteria are met.</li>\n<li>Collection and storage of cord blood is considered medically necessary only when an allogeneic transplant is imminent for an identified recipient and the above criteria are met. Storage will only be authorized at centers approved by one of the following:\t<ol> <li>Foundation for the Accreditation of Cellular Therapy (FACT); or</li> <li>NetCord-FACT; or</li> <li>National Cancer Institute (NCI); or</li> <li>National Marrow Donor Program (NMDP); or</li> <li>AABB (formerly known as American Association of Blood Banks); or</li> <li>California Department of Public Health.</li> </ol> </li>\n<li>Foundation for the Accreditation of Cellular Therapy (FACT); or</li>\n<li>NetCord-FACT; or</li>\n<li>National Cancer Institute (NCI); or</li>\n<li>National Marrow Donor Program (NMDP); or</li>\n<li>AABB (formerly known as American Association of Blood Banks); or</li>\n<li>California Department of Public Health.</li>\nInvestigational and Not Medically Necessary:\nThe use of umbilical cord blood progenitor cell transplantation is considered investigational and not medically necessary when criterion A is not met.\nProphylactic collection and storage of umbilical cord blood is considered investigational and not medically necessary when proposed for an unspecified future use for an autologous stem cell transplant in the original donor or for an unspecified future use as an allogeneic stem cell transplant in a related or unrelated donor.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Umbilical Cord Blood Progenitor Cell Transplantation",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "The use of umbilical cord blood progenitor cell transplantation is considered medically necessary for selected individuals when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "One or two donor cord unit(s) is used for a single recipient",
                  "conditions": null
                },
                {
                  "desc": "The total nucleated cell (TNC) count is equal to or greater than 2.3 x 10^7 per kg",
                  "conditions": null
                },
                {
                  "desc": "The umbilical cord blood stem cell unit(s) is used for an allogeneic stem cell transplant for an approved indication and the appropriate stem cell transplant criteria are met",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Collection and Storage of Cord Blood",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Collection and storage of cord blood is considered medically necessary only when an allogeneic transplant is imminent for an identified recipient and the above criteria are met. Storage will only be authorized at centers approved by one of the following:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Foundation for the Accreditation of Cellular Therapy (FACT)",
                  "conditions": null
                },
                {
                  "desc": "NetCord-FACT",
                  "conditions": null
                },
                {
                  "desc": "National Cancer Institute (NCI)",
                  "conditions": null
                },
                {
                  "desc": "National Marrow Donor Program (NMDP)",
                  "conditions": null
                },
                {
                  "desc": "AABB (formerly known as American Association of Blood Banks)",
                  "conditions": null
                },
                {
                  "desc": "California Department of Public Health",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Umbilical Cord Blood Progenitor Cell Transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "The use of umbilical cord blood progenitor cell transplantation is considered investigational and not medically necessary when criterion A is not met.",
            "conditions": null
          },
          {
            "medical_act": "Prophylactic Collection and Storage of Umbilical Cord Blood",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Prophylactic collection and storage of umbilical cord blood is considered investigational and not medically necessary when proposed for an unspecified future use for an autologous stem cell transplant in the original donor or for an unspecified future use as an allogeneic stem cell transplant in a related or unrelated donor.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 2008,
          "prompt_tokens": 1379,
          "completion_tokens": 629,
          "total_cost": 0.016329999999999997,
          "processing_time": 11.035604000091553
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a046252.html",
    "subject": "Pancreas Transplantation and Pancreas Kidney Transplantation",
    "document_number": "TRANS.00011",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p class=\"MsoAcetate\"><strong><em>Note:</em></strong><em> Members must meet the disease specific criteria as well as the General Individual Selection criteria below for the transplantation to be considered medically necessary.</em></p>\n<p><strong>Medically Necessary:</strong></p>\n<p>Simultaneous deceased-donor pancreas/kidney transplant (SPK) is considered <strong>medically necessary</strong> for individuals with insulin dependent diabetes mellitus (IDDM) who have end-stage renal disease.</p>\n<p>Simultaneous deceased-donor pancreas and living-donor kidney transplant (SPLK) is considered <strong>medically necessary </strong>for individuals with insulin dependent diabetes mellitus who have end-stage renal disease.</p>\n<p>Pancreas transplant alone (PTA) either deceased or living-donor segmental is considered <strong>medically necessary</strong> for individuals who have insulin dependent diabetes mellitus with severe disabling and documented life threatening hypoglycemic unawareness due to labile diabetes which persists despite optimal medical management.</p>\n<p>Pancreas after kidney transplant (PAK) is considered <strong>medically necessary </strong>for individuals with insulin dependent diabetes mellitus.</p>\n<p>One pancreas alone, one pancreas after kidney or one simultaneous pancreas/kidney (SPK or SPLK) re-transplantation after failure of the primary graft is considered <strong>medically necessary </strong>provided the individual meets the transplant criteria above.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Pancreas transplantation is considered <strong>investigational and not medically necessary </strong>for all other applications.</p>\n<p align=\"left\" class=\"MsoBodyText2\" style=\"text-align:left\">A third or subsequent pancreas alone, pancreas after kidney or SPK or SPLK transplantation is considered <strong>investigational and not medically necessary</strong> in all cases.</p>\n<p align=\"left\" class=\"MsoBodyText2\" style=\"text-align:left\"><strong>Note:</strong> For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with a concurrent medical condition which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member's candidacy for transplantation.</p>\n<p><strong>General Individual Selection Criteria</strong></p>\n<p>In addition to having the clinical indications above, the member must not have a contraindication as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001) listed below.</p>\n<p><strong>Absolute Contraindications- for Transplant <em>Recipients </em></strong>include, but are not limited to, the following:</p>\n<li>Metastatic cancer</li>\n<li>Ongoing or recurring infections that are not effectively treated</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm<sup>3</sup>) unless the following are noted:\t<ol>\t\t<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months</li>\t\t<li>HIV-1 RNA undetectable</li>\t\t<li>On stable anti-retroviral therapy greater than 3 months</li>\t\t<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li>\t\t<li>Meeting all other criteria for pancreas or pancreas/kidney transplantation.</li>\t</ol>\t</li>\n<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months</li>\n<li>HIV-1 RNA undetectable</li>\n<li>On stable anti-retroviral therapy greater than 3 months</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li>\n<li>Meeting all other criteria for pancreas or pancreas/kidney transplantation.</li>\n<p>Steinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. Vol. 71, 1189-1204, No. 9, May 15, 2001.</p>",
    "content": "Note: Members must meet the disease specific criteria as well as the General Individual Selection criteria below for the transplantation to be considered medically necessary.\nMedically Necessary:\nSimultaneous deceased-donor pancreas/kidney transplant (SPK) is considered medically necessary for individuals with insulin dependent diabetes mellitus (IDDM) who have end-stage renal disease.\nSimultaneous deceased-donor pancreas and living-donor kidney transplant (SPLK) is considered medically necessary for individuals with insulin dependent diabetes mellitus who have end-stage renal disease.\nPancreas transplant alone (PTA) either deceased or living-donor segmental is considered medically necessary for individuals who have insulin dependent diabetes mellitus with severe disabling and documented life threatening hypoglycemic unawareness due to labile diabetes which persists despite optimal medical management.\nPancreas after kidney transplant (PAK) is considered medically necessary for individuals with insulin dependent diabetes mellitus.\nOne pancreas alone, one pancreas after kidney or one simultaneous pancreas/kidney (SPK or SPLK) re-transplantation after failure of the primary graft is considered medically necessary provided the individual meets the transplant criteria above.\nInvestigational and Not Medically Necessary:\nPancreas transplantation is considered investigational and not medically necessary for all other applications.\nA third or subsequent pancreas alone, pancreas after kidney or SPK or SPLK transplantation is considered investigational and not medically necessary in all cases.\nNote: For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with a concurrent medical condition which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member's candidacy for transplantation.\nGeneral Individual Selection Criteria\nIn addition to having the clinical indications above, the member must not have a contraindication as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001) listed below.\nAbsolute Contraindications- for Transplant Recipients include, but are not limited to, the following:\n<li>Metastatic cancer</li>\n<li>Ongoing or recurring infections that are not effectively treated</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm<sup>3</sup>) unless the following are noted:\t<ol> <li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months</li> <li>HIV-1 RNA undetectable</li> <li>On stable anti-retroviral therapy greater than 3 months</li> <li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li> <li>Meeting all other criteria for pancreas or pancreas/kidney transplantation.</li> </ol> </li>\n<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months</li>\n<li>HIV-1 RNA undetectable</li>\n<li>On stable anti-retroviral therapy greater than 3 months</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li>\n<li>Meeting all other criteria for pancreas or pancreas/kidney transplantation.</li>\nSteinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. Vol. 71, 1189-1204, No. 9, May 15, 2001.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Simultaneous deceased-donor pancreas/kidney transplant (SPK)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Simultaneous deceased-donor pancreas/kidney transplant (SPK) is considered medically necessary for individuals with insulin dependent diabetes mellitus (IDDM) who have end-stage renal disease.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Insulin dependent diabetes mellitus (IDDM)",
                  "conditions": null
                },
                {
                  "desc": "End-stage renal disease",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Simultaneous deceased-donor pancreas and living-donor kidney transplant (SPLK)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Simultaneous deceased-donor pancreas and living-donor kidney transplant (SPLK) is considered medically necessary for individuals with insulin dependent diabetes mellitus who have end-stage renal disease.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Insulin dependent diabetes mellitus",
                  "conditions": null
                },
                {
                  "desc": "End-stage renal disease",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Pancreas transplant alone (PTA)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Pancreas transplant alone (PTA) either deceased or living-donor segmental is considered medically necessary for individuals who have insulin dependent diabetes mellitus with severe disabling and documented life threatening hypoglycemic unawareness due to labile diabetes which persists despite optimal medical management.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Insulin dependent diabetes mellitus",
                  "conditions": null
                },
                {
                  "desc": "Severe disabling and documented life threatening hypoglycemic unawareness due to labile diabetes",
                  "conditions": null
                },
                {
                  "desc": "Condition persists despite optimal medical management",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Pancreas after kidney transplant (PAK)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Pancreas after kidney transplant (PAK) is considered medically necessary for individuals with insulin dependent diabetes mellitus.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Insulin dependent diabetes mellitus",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "One pancreas alone, one pancreas after kidney or one simultaneous pancreas/kidney (SPK or SPLK) re-transplantation",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "One pancreas alone, one pancreas after kidney or one simultaneous pancreas/kidney (SPK or SPLK) re-transplantation after failure of the primary graft is considered medically necessary provided the individual meets the transplant criteria above.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Failure of the primary graft",
                  "conditions": null
                },
                {
                  "desc": "Meets the transplant criteria above",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Pancreas transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Pancreas transplantation is considered investigational and not medically necessary for all other applications.",
            "conditions": null
          },
          {
            "medical_act": "A third or subsequent pancreas alone, pancreas after kidney or SPK or SPLK transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A third or subsequent pancreas alone, pancreas after kidney or SPK or SPLK transplantation is considered investigational and not medically necessary in all cases.",
            "conditions": null
          },
          {
            "medical_act": "General Individual Selection Criteria",
            "sub_medical_act": null,
            "necessity_type": "Absolute Contraindications",
            "description": "In addition to having the clinical indications above, the member must not have a contraindication as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001) listed below.",
            "conditions": {
              "ANY": [
                {
                  "desc": "Metastatic cancer",
                  "conditions": null
                },
                {
                  "desc": "Ongoing or recurring infections that are not effectively treated",
                  "conditions": null
                },
                {
                  "desc": "Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery",
                  "conditions": null
                },
                {
                  "desc": "Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured",
                  "conditions": null
                },
                {
                  "desc": "Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations",
                  "conditions": null
                },
                {
                  "desc": "Potential complications from immunosuppressive medications are unacceptable to the patient",
                  "conditions": null
                },
                {
                  "ALL": [
                    {
                      "desc": "Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm\u00b3) unless the following are noted:",
                      "conditions": null
                    },
                    {
                      "desc": "CD4 count greater than 200 cells/mm\u00b3 for greater than 6 months",
                      "conditions": null
                    },
                    {
                      "desc": "HIV-1 RNA undetectable",
                      "conditions": null
                    },
                    {
                      "desc": "On stable anti-retroviral therapy greater than 3 months",
                      "conditions": null
                    },
                    {
                      "desc": "No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)",
                      "conditions": null
                    },
                    {
                      "desc": "Meeting all other criteria for pancreas or pancreas/kidney transplantation.",
                      "conditions": null
                    }
                  ]
                }
              ]
            }
          }
        ],
        "usage": {
          "total_tokens": 3056,
          "prompt_tokens": 1716,
          "completion_tokens": 1340,
          "total_cost": 0.02868,
          "processing_time": 22.775629997253418
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a047489.html",
    "subject": "Hematopoietic Stem Cell Transplantation for Hodgkin Disease and non-Hodgkin Lymphoma",
    "document_number": "TRANS.00028",
    "publish_date": "04/10/2024",
    "status": "Revised",
    "last_review_date": "02/15/2024",
    "html_content": "<p>I. Hodgkin Disease</p>\n<p><strong>Medically Necessary</strong></p>\n<li><em>An allogeneic (ablative and non-myeloablative) or autologous hematopoietic stem cell transplantation </em>is considered <strong>medically necessary</strong> for individuals with primary refractory Hodgkin disease or Hodgkin disease that has relapsed after an initial first remission (regardless of remission status at the time of transplant).</li>\n<li><em>An allogeneic hematopoietic stem cell transplantation after a prior autologous hematopoietic stem cell transplantation</em> is considered <strong>medically necessary</strong> for individuals with Hodgkin disease who meet the above criteria.</li>\n<li><em>A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation</em> due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></li>\n<li><em>A planned tandem<strong>* </strong>autologous (autologous/autologous) hematopoietic stem cell transplantation</em> is considered <strong>medically necessary</strong> for risk-adapted salvage treatment for either primary refractive Hodgkin disease or individuals who have relapsed after standard therapy.</li>\n<p style=\"margin-left:29px\"><strong>*</strong>Tandem transplantation refers to a planned infusion (transplant) of previously harvested hematopoietic stem cells with a repeat hematopoietic stem cell infusion (transplant) that is performed within 6 months of the initial transplant. This is distinguished from a repeat transplantation requested or performed more than 6 months after the first transplant, and is used as salvage therapy after failure of initial transplantation or relapsed disease.</p>\n<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> for all other uses in Hodgkin disease including, but not limited to, initial therapy for newly diagnosed disease to consolidate a first complete remission (i.e., in individuals with a complete response to standard-dose induction therapy for newly diagnosed disease).</li>\n<li><em>A planned tandem<strong>*</strong> allogeneic (allogeneic/allogeneic) hematopoietic stem cell transplantation </em>is considered <strong>investigational and not medically necessary.</strong></li>\n<li><em>A planned tandem autologous (autologous/autologous) hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary, </strong>except when criteria above are met.</li>\n<li class=\"MsoBodyTextIndent3\"><em>A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation </em>due to persistent, progressive or relapsed Hodgkin disease is considered <strong>investigational and not medically necessary.</strong></li>\n<li><em>Hematopoietic stem cell harvesting</em> for a future but unscheduled transplant is considered <strong>investigational and not medically necessary.</strong><em> </em></li>\n<p><strong>II. non-Hodgkin Lymphoma (NHL)</strong></p>\n<p><strong>Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation</em> is considered <strong>medically necessary </strong>to treat individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL classification system as \u201cIndolent\u201d in either of the following situations: <em>(see Rationale section for NCI classification)</em>\t<ol start=\"1\" style=\"list-style-type:decimal\">\t\t<li>As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy; <strong>or</strong></li>\t\t<li>To achieve or consolidate a CR for those in a documented chemosensitive first or subsequent relapse, whether or not their lymphoma has undergone transformation to a higher grade.</li>\t</ol>\t</li>\n<li>As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy; <strong>or</strong></li>\n<li>To achieve or consolidate a CR for those in a documented chemosensitive first or subsequent relapse, whether or not their lymphoma has undergone transformation to a higher grade.</li>\n<li><em>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation</em> is considered <strong>medically necessary </strong>to treat individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL system as \u201cAggressive\u201d in any of the following situations:<em> (see Rationale section for NCI classification)</em>\t<ol start=\"1\" style=\"list-style-type:decimal\">\t\t<li>As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy; <strong>or</strong></li>\t\t<li>To consolidate a first CR for those with an International Prognostic Index (IPI) or age-adjusted IPI score that predicts a high- or high-intermediate risk of relapse <em>(see Rationale section for IPI score description); </em><strong>or</strong></li>\t\t<li>To consolidate a first CR for those with acute or lymphoma-type adult T-cell lymphoma/leukemia who have achieved a first remission; <strong>or</strong></li>\t\t<li>To achieve or consolidate a CR for those in a chemosensitive first or subsequent relapse.</li>\t</ol>\t</li>\n<li>As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy; <strong>or</strong></li>\n<li>To consolidate a first CR for those with an International Prognostic Index (IPI) or age-adjusted IPI score that predicts a high- or high-intermediate risk of relapse <em>(see Rationale section for IPI score description); </em><strong>or</strong></li>\n<li>To consolidate a first CR for those with acute or lymphoma-type adult T-cell lymphoma/leukemia who have achieved a first remission; <strong>or</strong></li>\n<li>To achieve or consolidate a CR for those in a chemosensitive first or subsequent relapse.</li>\n<li><em>An autologous hematopoietic stem cell transplantation</em> is considered <strong>medically necessary</strong> to consolidate a first CR for individuals with mantle cell lymphoma. <strong>Note:</strong> criteria above or below may also apply to individuals with mantle cell lymphoma.</li>\n<li><em>An allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation after a prior autologous hematopoietic stem cell transplantation</em> is considered <strong>medically necessary</strong> to treat individuals with NHL who meet the above criteria.</li>\n<li><em>A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation</em> due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></li>\n<li><em>Hematopoietic stem cell harvesting</em>* for an anticipated but unscheduled transplant is considered <strong>medically necessary</strong> in individuals who meet <strong>all </strong>of the following:\t<ol start=\"1\" style=\"list-style-type:decimal\">\t\t<li>Follicular and low-grade non-Hodgkin lymphoma presenting with bone marrow involvement as documented by bone marrow biopsy/flow cytometry studies; <strong>and</strong></li>\t\t<li>Who meet the criteria above for transplant; <strong>and</strong></li>\t\t<li>The treating physician documents that a future transplant is likely; <strong>and</strong></li>\t\t<li>Harvesting is performed following chemotherapeutic treatment when the individual is in remission.<br>\t\t<em>*</em><strong>NOTE:</strong><em> </em>Hematopoietic stem cell harvesting does not include the transplant procedure<em>.</em></li>\t</ol>\t</li>\n<li>Follicular and low-grade non-Hodgkin lymphoma presenting with bone marrow involvement as documented by bone marrow biopsy/flow cytometry studies; <strong>and</strong></li>\n<li>Who meet the criteria above for transplant; <strong>and</strong></li>\n<li>The treating physician documents that a future transplant is likely; <strong>and</strong></li>\n<li>Harvesting is performed following chemotherapeutic treatment when the individual is in remission.<br>\t\t<em>*</em><strong>NOTE:</strong><em> </em>Hematopoietic stem cell harvesting does not include the transplant procedure<em>.</em></li>\n<p>&nbsp;<strong>Investigational and Not Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> when criteria above are not met, including in the following situations:\t<ol start=\"1\" style=\"list-style-type:decimal\">\t\t<li>As initial therapy (i.e., without a full course of standard-dose induction chemotherapy) for all NHL; <strong>or</strong></li>\t\t<li>To consolidate a first CR for individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL system as \u201cAggressive\u201d that does not meet the Medically Necessary criteria above.</li>\t</ol>\t</li>\n<li>As initial therapy (i.e., without a full course of standard-dose induction chemotherapy) for all NHL; <strong>or</strong></li>\n<li>To consolidate a first CR for individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL system as \u201cAggressive\u201d that does not meet the Medically Necessary criteria above.</li>\n<li><em>A planned tandem* allogeneic (allogeneic/allogeneic) hematopoietic stem cell transplantation </em>is considered <strong>investigational and not medically necessary</strong> as a treatment for individuals with NHL.</li>\n<li><em>A planned tandem* autologous (autologous/autologous) hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> as a treatment for individuals with NHL.</li>\n<li><em>A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplant</em> due to persistent, progressive or relapsed NHL is considered <strong>investigational and not medically necessary</strong>.</li>\n<li><em>Hematopoietic stem cell harvesting</em> for a future but unscheduled transplant is considered <strong>investigational and not medically necessary</strong> when the criteria above are not met.</li>\n<p style=\"margin-left:40px\"><strong><em>*</em></strong>Tandem transplantation refers to a planned infusion (transplant) of previously harvested hematopoietic stem cells with a repeat hematopoietic stem cell infusion (transplant) that is performed within 6 months of the initial transplant. This is distinguished from a repeat transplantation requested or performed more than 6 months after the first transplant, and is used as salvage therapy after failure of initial transplantation or relapsed disease.</p>",
    "content": "I. Hodgkin Disease\nMedically Necessary\n<li>An allogeneic (ablative and non-myeloablative) or autologous hematopoietic stem cell transplantation is considered medically necessary for individuals with primary refractory Hodgkin disease or Hodgkin disease that has relapsed after an initial first remission (regardless of remission status at the time of transplant).</li>\n<li>An allogeneic hematopoietic stem cell transplantation after a prior autologous hematopoietic stem cell transplantation is considered medically necessary for individuals with Hodgkin disease who meet the above criteria.</li>\n<li>A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.</li>\n<li>A planned tandem* autologous (autologous/autologous) hematopoietic stem cell transplantation is considered medically necessary for risk-adapted salvage treatment for either primary refractive Hodgkin disease or individuals who have relapsed after standard therapy.</li>\n*Tandem transplantation refers to a planned infusion (transplant) of previously harvested hematopoietic stem cells with a repeat hematopoietic stem cell infusion (transplant) that is performed within 6 months of the initial transplant. This is distinguished from a repeat transplantation requested or performed more than 6 months after the first transplant, and is used as salvage therapy after failure of initial transplantation or relapsed disease.\nInvestigational and Not Medically Necessary:\n<li>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for all other uses in Hodgkin disease including, but not limited to, initial therapy for newly diagnosed disease to consolidate a first complete remission (i.e., in individuals with a complete response to standard-dose induction therapy for newly diagnosed disease).</li>\n<li>A planned tandem* allogeneic (allogeneic/allogeneic) hematopoietic stem cell transplantation is considered investigational and not medically necessary.</li>\n<li>A planned tandem autologous (autologous/autologous) hematopoietic stem cell transplantation is considered investigational and not medically necessary, except when criteria above are met.</li>\n<li class=\"MsoBodyTextIndent3\">A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to persistent, progressive or relapsed Hodgkin disease is considered investigational and not medically necessary.</li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary. </li>\nII. non-Hodgkin Lymphoma (NHL)\nMedically Necessary:\n<li>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered medically necessary to treat individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL classification system as \u201cIndolent\u201d in either of the following situations: (see Rationale section for NCI classification) <ol start=\"1\" style=\"list-style-type:decimal\"> <li>As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy; or</li> <li>To achieve or consolidate a CR for those in a documented chemosensitive first or subsequent relapse, whether or not their lymphoma has undergone transformation to a higher grade.</li> </ol> </li>\n<li>As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy; or</li>\n<li>To achieve or consolidate a CR for those in a documented chemosensitive first or subsequent relapse, whether or not their lymphoma has undergone transformation to a higher grade.</li>\n<li>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered medically necessary to treat individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL system as \u201cAggressive\u201d in any of the following situations: (see Rationale section for NCI classification) <ol start=\"1\" style=\"list-style-type:decimal\"> <li>As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy; or</li> <li>To consolidate a first CR for those with an International Prognostic Index (IPI) or age-adjusted IPI score that predicts a high- or high-intermediate risk of relapse (see Rationale section for IPI score description); or</li> <li>To consolidate a first CR for those with acute or lymphoma-type adult T-cell lymphoma/leukemia who have achieved a first remission; or</li> <li>To achieve or consolidate a CR for those in a chemosensitive first or subsequent relapse.</li> </ol> </li>\n<li>As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy; or</li>\n<li>To consolidate a first CR for those with an International Prognostic Index (IPI) or age-adjusted IPI score that predicts a high- or high-intermediate risk of relapse (see Rationale section for IPI score description); or</li>\n<li>To consolidate a first CR for those with acute or lymphoma-type adult T-cell lymphoma/leukemia who have achieved a first remission; or</li>\n<li>To achieve or consolidate a CR for those in a chemosensitive first or subsequent relapse.</li>\n<li>An autologous hematopoietic stem cell transplantation is considered medically necessary to consolidate a first CR for individuals with mantle cell lymphoma. Note: criteria above or below may also apply to individuals with mantle cell lymphoma.</li>\n<li>An allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation after a prior autologous hematopoietic stem cell transplantation is considered medically necessary to treat individuals with NHL who meet the above criteria.</li>\n<li>A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.</li>\n<li>Hematopoietic stem cell harvesting* for an anticipated but unscheduled transplant is considered medically necessary in individuals who meet all of the following:\t<ol start=\"1\" style=\"list-style-type:decimal\"> <li>Follicular and low-grade non-Hodgkin lymphoma presenting with bone marrow involvement as documented by bone marrow biopsy/flow cytometry studies; and</li> <li>Who meet the criteria above for transplant; and</li> <li>The treating physician documents that a future transplant is likely; and</li> <li>Harvesting is performed following chemotherapeutic treatment when the individual is in remission.<br/> *NOTE: Hematopoietic stem cell harvesting does not include the transplant procedure.</li> </ol> </li>\n<li>Follicular and low-grade non-Hodgkin lymphoma presenting with bone marrow involvement as documented by bone marrow biopsy/flow cytometry studies; and</li>\n<li>Who meet the criteria above for transplant; and</li>\n<li>The treating physician documents that a future transplant is likely; and</li>\n<li>Harvesting is performed following chemotherapeutic treatment when the individual is in remission.<br/> *NOTE: Hematopoietic stem cell harvesting does not include the transplant procedure.</li>\n\u00a0Investigational and Not Medically Necessary:\n<li>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary when criteria above are not met, including in the following situations:\t<ol start=\"1\" style=\"list-style-type:decimal\"> <li>As initial therapy (i.e., without a full course of standard-dose induction chemotherapy) for all NHL; or</li> <li>To consolidate a first CR for individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL system as \u201cAggressive\u201d that does not meet the Medically Necessary criteria above.</li> </ol> </li>\n<li>As initial therapy (i.e., without a full course of standard-dose induction chemotherapy) for all NHL; or</li>\n<li>To consolidate a first CR for individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL system as \u201cAggressive\u201d that does not meet the Medically Necessary criteria above.</li>\n<li>A planned tandem* allogeneic (allogeneic/allogeneic) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment for individuals with NHL.</li>\n<li>A planned tandem* autologous (autologous/autologous) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment for individuals with NHL.</li>\n<li>A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplant due to persistent, progressive or relapsed NHL is considered investigational and not medically necessary.</li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.</li>\n*Tandem transplantation refers to a planned infusion (transplant) of previously harvested hematopoietic stem cells with a repeat hematopoietic stem cell infusion (transplant) that is performed within 6 months of the initial transplant. This is distinguished from a repeat transplantation requested or performed more than 6 months after the first transplant, and is used as salvage therapy after failure of initial transplantation or relapsed disease.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Hodgkin Disease",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An allogeneic (ablative and non-myeloablative) or autologous hematopoietic stem cell transplantation is considered medically necessary for individuals with primary refractory Hodgkin disease or Hodgkin disease that has relapsed after an initial first remission (regardless of remission status at the time of transplant).",
            "conditions": null
          },
          {
            "medical_act": "Hodgkin Disease",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An allogeneic hematopoietic stem cell transplantation after a prior autologous hematopoietic stem cell transplantation is considered medically necessary for individuals with Hodgkin disease who meet the above criteria.",
            "conditions": null
          },
          {
            "medical_act": "Hodgkin Disease",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Hodgkin Disease",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A planned tandem autologous (autologous/autologous) hematopoietic stem cell transplantation is considered medically necessary for risk-adapted salvage treatment for either primary refractive Hodgkin disease or individuals who have relapsed after standard therapy.",
            "conditions": null
          },
          {
            "medical_act": "Hodgkin Disease",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for all other uses in Hodgkin disease including, but not limited to, initial therapy for newly diagnosed disease to consolidate a first complete remission (i.e., in individuals with a complete response to standard-dose induction therapy for newly diagnosed disease).",
            "conditions": null
          },
          {
            "medical_act": "Hodgkin Disease",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A planned tandem allogeneic (allogeneic/allogeneic) hematopoietic stem cell transplantation is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Hodgkin Disease",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A planned tandem autologous (autologous/autologous) hematopoietic stem cell transplantation is considered investigational and not medically necessary, except when criteria above are met.",
            "conditions": null
          },
          {
            "medical_act": "Hodgkin Disease",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to persistent, progressive or relapsed Hodgkin disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Hodgkin Disease",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": "Indolent",
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered medically necessary to treat individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL classification system as 'Indolent' in either of the following situations:",
            "conditions": {
              "ANY": [
                {
                  "desc": "As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy",
                  "conditions": null
                },
                {
                  "desc": "To achieve or consolidate a CR for those in a documented chemosensitive first or subsequent relapse, whether or not their lymphoma has undergone transformation to a higher grade",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": "Aggressive",
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered medically necessary to treat individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL system as 'Aggressive' in any of the following situations:",
            "conditions": {
              "ANY": [
                {
                  "desc": "As salvage therapy for those who do not achieve a complete remission (CR) after first-line treatment (induction) with a full course of standard-dose chemotherapy",
                  "conditions": null
                },
                {
                  "desc": "To consolidate a first CR for those with an International Prognostic Index (IPI) or age-adjusted IPI score that predicts a high- or high-intermediate risk of relapse",
                  "conditions": null
                },
                {
                  "desc": "To consolidate a first CR for those with acute or lymphoma-type adult T-cell lymphoma/leukemia who have achieved a first remission",
                  "conditions": null
                },
                {
                  "desc": "To achieve or consolidate a CR for those in a chemosensitive first or subsequent relapse",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An autologous hematopoietic stem cell transplantation is considered medically necessary to consolidate a first CR for individuals with mantle cell lymphoma. Note: criteria above or below may also apply to individuals with mantle cell lymphoma.",
            "conditions": null
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation after a prior autologous hematopoietic stem cell transplantation is considered medically necessary to treat individuals with NHL who meet the above criteria.",
            "conditions": null
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for an anticipated but unscheduled transplant is considered medically necessary in individuals who meet all of the following:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Follicular and low-grade non-Hodgkin lymphoma presenting with bone marrow involvement as documented by bone marrow biopsy/flow cytometry studies",
                  "conditions": null
                },
                {
                  "desc": "Who meet the criteria above for transplant",
                  "conditions": null
                },
                {
                  "desc": "The treating physician documents that a future transplant is likely",
                  "conditions": null
                },
                {
                  "desc": "Harvesting is performed following chemotherapeutic treatment when the individual is in remission",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary when criteria above are not met, including in the following situations:",
            "conditions": {
              "ANY": [
                {
                  "desc": "As initial therapy (i.e., without a full course of standard-dose induction chemotherapy) for all NHL",
                  "conditions": null
                },
                {
                  "desc": "To consolidate a first CR for individuals with NHL subtypes classified by the National Cancer Institute (NCI) modified REAL system as 'Aggressive' that does not meet the Medically Necessary criteria above",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A planned tandem allogeneic (allogeneic/allogeneic) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment for individuals with NHL.",
            "conditions": null
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A planned tandem autologous (autologous/autologous) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment for individuals with NHL.",
            "conditions": null
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplant due to persistent, progressive or relapsed NHL is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "non-Hodgkin Lymphoma (NHL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 5402,
          "prompt_tokens": 2916,
          "completion_tokens": 2486,
          "total_cost": 0.05187,
          "processing_time": 40.34681963920593
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a053845.html",
    "subject": "Heart Transplantation",
    "document_number": "TRANS.00033",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p style=\"text-align:justify\"><strong>Medically Necessary:</strong></p>\n<p>Heart transplantation is considered <strong>medically necessary</strong> in carefully selected individuals when the following clinical indications <strong>and</strong> the General Individual Selection criteria below are met.</p>\n<p><strong>Adult Clinical Indications*</strong> - Adults with end-stage, irreversible, refractory, symptomatic heart failure requiring <em>maximal</em> continuous medical or mechanical support must have:</p>\n<li>A low functional status; <strong>and</strong></li>\n<li>A poor probability of survival; <strong>and</strong></li>\n<li><strong>ONE</strong> of the following underlying conditions:\t<ol>\t\t<li>Supported by a mechanical circulatory support device; <strong>or</strong></li>\t\t<li>Supported by an intra-aortic balloon pump (IABP); <strong>or</strong></li>\t\t<li>Refractory cardiogenic shock; <strong>or</strong></li>\t\t<li>Dependency on<strong> </strong>intravenous (IV) inotropic support to maintain adequate organ perfusion;<strong> or</strong></li>\t\t<li>Maximal VO<sub>2</sub> less than or equal to 10 ml/kg/min with achievement of anaerobic metabolism; <strong>or</strong></li>\t\t<li>Maximal VO<sub>2 </sub>greater than 10 and less than 15 ml/kg/min (or 55% of predicted) and major limitation of the individual\u2019s activities; <strong>or</strong></li>\t\t<li>Severe ischemia consistently limiting routine activity not amenable to bypass surgery or percutaneous coronary intervention (PCI); <strong>or</strong></li>\t\t<li>Recurrent unstable ischemia not amenable to bypass surgery or percutaneous coronary intervention (PCI); <strong>or</strong></li>\t\t<li>Recurrent symptomatic ventricular arrhythmias refractory to ALL therapeutic modalities; <strong>or</strong></li>\t\t<li>Ischemic cardiomyopathy not amenable to medical therapy or revascularization procedures.</li>\t</ol>\t</li>\n<li>Supported by a mechanical circulatory support device; <strong>or</strong></li>\n<li>Supported by an intra-aortic balloon pump (IABP); <strong>or</strong></li>\n<li>Refractory cardiogenic shock; <strong>or</strong></li>\n<li>Dependency on<strong> </strong>intravenous (IV) inotropic support to maintain adequate organ perfusion;<strong> or</strong></li>\n<li>Maximal VO<sub>2</sub> less than or equal to 10 ml/kg/min with achievement of anaerobic metabolism; <strong>or</strong></li>\n<li>Maximal VO<sub>2 </sub>greater than 10 and less than 15 ml/kg/min (or 55% of predicted) and major limitation of the individual\u2019s activities; <strong>or</strong></li>\n<li>Severe ischemia consistently limiting routine activity not amenable to bypass surgery or percutaneous coronary intervention (PCI); <strong>or</strong></li>\n<li>Recurrent unstable ischemia not amenable to bypass surgery or percutaneous coronary intervention (PCI); <strong>or</strong></li>\n<li>Recurrent symptomatic ventricular arrhythmias refractory to ALL therapeutic modalities; <strong>or</strong></li>\n<li>Ischemic cardiomyopathy not amenable to medical therapy or revascularization procedures.</li>\n<p><strong>Pediatric Clinical Indications*</strong> - Heart transplant is an accepted treatment option for selected children with end-stage heart disease characterized by intractable symptoms and heart failure that cannot be treated with conventional medical or surgical methods. Children must have:</p>\n<li>Low cardiac output; <strong>and</strong></li>\n<li><strong>ONE</strong> of the following conditions:\t<ol>\t\t<li>Intractable heart failure not amenable to medical or surgical interventions; <strong>or</strong></li>\t\t<li>Complex congenital heart disease not amenable to surgical repair or palliation or for which the surgical procedure carries a higher risk of mortality than transplantation; <strong>or</strong></li>\t\t<li>Heart disease with reactive pulmonary hypertension and a potential of developing fixed, irreversible increased pulmonary vascular resistance (PVR) that would preclude a future orthotopic heart transplantation; <strong>or</strong></li>\t\t<li>Heart disease associated with near sudden death; <strong>or</strong></li>\t\t<li>Life-threatening arrhythmias untreatable with medications or an implantable defibrillator.</li>\t</ol>\t</li>\n<li>Intractable heart failure not amenable to medical or surgical interventions; <strong>or</strong></li>\n<li>Complex congenital heart disease not amenable to surgical repair or palliation or for which the surgical procedure carries a higher risk of mortality than transplantation; <strong>or</strong></li>\n<li>Heart disease with reactive pulmonary hypertension and a potential of developing fixed, irreversible increased pulmonary vascular resistance (PVR) that would preclude a future orthotopic heart transplantation; <strong>or</strong></li>\n<li>Heart disease associated with near sudden death; <strong>or</strong></li>\n<li>Life-threatening arrhythmias untreatable with medications or an implantable defibrillator.</li>\n<p><strong>*Note:</strong> For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with a concurrent medical condition which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member\u2019s candidacy for transplantation.</p>\n<p><strong>Heart Retransplantation</strong></p>\n<p>Retransplantation in individuals with graft failure of an initial heart transplant, due to either technical reasons or hyperacute rejection is considered <strong>medically necessary.</strong></p>\n<p>Retransplantation in individuals with chronic rejection, moderate graft vasculopathy or recurrent disease is considered <strong>medically necessary</strong> when the individual meets general individual selection criteria as defined below.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>A heart transplantation is considered <strong>investigational and not medically necessary</strong> when the above criteria are not met.</p>\n<p style=\"text-align:justify\"><strong>General Individual Selection Criteria</strong></p>\n<p>In addition to having end-stage heart disease, the member must not have a contraindication to transplantation, as defined by the American Society of Transplantation (Steinman, 2001) and the International Society for Heart and Lung Transplantation (Mehra, 2016) as listed below.</p>\n<p><strong>Relative Contraindications for Transplant <em>Recipients</em></strong> include, but are not limited to, the following:</p>\n<li>Pulmonary hypertension that is fixed as evidenced by either:\t<ol>\t\t<li>Pulmonary vascular resistance (PVR) greater than 5 Wood units; <strong>or</strong></li>\t\t<li>Trans-pulmonary gradient (TPG) greater than or equal to 16 mm/Hg.</li>\t</ol>\t</li>\n<li>Pulmonary vascular resistance (PVR) greater than 5 Wood units; <strong>or</strong></li>\n<li>Trans-pulmonary gradient (TPG) greater than or equal to 16 mm/Hg.</li>\n<p><strong>Absolute Contraindications for Transplant <em>Recipients</em></strong> include, but are not limited to, the following:</p>\n<li>Metastatic cancer;</li>\n<li>Ongoing or recurring infections that are not effectively treated;</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery;</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured;</li>\n<li>Active, systemic lupus erythematosus or sarcoid with multisystem involvement;</li>\n<li>Any systemic condition with a high probability of recurrence in the transplanted heart;</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations;</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient;</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm<sup>3</sup>) unless the following are noted:\t<ol>\t\t<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months;</li>\t\t<li>HIV-1 RNA undetectable;</li>\t\t<li>On stable anti-retroviral therapy greater than 3 months;</li>\t\t<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li>\t\t<li>Meeting all other criteria for heart transplantation.</li>\t</ol>\t</li>\n<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months;</li>\n<li>HIV-1 RNA undetectable;</li>\n<li>On stable anti-retroviral therapy greater than 3 months;</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li>\n<li>Meeting all other criteria for heart transplantation.</li>",
    "content": "Medically Necessary:\nHeart transplantation is considered medically necessary in carefully selected individuals when the following clinical indications and the General Individual Selection criteria below are met.\nAdult Clinical Indications* - Adults with end-stage, irreversible, refractory, symptomatic heart failure requiring maximal continuous medical or mechanical support must have:\n<li>A low functional status; and</li>\n<li>A poor probability of survival; and</li>\n<li>ONE of the following underlying conditions:\t<ol> <li>Supported by a mechanical circulatory support device; or</li> <li>Supported by an intra-aortic balloon pump (IABP); or</li> <li>Refractory cardiogenic shock; or</li> <li>Dependency on intravenous (IV) inotropic support to maintain adequate organ perfusion; or</li> <li>Maximal VO<sub>2</sub> less than or equal to 10 ml/kg/min with achievement of anaerobic metabolism; or</li> <li>Maximal VO<sub>2 </sub>greater than 10 and less than 15 ml/kg/min (or 55% of predicted) and major limitation of the individual\u2019s activities; or</li> <li>Severe ischemia consistently limiting routine activity not amenable to bypass surgery or percutaneous coronary intervention (PCI); or</li> <li>Recurrent unstable ischemia not amenable to bypass surgery or percutaneous coronary intervention (PCI); or</li> <li>Recurrent symptomatic ventricular arrhythmias refractory to ALL therapeutic modalities; or</li> <li>Ischemic cardiomyopathy not amenable to medical therapy or revascularization procedures.</li> </ol> </li>\n<li>Supported by a mechanical circulatory support device; or</li>\n<li>Supported by an intra-aortic balloon pump (IABP); or</li>\n<li>Refractory cardiogenic shock; or</li>\n<li>Dependency on intravenous (IV) inotropic support to maintain adequate organ perfusion; or</li>\n<li>Maximal VO<sub>2</sub> less than or equal to 10 ml/kg/min with achievement of anaerobic metabolism; or</li>\n<li>Maximal VO<sub>2 </sub>greater than 10 and less than 15 ml/kg/min (or 55% of predicted) and major limitation of the individual\u2019s activities; or</li>\n<li>Severe ischemia consistently limiting routine activity not amenable to bypass surgery or percutaneous coronary intervention (PCI); or</li>\n<li>Recurrent unstable ischemia not amenable to bypass surgery or percutaneous coronary intervention (PCI); or</li>\n<li>Recurrent symptomatic ventricular arrhythmias refractory to ALL therapeutic modalities; or</li>\n<li>Ischemic cardiomyopathy not amenable to medical therapy or revascularization procedures.</li>\nPediatric Clinical Indications* - Heart transplant is an accepted treatment option for selected children with end-stage heart disease characterized by intractable symptoms and heart failure that cannot be treated with conventional medical or surgical methods. Children must have:\n<li>Low cardiac output; and</li>\n<li>ONE of the following conditions:\t<ol> <li>Intractable heart failure not amenable to medical or surgical interventions; or</li> <li>Complex congenital heart disease not amenable to surgical repair or palliation or for which the surgical procedure carries a higher risk of mortality than transplantation; or</li> <li>Heart disease with reactive pulmonary hypertension and a potential of developing fixed, irreversible increased pulmonary vascular resistance (PVR) that would preclude a future orthotopic heart transplantation; or</li> <li>Heart disease associated with near sudden death; or</li> <li>Life-threatening arrhythmias untreatable with medications or an implantable defibrillator.</li> </ol> </li>\n<li>Intractable heart failure not amenable to medical or surgical interventions; or</li>\n<li>Complex congenital heart disease not amenable to surgical repair or palliation or for which the surgical procedure carries a higher risk of mortality than transplantation; or</li>\n<li>Heart disease with reactive pulmonary hypertension and a potential of developing fixed, irreversible increased pulmonary vascular resistance (PVR) that would preclude a future orthotopic heart transplantation; or</li>\n<li>Heart disease associated with near sudden death; or</li>\n<li>Life-threatening arrhythmias untreatable with medications or an implantable defibrillator.</li>\n*Note: For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with a concurrent medical condition which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member\u2019s candidacy for transplantation.\nHeart Retransplantation\nRetransplantation in individuals with graft failure of an initial heart transplant, due to either technical reasons or hyperacute rejection is considered medically necessary.\nRetransplantation in individuals with chronic rejection, moderate graft vasculopathy or recurrent disease is considered medically necessary when the individual meets general individual selection criteria as defined below.\nInvestigational and Not Medically Necessary:\nA heart transplantation is considered investigational and not medically necessary when the above criteria are not met.\nGeneral Individual Selection Criteria\nIn addition to having end-stage heart disease, the member must not have a contraindication to transplantation, as defined by the American Society of Transplantation (Steinman, 2001) and the International Society for Heart and Lung Transplantation (Mehra, 2016) as listed below.\nRelative Contraindications for Transplant Recipients include, but are not limited to, the following:\n<li>Pulmonary hypertension that is fixed as evidenced by either:\t<ol> <li>Pulmonary vascular resistance (PVR) greater than 5 Wood units; or</li> <li>Trans-pulmonary gradient (TPG) greater than or equal to 16 mm/Hg.</li> </ol> </li>\n<li>Pulmonary vascular resistance (PVR) greater than 5 Wood units; or</li>\n<li>Trans-pulmonary gradient (TPG) greater than or equal to 16 mm/Hg.</li>\nAbsolute Contraindications for Transplant Recipients include, but are not limited to, the following:\n<li>Metastatic cancer;</li>\n<li>Ongoing or recurring infections that are not effectively treated;</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery;</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured;</li>\n<li>Active, systemic lupus erythematosus or sarcoid with multisystem involvement;</li>\n<li>Any systemic condition with a high probability of recurrence in the transplanted heart;</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations;</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient;</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm<sup>3</sup>) unless the following are noted:\t<ol> <li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months;</li> <li>HIV-1 RNA undetectable;</li> <li>On stable anti-retroviral therapy greater than 3 months;</li> <li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li> <li>Meeting all other criteria for heart transplantation.</li> </ol> </li>\n<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months;</li>\n<li>HIV-1 RNA undetectable;</li>\n<li>On stable anti-retroviral therapy greater than 3 months;</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li>\n<li>Meeting all other criteria for heart transplantation.</li>",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Heart transplantation",
            "sub_medical_act": "Adult Clinical Indications",
            "necessity_type": "Medically Necessary",
            "description": "Heart transplantation is considered medically necessary in carefully selected individuals when the following clinical indications and the General Individual Selection criteria below are met.",
            "conditions": {
              "ALL": [
                {
                  "desc": "A low functional status",
                  "conditions": null
                },
                {
                  "desc": "A poor probability of survival",
                  "conditions": null
                },
                {
                  "ANY": [
                    {
                      "desc": "Supported by a mechanical circulatory support device",
                      "conditions": null
                    },
                    {
                      "desc": "Supported by an intra-aortic balloon pump (IABP)",
                      "conditions": null
                    },
                    {
                      "desc": "Refractory cardiogenic shock",
                      "conditions": null
                    },
                    {
                      "desc": "Dependency on intravenous (IV) inotropic support to maintain adequate organ perfusion",
                      "conditions": null
                    },
                    {
                      "desc": "Maximal VO2 less than or equal to 10 ml/kg/min with achievement of anaerobic metabolism",
                      "conditions": null
                    },
                    {
                      "desc": "Maximal VO2 greater than 10 and less than 15 ml/kg/min (or 55% of predicted) and major limitation of the individual\u2019s activities",
                      "conditions": null
                    },
                    {
                      "desc": "Severe ischemia consistently limiting routine activity not amenable to bypass surgery or percutaneous coronary intervention (PCI)",
                      "conditions": null
                    },
                    {
                      "desc": "Recurrent unstable ischemia not amenable to bypass surgery or percutaneous coronary intervention (PCI)",
                      "conditions": null
                    },
                    {
                      "desc": "Recurrent symptomatic ventricular arrhythmias refractory to ALL therapeutic modalities",
                      "conditions": null
                    },
                    {
                      "desc": "Ischemic cardiomyopathy not amenable to medical therapy or revascularization procedures",
                      "conditions": null
                    }
                  ]
                }
              ]
            }
          },
          {
            "medical_act": "Heart transplantation",
            "sub_medical_act": "Pediatric Clinical Indications",
            "necessity_type": "Medically Necessary",
            "description": "Heart transplant is an accepted treatment option for selected children with end-stage heart disease characterized by intractable symptoms and heart failure that cannot be treated with conventional medical or surgical methods. Children must have:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Low cardiac output",
                  "conditions": null
                },
                {
                  "ANY": [
                    {
                      "desc": "Intractable heart failure not amenable to medical or surgical interventions",
                      "conditions": null
                    },
                    {
                      "desc": "Complex congenital heart disease not amenable to surgical repair or palliation or for which the surgical procedure carries a higher risk of mortality than transplantation",
                      "conditions": null
                    },
                    {
                      "desc": "Heart disease with reactive pulmonary hypertension and a potential of developing fixed, irreversible increased pulmonary vascular resistance (PVR) that would preclude a future orthotopic heart transplantation",
                      "conditions": null
                    },
                    {
                      "desc": "Heart disease associated with near sudden death",
                      "conditions": null
                    },
                    {
                      "desc": "Life-threatening arrhythmias untreatable with medications or an implantable defibrillator",
                      "conditions": null
                    }
                  ]
                }
              ]
            }
          },
          {
            "medical_act": "Heart Retransplantation",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Retransplantation in individuals with graft failure of an initial heart transplant, due to either technical reasons or hyperacute rejection is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Heart Retransplantation",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Retransplantation in individuals with chronic rejection, moderate graft vasculopathy or recurrent disease is considered medically necessary when the individual meets general individual selection criteria as defined below.",
            "conditions": null
          },
          {
            "medical_act": "Heart transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A heart transplantation is considered investigational and not medically necessary when the above criteria are not met.",
            "conditions": null
          },
          {
            "medical_act": "General Individual Selection Criteria",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "In addition to having end-stage heart disease, the member must not have a contraindication to transplantation, as defined by the American Society of Transplantation (Steinman, 2001) and the International Society for Heart and Lung Transplantation (Mehra, 2016) as listed below.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Relative Contraindications for Transplant Recipients include, but are not limited to, the following:",
                  "conditions": {
                    "ANY": [
                      {
                        "ALL": [
                          {
                            "desc": "Pulmonary vascular resistance (PVR) greater than 5 Wood units",
                            "conditions": null
                          },
                          {
                            "desc": "Trans-pulmonary gradient (TPG) greater than or equal to 16 mm/Hg",
                            "conditions": null
                          }
                        ]
                      }
                    ]
                  }
                },
                {
                  "desc": "Absolute Contraindications for Transplant Recipients include, but are not limited to, the following:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Metastatic cancer",
                        "conditions": null
                      },
                      {
                        "desc": "Ongoing or recurring infections that are not effectively treated",
                        "conditions": null
                      },
                      {
                        "desc": "Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery",
                        "conditions": null
                      },
                      {
                        "desc": "Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured",
                        "conditions": null
                      },
                      {
                        "desc": "Active, systemic lupus erythematosus or sarcoid with multisystem involvement",
                        "conditions": null
                      },
                      {
                        "desc": "Any systemic condition with a high probability of recurrence in the transplanted heart",
                        "conditions": null
                      },
                      {
                        "desc": "Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations",
                        "conditions": null
                      },
                      {
                        "desc": "Potential complications from immunosuppressive medications are unacceptable to the patient",
                        "conditions": null
                      },
                      {
                        "ALL": [
                          {
                            "desc": "CD4 count greater than 200 cells/mm3 for greater than 6 months",
                            "conditions": null
                          },
                          {
                            "desc": "HIV-1 RNA undetectable",
                            "conditions": null
                          },
                          {
                            "desc": "On stable anti-retroviral therapy greater than 3 months",
                            "conditions": null
                          },
                          {
                            "desc": "No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)",
                            "conditions": null
                          },
                          {
                            "desc": "Meeting all other criteria for heart transplantation",
                            "conditions": null
                          }
                        ]
                      }
                    ]
                  }
                }
              ]
            }
          }
        ],
        "usage": {
          "total_tokens": 4136,
          "prompt_tokens": 2587,
          "completion_tokens": 1549,
          "total_cost": 0.03617,
          "processing_time": 34.05956292152405
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e000978.html",
    "subject": "Uterine Transplantation",
    "document_number": "TRANS.00037",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Uterine transplantation is considered <strong>investigational and not medically necessary</strong> for all uses, including but not limited to the treatment of uterine factor infertility due to nonfunctioning or absent uterus.</p>",
    "content": "Investigational and Not Medically Necessary:\nUterine transplantation is considered investigational and not medically necessary for all uses, including but not limited to the treatment of uterine factor infertility due to nonfunctioning or absent uterus.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Uterine transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Uterine transplantation is considered investigational and not medically necessary for all uses, including but not limited to the treatment of uterine factor infertility due to nonfunctioning or absent uterus.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 947,
          "prompt_tokens": 858,
          "completion_tokens": 89,
          "total_cost": 0.005625,
          "processing_time": 1.7627489566802979
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e001585.html",
    "subject": "Thymus Tissue Transplantation",
    "document_number": "TRANS.00038",
    "publish_date": "04/10/2024",
    "status": "Reviewed",
    "last_review_date": "02/15/2024",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>A single administration of allogeneic processed thymus tissue is considered <strong>medically necessary</strong> for immune reconstitution in the pediatric population* with congenital athymia when <strong>all</strong> of the following criteria are met:</p>\n<li>Congenital athymia is confirmed via flow cytometry as less than 50 na\u00efve T cells/mm<sup>3</sup> in the peripheral blood or less than 5% of total T cells being na\u00efve in phenotype; <strong>and</strong></li>\n<li>Documentation that infection control measures, including immunoprophylaxis, can reasonably be maintained until the development of thymic function is established; <strong>and</strong></li>\n<li>Absence of comorbidities, in the opinion of the treating clinician, that are reasonably likely to result in severe complications, including death from administration of allogeneic processed thymus tissue (for example, pre-existing renal impairment, or cytomegalovirus or Epstein-Barr virus infection).</li>\n<p>*<strong>Note:</strong> Pediatric population (generally age below 18 years of age)</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Use of allogeneic processed thymus tissue is considered <strong>investigational and</strong> <strong>not medically necessary</strong> for administration of all other uses, including but not limited to immune reconstitution in individuals with severe combined immunodeficiency.</p>",
    "content": "Medically Necessary:\nA single administration of allogeneic processed thymus tissue is considered medically necessary for immune reconstitution in the pediatric population* with congenital athymia when all of the following criteria are met:\n<li>Congenital athymia is confirmed via flow cytometry as less than 50 na\u00efve T cells/mm<sup>3</sup> in the peripheral blood or less than 5% of total T cells being na\u00efve in phenotype; and</li>\n<li>Documentation that infection control measures, including immunoprophylaxis, can reasonably be maintained until the development of thymic function is established; and</li>\n<li>Absence of comorbidities, in the opinion of the treating clinician, that are reasonably likely to result in severe complications, including death from administration of allogeneic processed thymus tissue (for example, pre-existing renal impairment, or cytomegalovirus or Epstein-Barr virus infection).</li>\n*Note: Pediatric population (generally age below 18 years of age)\nInvestigational and Not Medically Necessary:\nUse of allogeneic processed thymus tissue is considered investigational and not medically necessary for administration of all other uses, including but not limited to immune reconstitution in individuals with severe combined immunodeficiency.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Single administration of allogeneic processed thymus tissue",
            "sub_medical_act": "Pediatric population with congenital athymia",
            "necessity_type": "Medically Necessary",
            "description": "A single administration of allogeneic processed thymus tissue is considered medically necessary for immune reconstitution in the pediatric population with congenital athymia when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Congenital athymia is confirmed via flow cytometry as less than 50 na\u00efve T cells/mm<sup>3</sup> in the peripheral blood or less than 5% of total T cells being na\u00efve in phenotype",
                  "conditions": null
                },
                {
                  "desc": "Documentation that infection control measures, including immunoprophylaxis, can reasonably be maintained until the development of thymic function is established",
                  "conditions": null
                },
                {
                  "desc": "Absence of comorbidities, in the opinion of the treating clinician, that are reasonably likely to result in severe complications, including death from administration of allogeneic processed thymus tissue (for example, pre-existing renal impairment, or cytomegalovirus or Epstein-Barr virus infection)",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Use of allogeneic processed thymus tissue",
            "sub_medical_act": "All other uses",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Use of allogeneic processed thymus tissue is considered investigational and not medically necessary for administration of all other uses, including but not limited to immune reconstitution in individuals with severe combined immunodeficiency.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1461,
          "prompt_tokens": 1071,
          "completion_tokens": 390,
          "total_cost": 0.011205,
          "processing_time": 8.466594934463501
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a053840.html",
    "subject": "Heart/Lung Transplantation",
    "document_number": "TRANS.00026",
    "publish_date": "01/03/2024",
    "status": "Revised",
    "last_review_date": "11/09/2023",
    "html_content": "<p style=\"text-align:justify\"><strong>Medically Necessary:</strong></p>\n<p>Heart/lung transplantation is considered <strong>medically necessary</strong> when the following clinical indications <strong>and</strong> the general individual selection criteria listed below are met.</p>\n<p style=\"text-align:justify\"><strong>Clinical Indications -</strong> Individuals must meet <strong>one</strong> of the following criteria:</p>\n<li>Irreversible primary pulmonary hypertension with heart failure; <strong>or</strong></li>\n<li>Secondary pulmonary hypertension and resulting heart failure due to pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease or emphysema; <strong>or</strong></li>\n<li>Eisenmenger's complex or other types of congenital heart disease with irreversible pulmonary hypertension and heart failure.</li>\n<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>A heart/lung transplantation is considered <strong>investigational and not medically necessary</strong> when the above criteria are not met.</p>\n<p><strong>Note:</strong> For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with concurrent medical conditions which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member\u2019s candidacy for transplantation.</p>\n<p><strong>General Individual Selection Criteria</strong></p>\n<p>In addition to having one of the clinical indications above, the member must not have a contraindication, as defined by the American Society of Transplantation in<em> Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation</em> (2001) listed below.</p>\n<p style=\"text-align:justify\"><strong>Absolute Contraindications \u2013 for Transplant <em>Recipients*</em></strong> include, but are not limited to, the following:</p>\n<li>Metastatic cancer;</li>\n<li>Ongoing or recurring infections that are not effectively treated;</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery;</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured;</li>\n<li>Active, systemic lupus erythematosus or sarcoid with multisystem involvement;</li>\n<li>Any systemic condition with a high probability of recurrence in the transplanted heart;</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations;</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient;</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200cells/mm<sup>3</sup>) unless the following are noted:\t<ol>\t\t<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months;</li>\t\t<li>HIV-1 RNA undetectable;</li>\t\t<li>On stable anti-retroviral therapy greater than 3 months;</li>\t\t<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li>\t\t<li>Meeting all other criteria for heart-lung transplantation.</li>\t</ol>\t</li>\n<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months;</li>\n<li>HIV-1 RNA undetectable;</li>\n<li>On stable anti-retroviral therapy greater than 3 months;</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li>\n<li>Meeting all other criteria for heart-lung transplantation.</li>\n<p>*Steinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. 2022; 71(9):1189-1204.</p>",
    "content": "Medically Necessary:\nHeart/lung transplantation is considered medically necessary when the following clinical indications and the general individual selection criteria listed below are met.\nClinical Indications - Individuals must meet one of the following criteria:\n<li>Irreversible primary pulmonary hypertension with heart failure; or</li>\n<li>Secondary pulmonary hypertension and resulting heart failure due to pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease or emphysema; or</li>\n<li>Eisenmenger's complex or other types of congenital heart disease with irreversible pulmonary hypertension and heart failure.</li>\nInvestigational and Not Medically Necessary:\nA heart/lung transplantation is considered investigational and not medically necessary when the above criteria are not met.\nNote: For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with concurrent medical conditions which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member\u2019s candidacy for transplantation.\nGeneral Individual Selection Criteria\nIn addition to having one of the clinical indications above, the member must not have a contraindication, as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001) listed below.\nAbsolute Contraindications \u2013 for Transplant Recipients* include, but are not limited to, the following:\n<li>Metastatic cancer;</li>\n<li>Ongoing or recurring infections that are not effectively treated;</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery;</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured;</li>\n<li>Active, systemic lupus erythematosus or sarcoid with multisystem involvement;</li>\n<li>Any systemic condition with a high probability of recurrence in the transplanted heart;</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations;</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient;</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200cells/mm<sup>3</sup>) unless the following are noted:\t<ol> <li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months;</li> <li>HIV-1 RNA undetectable;</li> <li>On stable anti-retroviral therapy greater than 3 months;</li> <li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li> <li>Meeting all other criteria for heart-lung transplantation.</li> </ol> </li>\n<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months;</li>\n<li>HIV-1 RNA undetectable;</li>\n<li>On stable anti-retroviral therapy greater than 3 months;</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li>\n<li>Meeting all other criteria for heart-lung transplantation.</li>\n*Steinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. 2022; 71(9):1189-1204.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Heart/lung transplantation",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Heart/lung transplantation is considered medically necessary when the following clinical indications and the general individual selection criteria listed below are met.",
            "conditions": {
              "ALL": [
                {
                  "ANY": [
                    {
                      "desc": "Irreversible primary pulmonary hypertension with heart failure",
                      "conditions": null
                    },
                    {
                      "desc": "Secondary pulmonary hypertension and resulting heart failure due to pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease or emphysema",
                      "conditions": null
                    },
                    {
                      "desc": "Eisenmenger's complex or other types of congenital heart disease with irreversible pulmonary hypertension and heart failure",
                      "conditions": null
                    }
                  ]
                },
                {
                  "ALL": [
                    {
                      "desc": "Metastatic cancer",
                      "conditions": null
                    },
                    {
                      "desc": "Ongoing or recurring infections that are not effectively treated",
                      "conditions": null
                    },
                    {
                      "desc": "Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery",
                      "conditions": null
                    },
                    {
                      "desc": "Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured",
                      "conditions": null
                    },
                    {
                      "desc": "Active, systemic lupus erythematosus or sarcoid with multisystem involvement",
                      "conditions": null
                    },
                    {
                      "desc": "Any systemic condition with a high probability of recurrence in the transplanted heart",
                      "conditions": null
                    },
                    {
                      "desc": "Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations",
                      "conditions": null
                    },
                    {
                      "desc": "Potential complications from immunosuppressive medications are unacceptable to the patient",
                      "conditions": null
                    },
                    {
                      "ALL": [
                        {
                          "desc": "Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200cells/mm\u00b3) unless the following are noted:",
                          "conditions": {
                            "ALL": [
                              {
                                "desc": "CD4 count greater than 200 cells/mm\u00b3 for greater than 6 months",
                                "conditions": null
                              },
                              {
                                "desc": "HIV-1 RNA undetectable",
                                "conditions": null
                              },
                              {
                                "desc": "On stable anti-retroviral therapy greater than 3 months",
                                "conditions": null
                              },
                              {
                                "desc": "No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)",
                                "conditions": null
                              },
                              {
                                "desc": "Meeting all other criteria for heart-lung transplantation",
                                "conditions": null
                              }
                            ]
                          }
                        }
                      ]
                    }
                  ]
                }
              ]
            }
          },
          {
            "medical_act": "Heart/lung transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A heart/lung transplantation is considered investigational and not medically necessary when the above criteria are not met.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 2303,
          "prompt_tokens": 1610,
          "completion_tokens": 693,
          "total_cost": 0.018444999999999996,
          "processing_time": 9.94455599784851
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a045963.html",
    "subject": "Hematopoietic Stem Cell Transplantation for Multiple Myeloma and Other Plasma Cell Dyscrasias",
    "document_number": "TRANS.00023",
    "publish_date": "01/03/2024",
    "status": "Revised",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong><em>Multiple Myeloma</em></strong></p>\n<p><strong>Medically Necessary:</strong></p>\n<p align=\"left\" class=\"MsoBodyTextIndent\" style=\"text-align:left\"><em>Autologous hematopoietic stem cell transplantation</em> <em>(AutoHSCT) </em>for treatment of individuals with multiple myeloma is considered <strong>medically necessary</strong> when used as:</p>\n<li class=\"MsoBodyTextIndent\">As a single transplant (AutoHSCT); <strong>or</strong></li>\n<li class=\"MsoBodyTextIndent\">As a tandem* transplant (two AutoHSCTs separated by 30 to 180 days); <strong>or</strong></li>\n<li class=\"MsoBodyTextIndent\">As a repeat procedure (AutoHSCT greater than 180 days following a previous AutoHSCT); <strong>or</strong></li>\n<li class=\"MsoBodyTextIndent\">As a pretreatment for a non-myeloablative allogeneic hematopoietic stem cell transplant; <strong>or</strong></li>\n<li class=\"MsoBodyTextIndent\">As salvage therapy after:\t<ol>\t\t<li class=\"MsoBodyTextIndent\">Primary graft failure;<strong> or</strong></li>\t\t<li class=\"MsoBodyTextIndent\">Failure to engraft; <strong>or</strong></li>\t\t<li class=\"MsoBodyTextIndent\">Rejection following an allogeneic HSCT.</li>\t</ol>\t</li>\n<li class=\"MsoBodyTextIndent\">Primary graft failure;<strong> or</strong></li>\n<li class=\"MsoBodyTextIndent\">Failure to engraft; <strong>or</strong></li>\n<li class=\"MsoBodyTextIndent\">Rejection following an allogeneic HSCT.</li>\n<p><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation</em><strong> </strong>after a previous autologous stem cell transplant for treatment of individuals with multiple myeloma is considered <strong>medically necessary.</strong></p>\n<p><em>A planned</em> <em>tandem non-myeloablative allogeneic transplantation</em> following an autologous transplantation is considered <strong>medically necessary </strong>for treatment of individuals with multiple myeloma.</p>\n<p>A <em>repeat allogeneic (ablative or non-myeloablative) stem cell transplantation</em> due to primary graft failure, failure to engraft or rejection is considered <strong>medically necessary<em>.</em></strong></p>\n<p><em>Hematopoietic stem cell harvesting** </em>for an anticipated but unscheduled transplant is considered <strong>medically necessary </strong>in individuals with multiple myeloma who meet one of the above criteria and for whom the treating physician documents that a future transplant is likely.</p>\n<p class=\"MsoBodyTextIndent\" style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<p><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation or autologous stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> for individuals with multiple myeloma who do not meet the above criteria.</p>\n<p><em>Hematopoietic stem cell harvesting</em> for a future but unscheduled transplant is considered <strong>investigational and not medically necessary </strong>when the criteria above are not met.</p>\n<p class=\"MsoBodyTextIndent3\"><em>A repeat allogeneic (ablative or non-myeloablative) stem cell</em> <em>transplantation </em>due to persistent, progressive or relapsed disease is considered<strong> investigational and not medically necessary.</strong></p>\n<p>Three or more <em>autologous hematopoietic stem cell transplant</em><em>ations</em> within a 12-month period are considered <strong>investigational and not medically necessary.</strong></p>\n<p><strong><em>Amyloidosis</em></strong></p>\n<p style=\"text-align:justify\"><strong>Medically Necessary:</strong></p>\n<p><em>Autologous stem cell transplantation</em> is considered <strong>medically necessary</strong> for individuals with primary amyloidosis (AL) who meet the following criteria:<br><strong>Note:</strong> (If the individual has a preceding diagnosis of multiple myeloma, use the transplant criteria above for multiple myeloma).</p>\n<li>If the heart is involved with AL, the individual is asymptomatic or has compensated congestive heart failure; <strong>and</strong></li>\n<li>Left ventricular ejection fraction (LVEF) greater than or equal to 45%; <strong>and</strong></li>\n<li>Must have documented disease on biopsy without a preceding diagnosis of multiple myeloma.</li>\n<p><em>A repeat autologous stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting** </em>for an anticipated but unscheduled transplant is considered <strong>medically necessary </strong>in individuals with amyloidosis who meet one of the above criteria and for whom the treating physician documents that a future transplant is likely.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p><em>Autologous stem cell transplantation</em> is considered <strong>investigational and not medically necessary </strong>in the treatment of primary amyloidosis in individuals with symptomatic heart failure regardless of the number of organs involved.</p>\n<p><em>Allogeneic</em><em> (ablative or non-myeloablative) stem cell transplantation</em> is considered <strong>investigational and not medically necessary </strong>for treatment of individuals with amyloidosis.</p>\n<p><em>A tandem* autologous stem cell transplantation</em> is considered <strong>investigational and not medically necessary </strong>for treatment of individuals with amyloidosis.</p>\n<p class=\"MsoBodyTextIndent3\"><em>A repeat autologous stem cell transplantation </em>due to persistent, progressive or relapsed disease is considered<strong> investigational and not medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting</em> for a future but unscheduled transplant is considered <strong>investigational and not medically necessary </strong>when the criteria above are not met.</p>\n<p><strong><em>POEMS</em></strong><strong><em> Syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes)</em></strong></p>\n<p style=\"text-align:justify\"><strong>Medically Necessary:</strong></p>\n<p><em>Autologous stem cell transplantation is </em>considered <strong>medically necessary</strong> for treatment of POEMS Syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) when diagnostic criteria for that syndrome are met.</p>\n<p><em>A repeat autologous stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting** </em>for an anticipated but unscheduled transplant is considered <strong>medically necessary </strong>in individuals with POEMS syndrome who meet one of the above criteria and for whom the treating physician documents that a future transplant is likely.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p><em>Autologous stem cell transplantation</em> for treatment of individuals with POEMS Syndrome is considered <strong>investigational and not medically necessary </strong>when the above criteria are not met.</p>\n<p><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation</em> for treatment of individuals with POEMS Syndrome is considered <strong>investigational and not medically necessary.</strong></p>\n<p><em>A tandem* autologous stem cell transplantation</em> for treatment of individuals with POEMS Syndrome is considered <strong>investigational and not medically necessary.</strong></p>\n<p class=\"MsoBodyTextIndent3\"><em>A repeat autologous stem cell transplantation </em>due to persistent, progressive or relapsed POEMS is considered<strong> investigational and not medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting</em> for a future but unscheduled transplant is considered <strong>investigational and not medically necessary </strong>when the criteria above are not met.</p>\n<p>* Tandem transplantation refers to a planned infusion (transplant) of previously harvested hematopoietic stem cells with a repeat hematopoietic stem cell infusion (transplant) that is performed within 6 months of the initial transplant. This is distinguished from a repeat transplantation requested or performed more than 6 months after the first transplant, and is used as salvage therapy after failure of initial transplantation or relapsed disease.</p>\n<p>** Hematopoietic stem cell harvesting does not include the transplant procedure.</p>",
    "content": "Multiple Myeloma\nMedically Necessary:\nAutologous hematopoietic stem cell transplantation (AutoHSCT) for treatment of individuals with multiple myeloma is considered medically necessary when used as:\n<li class=\"MsoBodyTextIndent\">As a single transplant (AutoHSCT); or</li>\n<li class=\"MsoBodyTextIndent\">As a tandem* transplant (two AutoHSCTs separated by 30 to 180 days); or</li>\n<li class=\"MsoBodyTextIndent\">As a repeat procedure (AutoHSCT greater than 180 days following a previous AutoHSCT); or</li>\n<li class=\"MsoBodyTextIndent\">As a pretreatment for a non-myeloablative allogeneic hematopoietic stem cell transplant; or</li>\n<li class=\"MsoBodyTextIndent\">As salvage therapy after:\t<ol> <li class=\"MsoBodyTextIndent\">Primary graft failure; or</li> <li class=\"MsoBodyTextIndent\">Failure to engraft; or</li> <li class=\"MsoBodyTextIndent\">Rejection following an allogeneic HSCT.</li> </ol> </li>\n<li class=\"MsoBodyTextIndent\">Primary graft failure; or</li>\n<li class=\"MsoBodyTextIndent\">Failure to engraft; or</li>\n<li class=\"MsoBodyTextIndent\">Rejection following an allogeneic HSCT.</li>\nAllogeneic (ablative or non-myeloablative) stem cell transplantation after a previous autologous stem cell transplant for treatment of individuals with multiple myeloma is considered medically necessary.\nA planned tandem non-myeloablative allogeneic transplantation following an autologous transplantation is considered medically necessary for treatment of individuals with multiple myeloma.\nA repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure, failure to engraft or rejection is considered medically necessary.\nHematopoietic stem cell harvesting** for an anticipated but unscheduled transplant is considered medically necessary in individuals with multiple myeloma who meet one of the above criteria and for whom the treating physician documents that a future transplant is likely.\nInvestigational and Not Medically Necessary:\nAllogeneic (ablative or non-myeloablative) stem cell transplantation or autologous stem cell transplantation is considered investigational and not medically necessary for individuals with multiple myeloma who do not meet the above criteria.\nHematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.\nA repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.\nThree or more autologous hematopoietic stem cell transplantations within a 12-month period are considered investigational and not medically necessary.\nAmyloidosis\nMedically Necessary:\nAutologous stem cell transplantation is considered medically necessary for individuals with primary amyloidosis (AL) who meet the following criteria:<br/>Note: (If the individual has a preceding diagnosis of multiple myeloma, use the transplant criteria above for multiple myeloma).\n<li>If the heart is involved with AL, the individual is asymptomatic or has compensated congestive heart failure; and</li>\n<li>Left ventricular ejection fraction (LVEF) greater than or equal to 45%; and</li>\n<li>Must have documented disease on biopsy without a preceding diagnosis of multiple myeloma.</li>\nA repeat autologous stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.\nHematopoietic stem cell harvesting** for an anticipated but unscheduled transplant is considered medically necessary in individuals with amyloidosis who meet one of the above criteria and for whom the treating physician documents that a future transplant is likely.\nInvestigational and Not Medically Necessary:\nAutologous stem cell transplantation is considered investigational and not medically necessary in the treatment of primary amyloidosis in individuals with symptomatic heart failure regardless of the number of organs involved.\nAllogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for treatment of individuals with amyloidosis.\nA tandem* autologous stem cell transplantation is considered investigational and not medically necessary for treatment of individuals with amyloidosis.\nA repeat autologous stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.\nHematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.\nPOEMS Syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes)\nMedically Necessary:\nAutologous stem cell transplantation is considered medically necessary for treatment of POEMS Syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) when diagnostic criteria for that syndrome are met.\nA repeat autologous stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.\nHematopoietic stem cell harvesting** for an anticipated but unscheduled transplant is considered medically necessary in individuals with POEMS syndrome who meet one of the above criteria and for whom the treating physician documents that a future transplant is likely.\nInvestigational and Not Medically Necessary:\nAutologous stem cell transplantation for treatment of individuals with POEMS Syndrome is considered investigational and not medically necessary when the above criteria are not met.\nAllogeneic (ablative or non-myeloablative) stem cell transplantation for treatment of individuals with POEMS Syndrome is considered investigational and not medically necessary.\nA tandem* autologous stem cell transplantation for treatment of individuals with POEMS Syndrome is considered investigational and not medically necessary.\nA repeat autologous stem cell transplantation due to persistent, progressive or relapsed POEMS is considered investigational and not medically necessary.\nHematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.\n* Tandem transplantation refers to a planned infusion (transplant) of previously harvested hematopoietic stem cells with a repeat hematopoietic stem cell infusion (transplant) that is performed within 6 months of the initial transplant. This is distinguished from a repeat transplantation requested or performed more than 6 months after the first transplant, and is used as salvage therapy after failure of initial transplantation or relapsed disease.\n** Hematopoietic stem cell harvesting does not include the transplant procedure.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Multiple Myeloma",
            "sub_medical_act": "Autologous hematopoietic stem cell transplantation (AutoHSCT)",
            "necessity_type": "Medically Necessary",
            "description": "Autologous hematopoietic stem cell transplantation (AutoHSCT) for treatment of individuals with multiple myeloma is considered medically necessary when used as:",
            "conditions": {
              "ANY": [
                {
                  "desc": "As a single transplant (AutoHSCT)",
                  "conditions": null
                },
                {
                  "desc": "As a tandem transplant (two AutoHSCTs separated by 30 to 180 days)",
                  "conditions": null
                },
                {
                  "desc": "As a repeat procedure (AutoHSCT greater than 180 days following a previous AutoHSCT)",
                  "conditions": null
                },
                {
                  "desc": "As a pretreatment for a non-myeloablative allogeneic hematopoietic stem cell transplant",
                  "conditions": null
                },
                {
                  "desc": "As salvage therapy after:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Primary graft failure",
                        "conditions": null
                      },
                      {
                        "desc": "Failure to engraft",
                        "conditions": null
                      },
                      {
                        "desc": "Rejection following an allogeneic HSCT",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Primary graft failure",
                  "conditions": null
                },
                {
                  "desc": "Failure to engraft",
                  "conditions": null
                },
                {
                  "desc": "Rejection following an allogeneic HSCT",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Multiple Myeloma",
            "sub_medical_act": "Allogeneic (ablative or non-myeloablative) stem cell transplantation after a previous autologous stem cell transplant",
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation after a previous autologous stem cell transplant for treatment of individuals with multiple myeloma is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Multiple Myeloma",
            "sub_medical_act": "Planned tandem non-myeloablative allogeneic transplantation following an autologous transplantation",
            "necessity_type": "Medically Necessary",
            "description": "A planned tandem non-myeloablative allogeneic transplantation following an autologous transplantation is considered medically necessary for treatment of individuals with multiple myeloma.",
            "conditions": null
          },
          {
            "medical_act": "Multiple Myeloma",
            "sub_medical_act": "Repeat allogeneic (ablative or non-myeloablative) stem cell transplantation",
            "necessity_type": "Medically Necessary",
            "description": "A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure, failure to engraft or rejection is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Multiple Myeloma",
            "sub_medical_act": "Hematopoietic stem cell harvesting",
            "necessity_type": "Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for an anticipated but unscheduled transplant is considered medically necessary in individuals with multiple myeloma who meet one of the above criteria and for whom the treating physician documents that a future transplant is likely.",
            "conditions": null
          },
          {
            "medical_act": "Multiple Myeloma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation or autologous stem cell transplantation is considered investigational and not medically necessary for individuals with multiple myeloma who do not meet the above criteria.",
            "conditions": null
          },
          {
            "medical_act": "Multiple Myeloma",
            "sub_medical_act": "Hematopoietic stem cell harvesting",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          },
          {
            "medical_act": "Multiple Myeloma",
            "sub_medical_act": "Repeat allogeneic (ablative or non-myeloablative) stem cell transplantation",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Multiple Myeloma",
            "sub_medical_act": "Autologous hematopoietic stem cell transplantation (AutoHSCT)",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Three or more autologous hematopoietic stem cell transplantations within a 12-month period are considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Amyloidosis",
            "sub_medical_act": "Autologous stem cell transplantation",
            "necessity_type": "Medically Necessary",
            "description": "Autologous stem cell transplantation is considered medically necessary for individuals with primary amyloidosis (AL) who meet the following criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "If the heart is involved with AL, the individual is asymptomatic or has compensated congestive heart failure",
                  "conditions": null
                },
                {
                  "desc": "Left ventricular ejection fraction (LVEF) greater than or equal to 45%",
                  "conditions": null
                },
                {
                  "desc": "Must have documented disease on biopsy without a preceding diagnosis of multiple myeloma",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Amyloidosis",
            "sub_medical_act": "Repeat autologous stem cell transplantation",
            "necessity_type": "Medically Necessary",
            "description": "A repeat autologous stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Amyloidosis",
            "sub_medical_act": "Hematopoietic stem cell harvesting",
            "necessity_type": "Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for an anticipated but unscheduled transplant is considered medically necessary in individuals with amyloidosis who meet one of the above criteria and for whom the treating physician documents that a future transplant is likely.",
            "conditions": null
          },
          {
            "medical_act": "Amyloidosis",
            "sub_medical_act": "Autologous stem cell transplantation",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous stem cell transplantation is considered investigational and not medically necessary in the treatment of primary amyloidosis in individuals with symptomatic heart failure regardless of the number of organs involved.",
            "conditions": null
          },
          {
            "medical_act": "Amyloidosis",
            "sub_medical_act": "Allogeneic (ablative or non-myeloablative) stem cell transplantation",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for treatment of individuals with amyloidosis.",
            "conditions": null
          },
          {
            "medical_act": "Amyloidosis",
            "sub_medical_act": "Tandem autologous stem cell transplantation",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A tandem autologous stem cell transplantation is considered investigational and not medically necessary for treatment of individuals with amyloidosis.",
            "conditions": null
          },
          {
            "medical_act": "Amyloidosis",
            "sub_medical_act": "Repeat autologous stem cell transplantation",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A repeat autologous stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Amyloidosis",
            "sub_medical_act": "Hematopoietic stem cell harvesting",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          },
          {
            "medical_act": "POEMS Syndrome",
            "sub_medical_act": "Autologous stem cell transplantation",
            "necessity_type": "Medically Necessary",
            "description": "Autologous stem cell transplantation is considered medically necessary for treatment of POEMS Syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) when diagnostic criteria for that syndrome are met.",
            "conditions": null
          },
          {
            "medical_act": "POEMS Syndrome",
            "sub_medical_act": "Repeat autologous stem cell transplantation",
            "necessity_type": "Medically Necessary",
            "description": "A repeat autologous stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "POEMS Syndrome",
            "sub_medical_act": "Hematopoietic stem cell harvesting",
            "necessity_type": "Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for an anticipated but unscheduled transplant is considered medically necessary in individuals with POEMS syndrome who meet one of the above criteria and for whom the treating physician documents that a future transplant is likely.",
            "conditions": null
          },
          {
            "medical_act": "POEMS Syndrome",
            "sub_medical_act": "Autologous stem cell transplantation",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous stem cell transplantation for treatment of individuals with POEMS Syndrome is considered investigational and not medically necessary when the above criteria are not met.",
            "conditions": null
          },
          {
            "medical_act": "POEMS Syndrome",
            "sub_medical_act": "Allogeneic (ablative or non-myeloablative) stem cell transplantation",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation for treatment of individuals with POEMS Syndrome is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "POEMS Syndrome",
            "sub_medical_act": "Tandem autologous stem cell transplantation",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A tandem autologous stem cell transplantation for treatment of individuals with POEMS Syndrome is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "POEMS Syndrome",
            "sub_medical_act": "Repeat autologous stem cell transplantation",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A repeat autologous stem cell transplantation due to persistent, progressive or relapsed POEMS is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "POEMS Syndrome",
            "sub_medical_act": "Hematopoietic stem cell harvesting",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 4820,
          "prompt_tokens": 2184,
          "completion_tokens": 2636,
          "total_cost": 0.05046,
          "processing_time": 51.67430400848389
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a045973.html",
    "subject": "Hematopoietic Stem Cell Transplantation for Select Leukemias and Myelodysplastic Syndrome",
    "document_number": "TRANS.00024",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>I.&nbsp;<em> Acute Myeloid Leukemia (AML)</em></strong></p>\n<p><strong>Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation</em> is considered <strong>medically necessary</strong> for individuals with AML in any phase of illness after induction when <em>none</em> of the following indicators of a favorable AML classification are present:\t<ol>\t\t<li>Core binding factor (CBF) AML [inv(16) or t(8;21)] with unmutated (wild-type) C-Kit; <strong>or </strong></li>\t\t<li>Acute promyelocytic leukemia (APL) t(15;17) in first complete remission; <strong>or</strong></li>\t\t<li>Cytogenetically normal AML with FLT3-ITD non-mutated (wild-type) and NPM1 mutated.</li>\t</ol>\t</li>\n<li>Core binding factor (CBF) AML [inv(16) or t(8;21)] with unmutated (wild-type) C-Kit; <strong>or </strong></li>\n<li>Acute promyelocytic leukemia (APL) t(15;17) in first complete remission; <strong>or</strong></li>\n<li>Cytogenetically normal AML with FLT3-ITD non-mutated (wild-type) and NPM1 mutated.</li>\n<li>A<em> repeat allogeneic (ablative or non-myeloablative) stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></li>\n<li>A <em>second or repeat allogeneic (ablative or non-myeloablative) stem cell transplantation</em> due to relapsed disease is considered <strong>medically necessary.</strong></li>\n<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation </em>is considered <strong>investigational and not medically necessary</strong> for individuals with AML when <em>any</em> of the following indicators of a favorable classification are present:\t<ol>\t\t<li>Core binding factor (CBF) AML [inv(16), t(8;21)] with unmutated (wild-type) C-Kit; <strong>or</strong></li>\t\t<li>Acute promyelocytic leukemia (APL) t(15;17) in first complete remission; <strong>or</strong></li>\t\t<li>Cytogenetically normal AML with FLT3-ITD non mutated (wild-type) and NPM1 mutated.</li>\t</ol>\t</li>\n<li>Core binding factor (CBF) AML [inv(16), t(8;21)] with unmutated (wild-type) C-Kit; <strong>or</strong></li>\n<li>Acute promyelocytic leukemia (APL) t(15;17) in first complete remission; <strong>or</strong></li>\n<li>Cytogenetically normal AML with FLT3-ITD non mutated (wild-type) and NPM1 mutated.</li>\n<li><em>Autologous </em>stem cell transplantation is considered <strong>investigational and not medically necessary</strong> for individuals with AML.</li>\n<li>A <em>second or repeat allogeneic (ablative or non-myeloablative) transplant</em> due to persistent or progressive disease is considered<strong> investigational and not medically necessary.</strong></li>\n<li><em>Hematopoietic stem cell harvesting</em> for a future but unscheduled transplant is considered <strong>investigational and not medically necessary.</strong></li>\n<p><strong>II.<em>&nbsp; Acute Lymphoblastic Leukemia </em></strong><strong><em>(ALL)</em></strong></p>\n<p><strong>Note:</strong> There is no clear age cut-off that distinguishes adult from childhood ALL. Published data generally group outcomes according to whether the individual is treated by an adult or pediatric oncologist.</p>\n<p style=\"text-align:justify\"><strong>Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation</em> is considered <strong>medically necessary</strong> provided the individual has a diagnosis of ALL and <strong>one </strong>of the following:\t<ol>\t\t<li>Individual is in <strong>first complete remission</strong> and has <strong>one or more</strong> of the following \"high-risk\" factors:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Philadelphia chromosome positive [t(9;22) or BCR-ABL positive];</li>\t\t\t<li>Any of the following cytogenetic or molecular abnormalities:&nbsp; t(4;11), t(1;19), t(8;14), del(7q), trisomy 8, 11q23 (MLL) translocation;</li>\t\t\t<li>Hypodiploidy (less than 44 chromosomes);</li>\t\t\t<li>B-cell immunophenotype;</li>\t\t\t<li>Age greater than 15 years;</li>\t\t\t<li>Leukocyte count greater than 50 x 10<sup>9</sup>/L;</li>\t\t\t<li>Extramedullary disease (especially central nervous system);</li>\t\t\t<li>Failure to achieve a complete remission within 6 weeks of the start of induction therapy;</li>\t\t\t<li>Minimal residual disease (MRD) positivity following induction;<strong> or</strong></li>\t\t</ol>\t\t</li>\t\t<li>Individual is in <strong>second</strong> <strong>or subsequent complete remission;</strong> <strong>or</strong></li>\t\t<li>Individual is in <strong>any relapse.</strong></li>\t</ol>\t</li>\n<li>Individual is in <strong>first complete remission</strong> and has <strong>one or more</strong> of the following \"high-risk\" factors:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Philadelphia chromosome positive [t(9;22) or BCR-ABL positive];</li>\t\t\t<li>Any of the following cytogenetic or molecular abnormalities:&nbsp; t(4;11), t(1;19), t(8;14), del(7q), trisomy 8, 11q23 (MLL) translocation;</li>\t\t\t<li>Hypodiploidy (less than 44 chromosomes);</li>\t\t\t<li>B-cell immunophenotype;</li>\t\t\t<li>Age greater than 15 years;</li>\t\t\t<li>Leukocyte count greater than 50 x 10<sup>9</sup>/L;</li>\t\t\t<li>Extramedullary disease (especially central nervous system);</li>\t\t\t<li>Failure to achieve a complete remission within 6 weeks of the start of induction therapy;</li>\t\t\t<li>Minimal residual disease (MRD) positivity following induction;<strong> or</strong></li>\t\t</ol>\t\t</li>\n<li>Philadelphia chromosome positive [t(9;22) or BCR-ABL positive];</li>\n<li>Any of the following cytogenetic or molecular abnormalities:&nbsp; t(4;11), t(1;19), t(8;14), del(7q), trisomy 8, 11q23 (MLL) translocation;</li>\n<li>Hypodiploidy (less than 44 chromosomes);</li>\n<li>B-cell immunophenotype;</li>\n<li>Age greater than 15 years;</li>\n<li>Leukocyte count greater than 50 x 10<sup>9</sup>/L;</li>\n<li>Extramedullary disease (especially central nervous system);</li>\n<li>Failure to achieve a complete remission within 6 weeks of the start of induction therapy;</li>\n<li>Minimal residual disease (MRD) positivity following induction;<strong> or</strong></li>\n<li>Individual is in <strong>second</strong> <strong>or subsequent complete remission;</strong> <strong>or</strong></li>\n<li>Individual is in <strong>any relapse.</strong></li>\n<li><em>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></li>\n<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation </em>is considered <strong>investigational and not medically necessary</strong> for individuals who do not meet the above criteria.</li>\n<li><em>A second or repeat allogeneic (ablative or non-myeloablative) transplant</em> due to persistent, progressive or<em> </em>relapsed disease is considered<strong> investigational and not medically necessary.</strong></li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered<strong> investigational and not medically necessary.</strong></li>\n<li><em>Autologous stem cell transplant </em>is considered <strong>investigational and not medically necessary </strong>for individuals with ALL.</li>\n<p><strong>III.&nbsp;<em> Chronic Myeloid Leukemia </em></strong><strong><em>(CML)</em></strong></p>\n<p style=\"text-align:justify\"><strong>Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation </em>is considered <strong>medically necessary</strong> for individuals with CML and <strong>any</strong> of the following indications:\t<ol>\t\t<li>No hematologic response at 3 months; <strong>or</strong></li>\t\t<li>No cytogenetic response at 6 months; <strong>or</strong></li>\t\t<li>Cytogenetic relapse at 12 or 18 months after achieving initial hematologic remission;<strong> or</strong></li>\t\t<li>Partial cytogenetic response at 18 months; <strong>or </strong></li>\t\t<li>Individuals with T315-I mutation; <strong>or </strong></li>\t\t<li>Individuals in accelerated or blast phase.</li>\t</ol>\t</li>\n<li>No hematologic response at 3 months; <strong>or</strong></li>\n<li>No cytogenetic response at 6 months; <strong>or</strong></li>\n<li>Cytogenetic relapse at 12 or 18 months after achieving initial hematologic remission;<strong> or</strong></li>\n<li>Partial cytogenetic response at 18 months; <strong>or </strong></li>\n<li>Individuals with T315-I mutation; <strong>or </strong></li>\n<li>Individuals in accelerated or blast phase.</li>\n<li><em>An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation</em> is considered <strong>medically necessary</strong> for individuals who meet the above criteria.<br>\t<strong>Note:</strong> This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as <strong>investigational and not medically necessary.</strong></li>\n<li><em>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></li>\n<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation </em>is considered <strong>investigational and not medically necessary</strong> for individuals who do not meet the above criteria.</li>\n<li><em>Autologous stem cell transplantation</em> is considered <strong>investigational and not medically necessary.</strong></li>\n<li><em>A second or repeat allogeneic (ablative or non-myeloablative) transplant</em> due to persistent, progressive or<em> </em>relapsed disease is considered<strong> investigational and not medically necessary.</strong></li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered<strong> investigational and not medically necessary.</strong></li>\n<p style=\"text-align:justify\"><strong>IV.&nbsp; <em>Chronic Lymphocytic Leukemia </em></strong><strong><em>(CLL)/Small Lymphocytic Lymphoma (SLL)</em></strong></p>\n<p style=\"text-align:justify\"><strong>Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation</em> is considered <strong>medically necessary</strong> for individuals<em> </em>with CLL or SLL who are refractory to small molecule inhibitor therapy.</li>\n<li><em>An allogeneic stem cell transplantation </em><em>(ablative or non-myeloablative) after a prior autologous stem cell transplantation*</em> is considered <strong>medically necessary</strong> for individuals with CLL or SLL who meet the above criteria.<br>\t<strong>*Note:</strong> This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as <strong>investigational and not medically necessary.</strong></li>\n<li><em>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></li>\n<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> for individuals with CLL or SLL who do not meet the above criteria.</li>\n<li><em>Autologous stem cell transplantation in individuals</em> with CLL or SLL is considered <strong>investigational and not medically necessary.</strong></li>\n<li><em>A second or repeat allogeneic (ablative or non-myeloablative) transplant</em> due to persistent, progressive or<em> </em>relapsed disease is considered<strong> investigational and not medically necessary.</strong></li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered<strong> investigational and not medically necessary.</strong></li>\n<p><strong>V.<em>&nbsp; Myelodysplastic Syndromes </em></strong><strong><em>(MDS) including Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)</em></strong></p>\n<p style=\"text-align:justify\"><strong>Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation</em> is considered <strong>medically necessary</strong> for individuals who have chronic myelomonocytic leukemia (CMML) or a <em>de novo or primary</em> myelodysplastic syndrome with an intermediate International Prognostic Scoring System (IPSS) score of 1.5-2.0 or a high IPSS score of greater than or equal to 2.5 or a Revised IPSS (IPSS-R) intermediate score of greater than 3.5 or a high or very high IPSS-R score. Individuals may have the allogeneic transplant as initial therapy.*&nbsp;</li>\n<li><em>Allogeneic (ablative and non-myeloablative) stem cell transplantation</em> is considered <strong>medically necessary</strong> for individuals who have a myelodysplastic syndrome with a low or intermediate IPSS of 0-1.0 or an IPSS-R of 3.5 or less who have not responded to prior therapy.*&nbsp;<br>\t<strong>*Note:</strong> An IPSS is not required for the treatment of de novo or primary myelodysplastic syndrome or juvenile myelomonocytic leukemia (JMML) in the pediatric population.</li>\n<li><em>Allogeneic (ablative and non-myeloablative) stem cell transplantation </em>is considered<em> </em><strong>medically necessary</strong><em> </em>for individuals who have <em>secondary</em> myelodysplastic syndrome.</li>\n<li><em>An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation</em> is considered <strong>medically necessary</strong> for individuals who meet the above criteria.<br>\t<strong>Note:</strong> This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as <strong>investigational and not medically necessary.</strong></li>\n<li><em>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></li>\n<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> for individuals who do not meet the above criteria.</li>\n<li><em>Autologous stem cell transplantation</em> in individuals with CMML, MDS or myeloproliferative neoplasms is considered <strong>investigational and not medically necessary.</strong></li>\n<li><em>Allogeneic (ablative and non-myeloablative) stem cell transplantation</em> is considered <strong>investigational and not</strong> <strong>medically necessary</strong> in individuals with the following myeloproliferative neoplasms (MPN: polycythemia vera, essential thrombocytopenia).</li>\n<li><em>A second or repeat allogeneic (ablative or non-myeloablative) transplant</em> due to persistent, progressive or<em> </em>relapsed disease is considered<strong> investigational and not medically necessary.</strong></li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered<strong> investigational and not medically necessary.</strong></li>\n<p><strong>VI.<em>&nbsp; Myelofibrosis</em></strong></p>\n<p><strong>Medically Necessary:</strong></p>\n<li><em>Allogeneic (ablative or non-myeloablative) stem cell transplantation</em> is considered <strong>medically necessary </strong>in individuals with myelofibrosis.</li>\n<li><em>An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation</em> is considered <strong>medically necessary.</strong><br>\t<strong><em>NOTE:</em></strong> This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as <strong>investigational and not medically necessary.</strong></li>\n<li><em>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<li><em>Autologous stem cell transplantation</em> in individuals with myelofibrosis is considered <strong>investigational and not medically necessary.</strong></li>\n<li><em>A second or repeat allogeneic (ablative or non-myeloablative) transplant</em> due to persistent, progressive or<em> </em>relapsed disease is considered<strong> investigational and not medically necessary.</strong></li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered<strong> investigational and not medically necessary.</strong></li>",
    "content": "I.\u00a0 Acute Myeloid Leukemia (AML)\nMedically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary for individuals with AML in any phase of illness after induction when none of the following indicators of a favorable AML classification are present:\t<ol> <li>Core binding factor (CBF) AML [inv(16) or t(8;21)] with unmutated (wild-type) C-Kit; or </li> <li>Acute promyelocytic leukemia (APL) t(15;17) in first complete remission; or</li> <li>Cytogenetically normal AML with FLT3-ITD non-mutated (wild-type) and NPM1 mutated.</li> </ol> </li>\n<li>Core binding factor (CBF) AML [inv(16) or t(8;21)] with unmutated (wild-type) C-Kit; or </li>\n<li>Acute promyelocytic leukemia (APL) t(15;17) in first complete remission; or</li>\n<li>Cytogenetically normal AML with FLT3-ITD non-mutated (wild-type) and NPM1 mutated.</li>\n<li>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.</li>\n<li>A second or repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to relapsed disease is considered medically necessary.</li>\nInvestigational and Not Medically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for individuals with AML when any of the following indicators of a favorable classification are present:\t<ol> <li>Core binding factor (CBF) AML [inv(16), t(8;21)] with unmutated (wild-type) C-Kit; or</li> <li>Acute promyelocytic leukemia (APL) t(15;17) in first complete remission; or</li> <li>Cytogenetically normal AML with FLT3-ITD non mutated (wild-type) and NPM1 mutated.</li> </ol> </li>\n<li>Core binding factor (CBF) AML [inv(16), t(8;21)] with unmutated (wild-type) C-Kit; or</li>\n<li>Acute promyelocytic leukemia (APL) t(15;17) in first complete remission; or</li>\n<li>Cytogenetically normal AML with FLT3-ITD non mutated (wild-type) and NPM1 mutated.</li>\n<li>Autologous stem cell transplantation is considered investigational and not medically necessary for individuals with AML.</li>\n<li>A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent or progressive disease is considered investigational and not medically necessary.</li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.</li>\nII.\u00a0 Acute Lymphoblastic Leukemia (ALL)\nNote: There is no clear age cut-off that distinguishes adult from childhood ALL. Published data generally group outcomes according to whether the individual is treated by an adult or pediatric oncologist.\nMedically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary provided the individual has a diagnosis of ALL and one of the following:\t<ol> <li>Individual is in first complete remission and has one or more of the following \"high-risk\" factors:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Philadelphia chromosome positive [t(9;22) or BCR-ABL positive];</li> <li>Any of the following cytogenetic or molecular abnormalities:\u00a0 t(4;11), t(1;19), t(8;14), del(7q), trisomy 8, 11q23 (MLL) translocation;</li> <li>Hypodiploidy (less than 44 chromosomes);</li> <li>B-cell immunophenotype;</li> <li>Age greater than 15 years;</li> <li>Leukocyte count greater than 50 x 10<sup>9</sup>/L;</li> <li>Extramedullary disease (especially central nervous system);</li> <li>Failure to achieve a complete remission within 6 weeks of the start of induction therapy;</li> <li>Minimal residual disease (MRD) positivity following induction; or</li> </ol> </li> <li>Individual is in second or subsequent complete remission; or</li> <li>Individual is in any relapse.</li> </ol> </li>\n<li>Individual is in first complete remission and has one or more of the following \"high-risk\" factors:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Philadelphia chromosome positive [t(9;22) or BCR-ABL positive];</li> <li>Any of the following cytogenetic or molecular abnormalities:\u00a0 t(4;11), t(1;19), t(8;14), del(7q), trisomy 8, 11q23 (MLL) translocation;</li> <li>Hypodiploidy (less than 44 chromosomes);</li> <li>B-cell immunophenotype;</li> <li>Age greater than 15 years;</li> <li>Leukocyte count greater than 50 x 10<sup>9</sup>/L;</li> <li>Extramedullary disease (especially central nervous system);</li> <li>Failure to achieve a complete remission within 6 weeks of the start of induction therapy;</li> <li>Minimal residual disease (MRD) positivity following induction; or</li> </ol> </li>\n<li>Philadelphia chromosome positive [t(9;22) or BCR-ABL positive];</li>\n<li>Any of the following cytogenetic or molecular abnormalities:\u00a0 t(4;11), t(1;19), t(8;14), del(7q), trisomy 8, 11q23 (MLL) translocation;</li>\n<li>Hypodiploidy (less than 44 chromosomes);</li>\n<li>B-cell immunophenotype;</li>\n<li>Age greater than 15 years;</li>\n<li>Leukocyte count greater than 50 x 10<sup>9</sup>/L;</li>\n<li>Extramedullary disease (especially central nervous system);</li>\n<li>Failure to achieve a complete remission within 6 weeks of the start of induction therapy;</li>\n<li>Minimal residual disease (MRD) positivity following induction; or</li>\n<li>Individual is in second or subsequent complete remission; or</li>\n<li>Individual is in any relapse.</li>\n<li>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.</li>\nInvestigational and Not Medically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for individuals who do not meet the above criteria.</li>\n<li>A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.</li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.</li>\n<li>Autologous stem cell transplant is considered investigational and not medically necessary for individuals with ALL.</li>\nIII.\u00a0 Chronic Myeloid Leukemia (CML)\nMedically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary for individuals with CML and any of the following indications:\t<ol> <li>No hematologic response at 3 months; or</li> <li>No cytogenetic response at 6 months; or</li> <li>Cytogenetic relapse at 12 or 18 months after achieving initial hematologic remission; or</li> <li>Partial cytogenetic response at 18 months; or </li> <li>Individuals with T315-I mutation; or </li> <li>Individuals in accelerated or blast phase.</li> </ol> </li>\n<li>No hematologic response at 3 months; or</li>\n<li>No cytogenetic response at 6 months; or</li>\n<li>Cytogenetic relapse at 12 or 18 months after achieving initial hematologic remission; or</li>\n<li>Partial cytogenetic response at 18 months; or </li>\n<li>Individuals with T315-I mutation; or </li>\n<li>Individuals in accelerated or blast phase.</li>\n<li>An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation is considered medically necessary for individuals who meet the above criteria.<br/> Note: This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as investigational and not medically necessary.</li>\n<li>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.</li>\nInvestigational and Not Medically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for individuals who do not meet the above criteria.</li>\n<li>Autologous stem cell transplantation is considered investigational and not medically necessary.</li>\n<li>A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.</li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.</li>\nIV.\u00a0 Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)\nMedically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary for individuals with CLL or SLL who are refractory to small molecule inhibitor therapy.</li>\n<li>An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation* is considered medically necessary for individuals with CLL or SLL who meet the above criteria.<br/> *Note: This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as investigational and not medically necessary.</li>\n<li>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.</li>\nInvestigational and Not Medically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for individuals with CLL or SLL who do not meet the above criteria.</li>\n<li>Autologous stem cell transplantation in individuals with CLL or SLL is considered investigational and not medically necessary.</li>\n<li>A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.</li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.</li>\nV.\u00a0 Myelodysplastic Syndromes (MDS) including Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)\nMedically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary for individuals who have chronic myelomonocytic leukemia (CMML) or a de novo or primary myelodysplastic syndrome with an intermediate International Prognostic Scoring System (IPSS) score of 1.5-2.0 or a high IPSS score of greater than or equal to 2.5 or a Revised IPSS (IPSS-R) intermediate score of greater than 3.5 or a high or very high IPSS-R score. Individuals may have the allogeneic transplant as initial therapy.*\u00a0</li>\n<li>Allogeneic (ablative and non-myeloablative) stem cell transplantation is considered medically necessary for individuals who have a myelodysplastic syndrome with a low or intermediate IPSS of 0-1.0 or an IPSS-R of 3.5 or less who have not responded to prior therapy.*\u00a0<br/> *Note: An IPSS is not required for the treatment of de novo or primary myelodysplastic syndrome or juvenile myelomonocytic leukemia (JMML) in the pediatric population.</li>\n<li>Allogeneic (ablative and non-myeloablative) stem cell transplantation is considered medically necessary for individuals who have secondary myelodysplastic syndrome.</li>\n<li>An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation is considered medically necessary for individuals who meet the above criteria.<br/> Note: This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as investigational and not medically necessary.</li>\n<li>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.</li>\nInvestigational and Not Medically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for individuals who do not meet the above criteria.</li>\n<li>Autologous stem cell transplantation in individuals with CMML, MDS or myeloproliferative neoplasms is considered investigational and not medically necessary.</li>\n<li>Allogeneic (ablative and non-myeloablative) stem cell transplantation is considered investigational and not medically necessary in individuals with the following myeloproliferative neoplasms (MPN: polycythemia vera, essential thrombocytopenia).</li>\n<li>A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.</li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.</li>\nVI.\u00a0 Myelofibrosis\nMedically Necessary:\n<li>Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary in individuals with myelofibrosis.</li>\n<li>An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation is considered medically necessary.<br/> NOTE: This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as investigational and not medically necessary.</li>\n<li>A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.</li>\nInvestigational and Not Medically Necessary:\n<li>Autologous stem cell transplantation in individuals with myelofibrosis is considered investigational and not medically necessary.</li>\n<li>A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.</li>\n<li>Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.</li>",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Acute Myeloid Leukemia (AML)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary for individuals with AML in any phase of illness after induction when none of the following indicators of a favorable AML classification are present:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Core binding factor (CBF) AML [inv(16) or t(8;21)] with unmutated (wild-type) C-Kit",
                  "conditions": null
                },
                {
                  "desc": "Acute promyelocytic leukemia (APL) t(15;17) in first complete remission",
                  "conditions": null
                },
                {
                  "desc": "Cytogenetically normal AML with FLT3-ITD non-mutated (wild-type) and NPM1 mutated",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Acute Myeloid Leukemia (AML)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Acute Myeloid Leukemia (AML)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A second or repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to relapsed disease is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Acute Myeloid Leukemia (AML)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for individuals with AML when any of the following indicators of a favorable classification are present:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Core binding factor (CBF) AML [inv(16), t(8;21)] with unmutated (wild-type) C-Kit",
                  "conditions": null
                },
                {
                  "desc": "Acute promyelocytic leukemia (APL) t(15;17) in first complete remission",
                  "conditions": null
                },
                {
                  "desc": "Cytogenetically normal AML with FLT3-ITD non mutated (wild-type) and NPM1 mutated",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Acute Myeloid Leukemia (AML)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous stem cell transplantation is considered investigational and not medically necessary for individuals with AML.",
            "conditions": null
          },
          {
            "medical_act": "Acute Myeloid Leukemia (AML)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent or progressive disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Acute Myeloid Leukemia (AML)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Acute Lymphoblastic Leukemia (ALL)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary provided the individual has a diagnosis of ALL and one of the following:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Individual is in first complete remission and has one or more of the following 'high-risk' factors:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Philadelphia chromosome positive [t(9;22) or BCR-ABL positive]",
                        "conditions": null
                      },
                      {
                        "desc": "Any of the following cytogenetic or molecular abnormalities: t(4;11), t(1;19), t(8;14), del(7q), trisomy 8, 11q23 (MLL) translocation",
                        "conditions": null
                      },
                      {
                        "desc": "Hypodiploidy (less than 44 chromosomes)",
                        "conditions": null
                      },
                      {
                        "desc": "B-cell immunophenotype",
                        "conditions": null
                      },
                      {
                        "desc": "Age greater than 15 years",
                        "conditions": null
                      },
                      {
                        "desc": "Leukocyte count greater than 50 x 10^9/L",
                        "conditions": null
                      },
                      {
                        "desc": "Extramedullary disease (especially central nervous system)",
                        "conditions": null
                      },
                      {
                        "desc": "Failure to achieve a complete remission within 6 weeks of the start of induction therapy",
                        "conditions": null
                      },
                      {
                        "desc": "Minimal residual disease (MRD) positivity following induction",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Individual is in second or subsequent complete remission",
                  "conditions": null
                },
                {
                  "desc": "Individual is in any relapse",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Acute Lymphoblastic Leukemia (ALL)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Acute Lymphoblastic Leukemia (ALL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for individuals who do not meet the above criteria.",
            "conditions": null
          },
          {
            "medical_act": "Acute Lymphoblastic Leukemia (ALL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Acute Lymphoblastic Leukemia (ALL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Acute Lymphoblastic Leukemia (ALL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous stem cell transplant is considered investigational and not medically necessary for individuals with ALL.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Myeloid Leukemia (CML)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary for individuals with CML and any of the following indications:",
            "conditions": {
              "ANY": [
                {
                  "desc": "No hematologic response at 3 months",
                  "conditions": null
                },
                {
                  "desc": "No cytogenetic response at 6 months",
                  "conditions": null
                },
                {
                  "desc": "Cytogenetic relapse at 12 or 18 months after achieving initial hematologic remission",
                  "conditions": null
                },
                {
                  "desc": "Partial cytogenetic response at 18 months",
                  "conditions": null
                },
                {
                  "desc": "Individuals with T315-I mutation",
                  "conditions": null
                },
                {
                  "desc": "Individuals in accelerated or blast phase",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Chronic Myeloid Leukemia (CML)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation is considered medically necessary for individuals who meet the above criteria. Note: This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Myeloid Leukemia (CML)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Myeloid Leukemia (CML)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for individuals who do not meet the above criteria.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Myeloid Leukemia (CML)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous stem cell transplantation is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Myeloid Leukemia (CML)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Myeloid Leukemia (CML)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary for individuals with CLL or SLL who are refractory to small molecule inhibitor therapy.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation is considered medically necessary for individuals with CLL or SLL who meet the above criteria. Note: This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and not medically necessary for individuals with CLL or SLL who do not meet the above criteria.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous stem cell transplantation in individuals with CLL or SLL is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A second or repeat allogeneic (ablative or non-myeloablative) transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Myelodysplastic Syndromes (MDS) including Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered medically necessary for individuals who have chronic myelomonocytic leukemia (CMML) or a de novo or primary myelodysplastic syndrome with an intermediate International Prognostic Scoring System (IPSS) score of 1.5-2.0 or a high IPSS score of greater than or equal to 2.5 or a Revised IPSS (IPSS-R) intermediate score of greater than 3.5 or a high or very high IPSS-R score. Individuals may have the allogeneic transplant as initial therapy.",
            "conditions": null
          },
          {
            "medical_act": "Myelodysplastic Syndromes (MDS) including Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative and non-myeloablative) stem cell transplantation is considered medically necessary for individuals who have a myelodysplastic syndrome with a low or intermediate IPSS of 0-1.0 or an IPSS-R of 3.5 or less who have not responded to prior therapy. Note: An IPSS is not required for the treatment of de novo or primary myelodysplastic syndrome or juvenile myelomonocytic leukemia (JMML) in the pediatric population.",
            "conditions": null
          },
          {
            "medical_act": "Myelodysplastic Syndromes (MDS) including Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative and non-myeloablative) stem cell transplantation is considered medically necessary for individuals who have secondary myelodysplastic syndrome.",
            "conditions": null
          },
          {
            "medical_act": "Myelodysplastic Syndromes (MDS) including Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An allogeneic stem cell transplantation (ablative or non-myeloablative) after a prior autologous stem cell transplantation is considered medically necessary for individuals who meet the above criteria. Note: This applies if a previous autologous transplant was performed, regardless if the Position Statement deems autologous stem cell transplantation as investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Myelodysplastic Syndromes (MDS) including Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat allogeneic (ablative or non-myeloablative) stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Myelodysplastic Syndromes (MDS) including Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative or non-myeloablative) stem cell transplantation is considered investigational and"
          }
        ],
        "usage": {
          "total_tokens": 8320,
          "prompt_tokens": 4224,
          "completion_tokens": 4096,
          "total_cost": 0.08256,
          "processing_time": 63.70952868461609
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a047473.html",
    "subject": "Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors",
    "document_number": "TRANS.00027",
    "publish_date": "01/03/2024",
    "status": "Revised",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong><em>Neuroblastoma</em></strong></p>\n<p><strong>Medically Necessary:</strong></p>\n<p>An <em>autologous hematopoietic stem cell transplantation</em> is considered <strong>medically necessary</strong> as the initial treatment for high-risk neuroblastoma.</p>\n<p>A <em>planned autologous tandem* hematopoietic stem cell transplantation</em> is considered <strong>medically necessary</strong> as the initial treatment for high-risk neuroblastoma.</p>\n<p>An <em>autologous hematopoietic stem cell transplantation</em> is considered <strong>medically necessary</strong> as a treatment for primary refractory or recurrent neuroblastoma in individuals who have not previously undergone treatment with hematopoietic stem cell transplantation.</p>\n<p>A<em> repeat autologous hematopoietic stem cell transplantation</em> due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting</em>** for an anticipated but unscheduled transplant is considered <strong>medically necessary</strong> in individuals with neuroblastoma who meet the criteria above when the treating physician documents that a future transplant is likely.</p>\n<p>*Tandem transplantation refers to a planned infusion (transplant) of previously harvested hematopoietic stem cells with a repeat hematopoietic stem cell infusion (transplant) that is performed within 6 months of the initial transplant. This is distinguished from a repeat transplantation requested or performed more than 6 months after the first transplant, and is used as salvage therapy after failure of initial transplantation or relapsed disease.</p>\n<p>**Hematopoietic stem cell harvesting does not include the transplant procedure.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>An <em>autologous hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> for individuals who do not meet the above criteria.</p>\n<p>An <em>allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> as a treatment of neuroblastoma.</p>\n<p>A<em> planned tandem allogeneic (ablative or non-myeloablative) </em><em>hematopoietic stem cell transplantation </em>as a treatment of neuroblastoma is considered <strong>investigational and not medically necessary.</strong></p>\n<p class=\"MsoBodyTextIndent3\">A<em> second or repeat autologous hematopoietic stem cell transplantation</em> due to persistent, progressive or relapsed disease is considered<strong> investigational and not medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting </em>for a future but unscheduled transplant is considered <strong>investigational and not medically necessary </strong>when the criteria above are not met.</p>\n<p><strong><em>Primitive Neuroectodermal Tumors (PNETs) of the Central Nervous System, Ependymoma and Pineoblastoma</em></strong></p>\n<p><strong>Medically Necessary:</strong></p>\n<p>An <em>autologous hematopoietic stem cell transplantation</em> with or without associated radiotherapy, is considered <strong>medically necessary</strong> for the treatment of PNETs (such as medulloblastoma), arising in the central nervous system, ependymoma or pineoblastoma.</p>\n<p>A<em> repeat autologous hematopoietic stem cell transplantation</em> due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting</em> for an anticipated but unscheduled transplant is considered <strong>medically necessary</strong> in individuals with PNET, ependymoma or pineoblastoma who meet the criteria above when the treating physician documents that a future transplant is likely.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>An <em>allogeneic (ablative or non-myeloablative [mini transplant]) hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> for the treatment of PNETs (such as medulloblastoma), arising in the central nervous system, ependymoma or pineoblastoma.</p>\n<p>A<em> planned tandem allogeneic or autologous hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> for the treatment of PNETs (such as medulloblastoma), arising in the central nervous system, ependymoma or pineoblastoma.</p>\n<p class=\"MsoBodyTextIndent3\">A<em> second or repeat autologous</em><em> hematopoietic stem cell </em><em>transplantation</em> due to persistent, progressive or relapsed disease is considered<strong> investigational and not medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting </em>for a future but unscheduled transplant is considered <strong>investigational and not medically necessary </strong>when the criteria above are not met.</p>\n<p><strong><em>Other High-Risk Solid Tumors of Childhood </em></strong><strong>(<em>Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)</em></strong></p>\n<p><strong>Medically Necessary:</strong></p>\n<p>An <em>autologous hematopoietic stem cell transplantation</em> is considered <strong>medically necessary</strong> as a treatment for Ewing sarcoma (including extraosseous Ewing, peripheral neuroepithelioma and Askin's tumor).</p>\n<p>A <em>syngeneic allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation</em> is considered <strong>medically necessary</strong> as a treatment for Ewing sarcoma (including extraosseous Ewing, peripheral neuroepithelioma and Askin's tumor).</p>\n<p>A<em> repeat autologous or allogeneic (ablative or non-myeloablative) </em><em>hematopoietic </em><em>stem cell transplantation</em> due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting</em> for an anticipated but unscheduled transplant is considered <strong>medically necessary</strong> in individuals with Ewing sarcoma who meet the criteria above when the treating physician documents that a future transplant is likely.</p>\n<p>An <em>autologous hematopoietic stem cell transplantation </em>is considered <strong>medically necessary</strong> as a treatment for stage IVa and stage IVb retinoblastoma.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>An <em>allogeneic (ablative or non-myeloablative [mini transplant]) or autologous hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary </strong>for all other pediatric solid tumors, including but not limited to: Wilms\u2019 tumor (nephroblastoma), osteosarcoma, and rhabdomyosarcoma.</p>\n<p>An <em>autologous </em><em>hematopoietic stem cell transplantation </em>is considered <strong>investigational and not medically necessary </strong>for retinoblastoma other than stage IVa or stage IVb.</p>\n<p>An <em>allogeneic (ablative or non-myeloablative [mini transplant]) </em>is considered <strong>investigational and not medically necessary </strong>for retinoblastoma.</p>\n<p>An <em>allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> as a treatment of all high risk pediatric solid tumors relapsing after prior therapy with high-dose chemotherapy and autologous hematopoietic stem cell transplantation.</p>\n<p>A<em> planned tandem allogeneic or autologous hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> as a treatment of all high risk pediatric solid tumors of childhood.</p>\n<p class=\"MsoBodyTextIndent3\">A<em> second or repeat autologous or allogeneic (ablative or non-myeloablative) </em><em>hematopoietic stem cell transpla</em><em>ntation</em> due to persistent, progressive or relapsed disease is considered<strong> investigational and not medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting </em>for a future but unscheduled transplant is considered <strong>investigational and not medically necessary </strong>when the criteria above are not met.</p>",
    "content": "Neuroblastoma\nMedically Necessary:\nAn autologous hematopoietic stem cell transplantation is considered medically necessary as the initial treatment for high-risk neuroblastoma.\nA planned autologous tandem* hematopoietic stem cell transplantation is considered medically necessary as the initial treatment for high-risk neuroblastoma.\nAn autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment for primary refractory or recurrent neuroblastoma in individuals who have not previously undergone treatment with hematopoietic stem cell transplantation.\nA repeat autologous hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.\nHematopoietic stem cell harvesting** for an anticipated but unscheduled transplant is considered medically necessary in individuals with neuroblastoma who meet the criteria above when the treating physician documents that a future transplant is likely.\n*Tandem transplantation refers to a planned infusion (transplant) of previously harvested hematopoietic stem cells with a repeat hematopoietic stem cell infusion (transplant) that is performed within 6 months of the initial transplant. This is distinguished from a repeat transplantation requested or performed more than 6 months after the first transplant, and is used as salvage therapy after failure of initial transplantation or relapsed disease.\n**Hematopoietic stem cell harvesting does not include the transplant procedure.\nInvestigational and Not Medically Necessary:\nAn autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for individuals who do not meet the above criteria.\nAn allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of neuroblastoma.\nA planned tandem allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation as a treatment of neuroblastoma is considered investigational and not medically necessary.\nA second or repeat autologous hematopoietic stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.\nHematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.\nPrimitive Neuroectodermal Tumors (PNETs) of the Central Nervous System, Ependymoma and Pineoblastoma\nMedically Necessary:\nAn autologous hematopoietic stem cell transplantation with or without associated radiotherapy, is considered medically necessary for the treatment of PNETs (such as medulloblastoma), arising in the central nervous system, ependymoma or pineoblastoma.\nA repeat autologous hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.\nHematopoietic stem cell harvesting for an anticipated but unscheduled transplant is considered medically necessary in individuals with PNET, ependymoma or pineoblastoma who meet the criteria above when the treating physician documents that a future transplant is likely.\nInvestigational and Not Medically Necessary:\nAn allogeneic (ablative or non-myeloablative [mini transplant]) hematopoietic stem cell transplantation is considered investigational and not medically necessary for the treatment of PNETs (such as medulloblastoma), arising in the central nervous system, ependymoma or pineoblastoma.\nA planned tandem allogeneic or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for the treatment of PNETs (such as medulloblastoma), arising in the central nervous system, ependymoma or pineoblastoma.\nA second or repeat autologous hematopoietic stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.\nHematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.\nOther High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)\nMedically Necessary:\nAn autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment for Ewing sarcoma (including extraosseous Ewing, peripheral neuroepithelioma and Askin's tumor).\nA syngeneic allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation is considered medically necessary as a treatment for Ewing sarcoma (including extraosseous Ewing, peripheral neuroepithelioma and Askin's tumor).\nA repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.\nHematopoietic stem cell harvesting for an anticipated but unscheduled transplant is considered medically necessary in individuals with Ewing sarcoma who meet the criteria above when the treating physician documents that a future transplant is likely.\nAn autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment for stage IVa and stage IVb retinoblastoma.\nInvestigational and Not Medically Necessary:\nAn allogeneic (ablative or non-myeloablative [mini transplant]) or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for all other pediatric solid tumors, including but not limited to: Wilms\u2019 tumor (nephroblastoma), osteosarcoma, and rhabdomyosarcoma.\nAn autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for retinoblastoma other than stage IVa or stage IVb.\nAn allogeneic (ablative or non-myeloablative [mini transplant]) is considered investigational and not medically necessary for retinoblastoma.\nAn allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of all high risk pediatric solid tumors relapsing after prior therapy with high-dose chemotherapy and autologous hematopoietic stem cell transplantation.\nA planned tandem allogeneic or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of all high risk pediatric solid tumors of childhood.\nA second or repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.\nHematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An autologous hematopoietic stem cell transplantation is considered medically necessary as the initial treatment for high-risk neuroblastoma.",
            "conditions": null
          },
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A planned autologous tandem hematopoietic stem cell transplantation is considered medically necessary as the initial treatment for high-risk neuroblastoma.",
            "conditions": null
          },
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment for primary refractory or recurrent neuroblastoma in individuals who have not previously undergone treatment with hematopoietic stem cell transplantation.",
            "conditions": null
          },
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat autologous hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for an anticipated but unscheduled transplant is considered medically necessary in individuals with neuroblastoma who meet the criteria above when the treating physician documents that a future transplant is likely.",
            "conditions": null
          },
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for individuals who do not meet the above criteria.",
            "conditions": null
          },
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of neuroblastoma.",
            "conditions": null
          },
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A planned tandem allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation as a treatment of neuroblastoma is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A second or repeat autologous hematopoietic stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Neuroblastoma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          },
          {
            "medical_act": "Primitive Neuroectodermal Tumors (PNETs) of the Central Nervous System, Ependymoma and Pineoblastoma",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An autologous hematopoietic stem cell transplantation with or without associated radiotherapy, is considered medically necessary for the treatment of PNETs (such as medulloblastoma), arising in the central nervous system, ependymoma or pineoblastoma.",
            "conditions": null
          },
          {
            "medical_act": "Primitive Neuroectodermal Tumors (PNETs) of the Central Nervous System, Ependymoma and Pineoblastoma",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat autologous hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Primitive Neuroectodermal Tumors (PNETs) of the Central Nervous System, Ependymoma and Pineoblastoma",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for an anticipated but unscheduled transplant is considered medically necessary in individuals with PNET, ependymoma or pineoblastoma who meet the criteria above when the treating physician documents that a future transplant is likely.",
            "conditions": null
          },
          {
            "medical_act": "Primitive Neuroectodermal Tumors (PNETs) of the Central Nervous System, Ependymoma and Pineoblastoma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An allogeneic (ablative or non-myeloablative [mini transplant]) hematopoietic stem cell transplantation is considered investigational and not medically necessary for the treatment of PNETs (such as medulloblastoma), arising in the central nervous system, ependymoma or pineoblastoma.",
            "conditions": null
          },
          {
            "medical_act": "Primitive Neuroectodermal Tumors (PNETs) of the Central Nervous System, Ependymoma and Pineoblastoma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A planned tandem allogeneic or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for the treatment of PNETs (such as medulloblastoma), arising in the central nervous system, ependymoma or pineoblastoma.",
            "conditions": null
          },
          {
            "medical_act": "Primitive Neuroectodermal Tumors (PNETs) of the Central Nervous System, Ependymoma and Pineoblastoma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A second or repeat autologous hematopoietic stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Primitive Neuroectodermal Tumors (PNETs) of the Central Nervous System, Ependymoma and Pineoblastoma",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment for Ewing sarcoma (including extraosseous Ewing, peripheral neuroepithelioma and Askin's tumor).",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A syngeneic allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation is considered medically necessary as a treatment for Ewing sarcoma (including extraosseous Ewing, peripheral neuroepithelioma and Askin's tumor).",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for an anticipated but unscheduled transplant is considered medically necessary in individuals with Ewing sarcoma who meet the criteria above when the treating physician documents that a future transplant is likely.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "An autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment for stage IVa and stage IVb retinoblastoma.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An allogeneic (ablative or non-myeloablative [mini transplant]) or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for all other pediatric solid tumors, including but not limited to: Wilms\u2019 tumor (nephroblastoma), osteosarcoma, and rhabdomyosarcoma.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for retinoblastoma other than stage IVa or stage IVb.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An allogeneic (ablative or non-myeloablative [mini transplant]) is considered investigational and not medically necessary for retinoblastoma.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of all high risk pediatric solid tumors relapsing after prior therapy with high-dose chemotherapy and autologous hematopoietic stem cell transplantation.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A planned tandem allogeneic or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of all high risk pediatric solid tumors of childhood.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A second or repeat autologous or allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Other High-Risk Solid Tumors of Childhood (Ewing Sarcoma, Wilms\u2019 Tumor, Osteosarcoma, Retinoblastoma, and Rhabdomyosarcoma)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary when the criteria above are not met.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 5356,
          "prompt_tokens": 2199,
          "completion_tokens": 3157,
          "total_cost": 0.05835,
          "processing_time": 55.34683394432068
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a053842.html",
    "subject": "Hematopoietic Stem Cell Transplantation for Germ Cell Tumors",
    "document_number": "TRANS.00030",
    "publish_date": "01/03/2024",
    "status": "Revised",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>A<em> single autologous hematopoietic stem cell transplantation </em>is considered<strong> medically necessary</strong> as a treatment of primary germ cell tumors<strong>*</strong> in individuals treated with standard chemotherapy who had <strong>one </strong>of the following results:</p>\n<li>A partial response; <strong>or </strong></li>\n<li>Refractory germ cell tumors; <strong>or</strong></li>\n<li>Relapsed disease.</li>\n<p>A <em>planned tandem</em><strong> </strong><em>autologous hematopoietic stem cell transplantation </em>is considered<strong> medically necessary</strong> as a treatment of primary <em>testicular cancer</em> in individuals treated with standard chemotherapy who had one of the following results:</p>\n<li>A partial response; <strong>or </strong></li>\n<li>Refractory germ cell tumors; <strong>or </strong></li>\n<li>Relapsed disease.</li>\n<p><strong><em>*Note:</em></strong> <em>Ovarian germ cell tumors</em> must be distinguished from the far more common epithelial ovarian cancers. For epithelial ovarian carcinoma, please refer to<em> <strong>TRANS.00031 Hematopoietic Stem Cell Transplantation for Autoimmune Disease and Miscellaneous Solid Tumors.</strong></em></p>\n<p>A<em> repeat autologous hematopoietic stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>A<em> single autologous hematopoietic stem cell transplantation</em>, in lieu of a course of standard chemotherapy, is considered <strong>investigational and not medically necessary</strong> as initial treatment of poor prognosis germ cell tumors.</p>\n<p>A <em>planned tandem</em> <em>autologous hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> as a treatment of all other non-testicular germ cell tumors.</p>\n<p><em>Allogeneic (ablative and non-myeloablative [mini transplant]) hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary</strong> as a treatment of germ cell tumors, including but not limited to, use as a therapy after a prior failed high-dose chemotherapy with autologous hematopoietic stem cell support.</p>\n<p class=\"MsoBodyTextIndent3\">A<em> second or repeat autologous hematopoietic transplant </em>due to persistent, progressive or relapsed disease<em> </em>is considered<strong> investigational and not medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting</em> for a future but unscheduled transplant is considered<strong> investigational and not medically necessary.</strong></p>",
    "content": "Medically Necessary:\nA single autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment of primary germ cell tumors* in individuals treated with standard chemotherapy who had one of the following results:\n<li>A partial response; or </li>\n<li>Refractory germ cell tumors; or</li>\n<li>Relapsed disease.</li>\nA planned tandem autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment of primary testicular cancer in individuals treated with standard chemotherapy who had one of the following results:\n<li>A partial response; or </li>\n<li>Refractory germ cell tumors; or </li>\n<li>Relapsed disease.</li>\n*Note: Ovarian germ cell tumors must be distinguished from the far more common epithelial ovarian cancers. For epithelial ovarian carcinoma, please refer to TRANS.00031 Hematopoietic Stem Cell Transplantation for Autoimmune Disease and Miscellaneous Solid Tumors.\nA repeat autologous hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.\nInvestigational and Not Medically Necessary:\nA single autologous hematopoietic stem cell transplantation, in lieu of a course of standard chemotherapy, is considered investigational and not medically necessary as initial treatment of poor prognosis germ cell tumors.\nA planned tandem autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of all other non-testicular germ cell tumors.\nAllogeneic (ablative and non-myeloablative [mini transplant]) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of germ cell tumors, including but not limited to, use as a therapy after a prior failed high-dose chemotherapy with autologous hematopoietic stem cell support.\nA second or repeat autologous hematopoietic transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.\nHematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Autologous Hematopoietic Stem Cell Transplantation",
            "sub_medical_act": "Single",
            "necessity_type": "Medically Necessary",
            "description": "A single autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment of primary germ cell tumors in individuals treated with standard chemotherapy who had one of the following results:",
            "conditions": {
              "ANY": [
                {
                  "desc": "A partial response",
                  "conditions": null
                },
                {
                  "desc": "Refractory germ cell tumors",
                  "conditions": null
                },
                {
                  "desc": "Relapsed disease",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Autologous Hematopoietic Stem Cell Transplantation",
            "sub_medical_act": "Planned Tandem",
            "necessity_type": "Medically Necessary",
            "description": "A planned tandem autologous hematopoietic stem cell transplantation is considered medically necessary as a treatment of primary testicular cancer in individuals treated with standard chemotherapy who had one of the following results:",
            "conditions": {
              "ANY": [
                {
                  "desc": "A partial response",
                  "conditions": null
                },
                {
                  "desc": "Refractory germ cell tumors",
                  "conditions": null
                },
                {
                  "desc": "Relapsed disease",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Autologous Hematopoietic Stem Cell Transplantation",
            "sub_medical_act": "Repeat",
            "necessity_type": "Medically Necessary",
            "description": "A repeat autologous hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Autologous Hematopoietic Stem Cell Transplantation",
            "sub_medical_act": "Single",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A single autologous hematopoietic stem cell transplantation, in lieu of a course of standard chemotherapy, is considered investigational and not medically necessary as initial treatment of poor prognosis germ cell tumors.",
            "conditions": null
          },
          {
            "medical_act": "Autologous Hematopoietic Stem Cell Transplantation",
            "sub_medical_act": "Planned Tandem",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A planned tandem autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of all other non-testicular germ cell tumors.",
            "conditions": null
          },
          {
            "medical_act": "Allogeneic Hematopoietic Stem Cell Transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative and non-myeloablative [mini transplant]) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of germ cell tumors, including but not limited to, use as a therapy after a prior failed high-dose chemotherapy with autologous hematopoietic stem cell support.",
            "conditions": null
          },
          {
            "medical_act": "Autologous Hematopoietic Stem Cell Transplantation",
            "sub_medical_act": "Second or Repeat",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A second or repeat autologous hematopoietic transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Hematopoietic Stem Cell Harvesting",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 2130,
          "prompt_tokens": 1241,
          "completion_tokens": 889,
          "total_cost": 0.019540000000000002,
          "processing_time": 17.17830801010132
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a053844.html",
    "subject": "Hematopoietic Stem Cell Transplantation for Autoimmune Disease and Miscellaneous Solid Tumors",
    "document_number": "TRANS.00031",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p class=\"MsoAcetate\"><strong><em>Autoimmune Diseases</em></strong></p>\n<p><strong>Medically Necessary:</strong></p>\n<p style=\"margin-left:6px\">A <em>single</em> autologous (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation is considered <strong>medically necessary</strong> for individuals with <em>multiple sclerosis</em> when <strong>all</strong> of the following criteria are met:</p>\n<li>The transplant is used to treat <em>relapsing-remitting multiple sclerosis</em>; <strong>and</strong></li>\n<li>The individual is between 18 and 45 years of age with disease duration less than 10 years; <strong>and</strong></li>\n<li>The individual is disabled in at least one functional system but able to ambulate for 100 meters without aid or rest (expanded disability status scale [EDSS] score from 2.0 to 5.5); <strong>and</strong></li>\n<li>The individual has highly active and treatment resistant disease meeting criteria 1 <strong>and</strong> 2 below:\t<ol>\t\t<li>Highly active disease as seen by 1.a <strong>or</strong> 1.b below:\t\t<ol style=\"list-style-type:lower-alpha\">\t\t\t<li>Two or more clinical relapses at separate times but within the previous 12 months; <strong>or</strong></li>\t\t\t<li>One clinical relapse and one or more magnetic resonance imaging (MRI) lesions typical for MS (gadolinium-enhancing or T2-hyperintenase lesion), with the MRI lesion occurring at a separate time than the clinical relapse but both occurring within the previous 12 months; <strong>and</strong></li>\t\t</ol>\t\t</li>\t\t<li>Treatment resistant disease as seen by the disease activity meeting criteria D1 above occurring despite disease-modifying treatment (DMT) meeting <strong>all</strong> of the following requirements:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Each relapse or episode of new MRI lesion(s) must occur after at least 3 months of treatment with a U.S. Food and Drug Administration-approved DMT; <strong>and</strong></li>\t\t\t<li>At least 1 episode must be a clinical relapse, and MRI evidence of activity must include at least 2 unique or active lesions in the brain or spinal cord; <strong>and</strong></li>\t\t\t<li>At least 1 of those episodes must occur after treatment with a DMT considered to be highly efficacious (natalizumab, ocrelizumab, rituximab, or alemtuzumab).</li>\t\t</ol>\t\t</li>\t</ol>\t</li>\n<li>Highly active disease as seen by 1.a <strong>or</strong> 1.b below:\t\t<ol style=\"list-style-type:lower-alpha\">\t\t\t<li>Two or more clinical relapses at separate times but within the previous 12 months; <strong>or</strong></li>\t\t\t<li>One clinical relapse and one or more magnetic resonance imaging (MRI) lesions typical for MS (gadolinium-enhancing or T2-hyperintenase lesion), with the MRI lesion occurring at a separate time than the clinical relapse but both occurring within the previous 12 months; <strong>and</strong></li>\t\t</ol>\t\t</li>\n<li>Two or more clinical relapses at separate times but within the previous 12 months; <strong>or</strong></li>\n<li>One clinical relapse and one or more magnetic resonance imaging (MRI) lesions typical for MS (gadolinium-enhancing or T2-hyperintenase lesion), with the MRI lesion occurring at a separate time than the clinical relapse but both occurring within the previous 12 months; <strong>and</strong></li>\n<li>Treatment resistant disease as seen by the disease activity meeting criteria D1 above occurring despite disease-modifying treatment (DMT) meeting <strong>all</strong> of the following requirements:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Each relapse or episode of new MRI lesion(s) must occur after at least 3 months of treatment with a U.S. Food and Drug Administration-approved DMT; <strong>and</strong></li>\t\t\t<li>At least 1 episode must be a clinical relapse, and MRI evidence of activity must include at least 2 unique or active lesions in the brain or spinal cord; <strong>and</strong></li>\t\t\t<li>At least 1 of those episodes must occur after treatment with a DMT considered to be highly efficacious (natalizumab, ocrelizumab, rituximab, or alemtuzumab).</li>\t\t</ol>\t\t</li>\n<li>Each relapse or episode of new MRI lesion(s) must occur after at least 3 months of treatment with a U.S. Food and Drug Administration-approved DMT; <strong>and</strong></li>\n<li>At least 1 episode must be a clinical relapse, and MRI evidence of activity must include at least 2 unique or active lesions in the brain or spinal cord; <strong>and</strong></li>\n<li>At least 1 of those episodes must occur after treatment with a DMT considered to be highly efficacious (natalizumab, ocrelizumab, rituximab, or alemtuzumab).</li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p class=\"MsoAcetate\">A <em>single</em> autologous (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplant is considered <strong>investigational and not medically necessary</strong> as a treatment of multiple sclerosis when the above criteria are not met, including for primary progressive or secondary progressive forms of multiple sclerosis.</p>\n<p class=\"MsoAcetate\">A <em>repeat</em> autologous (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplant is considered <strong>investigational and not medically necessary</strong> as a treatment of relapsing-remitting multiple sclerosis.</p>\n<p class=\"MsoAcetate\">An allogeneic (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, or planned tandem is considered <strong>investigational and not medically necessary</strong> as a treatment of multiple sclerosis.</p>\n<p>An <em>autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation,</em> <em>single or planned tandem</em> is considered <strong>investigational and not medically necessary</strong> as a treatment of all other autoimmune diseases including, but not limited to:</p>\n<ul>\t<li>juvenile idiopathic arthritis;</li>\t<li>rheumatoid arthritis;</li>\t<li>systemic lupus erythematosus;</li>\t<li>systemic sclerosis</li></ul>\n<li>juvenile idiopathic arthritis;</li>\n<li>rheumatoid arthritis;</li>\n<li>systemic lupus erythematosus;</li>\n<li>systemic sclerosis</li>\n<p><strong><em>Epithelial Ovarian Cancer</em></strong></p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>An <em>autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem</em> is considered <strong>investigational and not medically necessary </strong>as a treatment of epithelial ovarian cancer.</p>\n<p><strong><em>Breast Cancer</em></strong></p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>An <em>autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem</em> is considered <strong>investigational and not medically necessary </strong>as a treatment of breast cancer.</p>\n<p><strong><em>Malignant Astrocytomas and Gliomas</em></strong></p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>An<em> autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem</em> is considered <strong>investigational and not medically necessary </strong>as a treatment of malignant astrocytomas and gliomas, including both glioblastoma multiforme and oligodendroglioma.</p>\n<p><strong><em>Other Miscellaneous Solid Tumors in Adults</em></strong></p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>An <em>autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem</em> is considered <strong>investigational and not medically necessary </strong>as a treatment of adult miscellaneous solid tumors, including but not limited to the following:</p>\n<ul>\t<li>Cancer of the bile duct;</li>\t<li>Cancer of the fallopian tubes;</li>\t<li>Cervical cancer;</li>\t<li>Colon cancer;</li>\t<li>Esophageal cancer;</li>\t<li>Gallbladder cancer;</li>\t<li>Lung cancer, any histology;</li>\t<li>Malignant melanoma;</li>\t<li>Neuroendocrine tumors;</li>\t<li>Nasopharyngeal cancer;</li>\t<li>Pancreas cancer;</li>\t<li>Paranasal sinus cancer;</li>\t<li>Prostate cancer;</li>\t<li>Rectal cancer;</li>\t<li>Renal cell cancer;</li>\t<li>Soft tissue sarcoma;</li>\t<li>Stomach cancer;</li>\t<li>Thyroid tumors;</li>\t<li>Tumors of the thymus;</li>\t<li>Uterine cancer;</li>\t<li>Undifferentiated tumors and tumors of unknown primary origin.</li></ul>\n<li>Cancer of the bile duct;</li>\n<li>Cancer of the fallopian tubes;</li>\n<li>Cervical cancer;</li>\n<li>Colon cancer;</li>\n<li>Esophageal cancer;</li>\n<li>Gallbladder cancer;</li>\n<li>Lung cancer, any histology;</li>\n<li>Malignant melanoma;</li>\n<li>Neuroendocrine tumors;</li>\n<li>Nasopharyngeal cancer;</li>\n<li>Pancreas cancer;</li>\n<li>Paranasal sinus cancer;</li>\n<li>Prostate cancer;</li>\n<li>Rectal cancer;</li>\n<li>Renal cell cancer;</li>\n<li>Soft tissue sarcoma;</li>\n<li>Stomach cancer;</li>\n<li>Thyroid tumors;</li>\n<li>Tumors of the thymus;</li>\n<li>Uterine cancer;</li>\n<li>Undifferentiated tumors and tumors of unknown primary origin.</li>",
    "content": "Autoimmune Diseases\nMedically Necessary:\nA single autologous (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation is considered medically necessary for individuals with multiple sclerosis when all of the following criteria are met:\n<li>The transplant is used to treat relapsing-remitting multiple sclerosis; and</li>\n<li>The individual is between 18 and 45 years of age with disease duration less than 10 years; and</li>\n<li>The individual is disabled in at least one functional system but able to ambulate for 100 meters without aid or rest (expanded disability status scale [EDSS] score from 2.0 to 5.5); and</li>\n<li>The individual has highly active and treatment resistant disease meeting criteria 1 and 2 below:\t<ol> <li>Highly active disease as seen by 1.a or 1.b below:\t\t<ol style=\"list-style-type:lower-alpha\"> <li>Two or more clinical relapses at separate times but within the previous 12 months; or</li> <li>One clinical relapse and one or more magnetic resonance imaging (MRI) lesions typical for MS (gadolinium-enhancing or T2-hyperintenase lesion), with the MRI lesion occurring at a separate time than the clinical relapse but both occurring within the previous 12 months; and</li> </ol> </li> <li>Treatment resistant disease as seen by the disease activity meeting criteria D1 above occurring despite disease-modifying treatment (DMT) meeting all of the following requirements:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Each relapse or episode of new MRI lesion(s) must occur after at least 3 months of treatment with a U.S. Food and Drug Administration-approved DMT; and</li> <li>At least 1 episode must be a clinical relapse, and MRI evidence of activity must include at least 2 unique or active lesions in the brain or spinal cord; and</li> <li>At least 1 of those episodes must occur after treatment with a DMT considered to be highly efficacious (natalizumab, ocrelizumab, rituximab, or alemtuzumab).</li> </ol> </li> </ol> </li>\n<li>Highly active disease as seen by 1.a or 1.b below:\t\t<ol style=\"list-style-type:lower-alpha\"> <li>Two or more clinical relapses at separate times but within the previous 12 months; or</li> <li>One clinical relapse and one or more magnetic resonance imaging (MRI) lesions typical for MS (gadolinium-enhancing or T2-hyperintenase lesion), with the MRI lesion occurring at a separate time than the clinical relapse but both occurring within the previous 12 months; and</li> </ol> </li>\n<li>Two or more clinical relapses at separate times but within the previous 12 months; or</li>\n<li>One clinical relapse and one or more magnetic resonance imaging (MRI) lesions typical for MS (gadolinium-enhancing or T2-hyperintenase lesion), with the MRI lesion occurring at a separate time than the clinical relapse but both occurring within the previous 12 months; and</li>\n<li>Treatment resistant disease as seen by the disease activity meeting criteria D1 above occurring despite disease-modifying treatment (DMT) meeting all of the following requirements:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Each relapse or episode of new MRI lesion(s) must occur after at least 3 months of treatment with a U.S. Food and Drug Administration-approved DMT; and</li> <li>At least 1 episode must be a clinical relapse, and MRI evidence of activity must include at least 2 unique or active lesions in the brain or spinal cord; and</li> <li>At least 1 of those episodes must occur after treatment with a DMT considered to be highly efficacious (natalizumab, ocrelizumab, rituximab, or alemtuzumab).</li> </ol> </li>\n<li>Each relapse or episode of new MRI lesion(s) must occur after at least 3 months of treatment with a U.S. Food and Drug Administration-approved DMT; and</li>\n<li>At least 1 episode must be a clinical relapse, and MRI evidence of activity must include at least 2 unique or active lesions in the brain or spinal cord; and</li>\n<li>At least 1 of those episodes must occur after treatment with a DMT considered to be highly efficacious (natalizumab, ocrelizumab, rituximab, or alemtuzumab).</li>\nInvestigational and Not Medically Necessary:\nA single autologous (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplant is considered investigational and not medically necessary as a treatment of multiple sclerosis when the above criteria are not met, including for primary progressive or secondary progressive forms of multiple sclerosis.\nA repeat autologous (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplant is considered investigational and not medically necessary as a treatment of relapsing-remitting multiple sclerosis.\nAn allogeneic (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, or planned tandem is considered investigational and not medically necessary as a treatment of multiple sclerosis.\nAn autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of all other autoimmune diseases including, but not limited to:\n<ul> <li>juvenile idiopathic arthritis;</li> <li>rheumatoid arthritis;</li> <li>systemic lupus erythematosus;</li> <li>systemic sclerosis</li></ul>\n<li>juvenile idiopathic arthritis;</li>\n<li>rheumatoid arthritis;</li>\n<li>systemic lupus erythematosus;</li>\n<li>systemic sclerosis</li>\nEpithelial Ovarian Cancer\nInvestigational and Not Medically Necessary:\nAn autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of epithelial ovarian cancer.\nBreast Cancer\nInvestigational and Not Medically Necessary:\nAn autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of breast cancer.\nMalignant Astrocytomas and Gliomas\nInvestigational and Not Medically Necessary:\nAn autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of malignant astrocytomas and gliomas, including both glioblastoma multiforme and oligodendroglioma.\nOther Miscellaneous Solid Tumors in Adults\nInvestigational and Not Medically Necessary:\nAn autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of adult miscellaneous solid tumors, including but not limited to the following:\n<ul> <li>Cancer of the bile duct;</li> <li>Cancer of the fallopian tubes;</li> <li>Cervical cancer;</li> <li>Colon cancer;</li> <li>Esophageal cancer;</li> <li>Gallbladder cancer;</li> <li>Lung cancer, any histology;</li> <li>Malignant melanoma;</li> <li>Neuroendocrine tumors;</li> <li>Nasopharyngeal cancer;</li> <li>Pancreas cancer;</li> <li>Paranasal sinus cancer;</li> <li>Prostate cancer;</li> <li>Rectal cancer;</li> <li>Renal cell cancer;</li> <li>Soft tissue sarcoma;</li> <li>Stomach cancer;</li> <li>Thyroid tumors;</li> <li>Tumors of the thymus;</li> <li>Uterine cancer;</li> <li>Undifferentiated tumors and tumors of unknown primary origin.</li></ul>\n<li>Cancer of the bile duct;</li>\n<li>Cancer of the fallopian tubes;</li>\n<li>Cervical cancer;</li>\n<li>Colon cancer;</li>\n<li>Esophageal cancer;</li>\n<li>Gallbladder cancer;</li>\n<li>Lung cancer, any histology;</li>\n<li>Malignant melanoma;</li>\n<li>Neuroendocrine tumors;</li>\n<li>Nasopharyngeal cancer;</li>\n<li>Pancreas cancer;</li>\n<li>Paranasal sinus cancer;</li>\n<li>Prostate cancer;</li>\n<li>Rectal cancer;</li>\n<li>Renal cell cancer;</li>\n<li>Soft tissue sarcoma;</li>\n<li>Stomach cancer;</li>\n<li>Thyroid tumors;</li>\n<li>Tumors of the thymus;</li>\n<li>Uterine cancer;</li>\n<li>Undifferentiated tumors and tumors of unknown primary origin.</li>",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Autoimmune Diseases",
            "sub_medical_act": "Multiple Sclerosis",
            "necessity_type": "Medically Necessary",
            "description": "A single autologous (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation is considered medically necessary for individuals with multiple sclerosis when all of the following criteria are met:",
            "conditions": {
              "ALL": [
                {
                  "desc": "The transplant is used to treat relapsing-remitting multiple sclerosis",
                  "conditions": null
                },
                {
                  "desc": "The individual is between 18 and 45 years of age with disease duration less than 10 years",
                  "conditions": null
                },
                {
                  "desc": "The individual is disabled in at least one functional system but able to ambulate for 100 meters without aid or rest (expanded disability status scale [EDSS] score from 2.0 to 5.5)",
                  "conditions": null
                },
                {
                  "desc": "The individual has highly active and treatment resistant disease meeting criteria 1 and 2 below:",
                  "conditions": {
                    "ALL": [
                      {
                        "desc": "Highly active disease as seen by 1.a or 1.b below:",
                        "conditions": {
                          "ANY": [
                            {
                              "desc": "Two or more clinical relapses at separate times but within the previous 12 months",
                              "conditions": null
                            },
                            {
                              "desc": "One clinical relapse and one or more magnetic resonance imaging (MRI) lesions typical for MS (gadolinium-enhancing or T2-hyperintenase lesion), with the MRI lesion occurring at a separate time than the clinical relapse but both occurring within the previous 12 months",
                              "conditions": null
                            }
                          ]
                        }
                      },
                      {
                        "desc": "Treatment resistant disease as seen by the disease activity meeting criteria D1 above occurring despite disease-modifying treatment (DMT) meeting all of the following requirements:",
                        "conditions": {
                          "ALL": [
                            {
                              "desc": "Each relapse or episode of new MRI lesion(s) must occur after at least 3 months of treatment with a U.S. Food and Drug Administration-approved DMT",
                              "conditions": null
                            },
                            {
                              "desc": "At least 1 episode must be a clinical relapse, and MRI evidence of activity must include at least 2 unique or active lesions in the brain or spinal cord",
                              "conditions": null
                            },
                            {
                              "desc": "At least 1 of those episodes must occur after treatment with a DMT considered to be highly efficacious (natalizumab, ocrelizumab, rituximab, or alemtuzumab)",
                              "conditions": null
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Autoimmune Diseases",
            "sub_medical_act": "Multiple Sclerosis",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A single autologous (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplant is considered investigational and not medically necessary as a treatment of multiple sclerosis when the above criteria are not met, including for primary progressive or secondary progressive forms of multiple sclerosis.",
            "conditions": null
          },
          {
            "medical_act": "Autoimmune Diseases",
            "sub_medical_act": "Multiple Sclerosis",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A repeat autologous (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplant is considered investigational and not medically necessary as a treatment of relapsing-remitting multiple sclerosis.",
            "conditions": null
          },
          {
            "medical_act": "Autoimmune Diseases",
            "sub_medical_act": "Multiple Sclerosis",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An allogeneic (ablative or non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, or planned tandem is considered investigational and not medically necessary as a treatment of multiple sclerosis.",
            "conditions": null
          },
          {
            "medical_act": "Autoimmune Diseases",
            "sub_medical_act": "Other Autoimmune Diseases",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of all other autoimmune diseases including, but not limited to:",
            "conditions": {
              "ANY": [
                {
                  "desc": "juvenile idiopathic arthritis",
                  "conditions": null
                },
                {
                  "desc": "rheumatoid arthritis",
                  "conditions": null
                },
                {
                  "desc": "systemic lupus erythematosus",
                  "conditions": null
                },
                {
                  "desc": "systemic sclerosis",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Epithelial Ovarian Cancer",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of epithelial ovarian cancer.",
            "conditions": null
          },
          {
            "medical_act": "Breast Cancer",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of breast cancer.",
            "conditions": null
          },
          {
            "medical_act": "Malignant Astrocytomas and Gliomas",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of malignant astrocytomas and gliomas, including both glioblastoma multiforme and oligodendroglioma.",
            "conditions": null
          },
          {
            "medical_act": "Other Miscellaneous Solid Tumors in Adults",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "An autologous or allogeneic (ablative and non-myeloablative [mini-transplant]) hematopoietic stem cell transplantation, single or planned tandem is considered investigational and not medically necessary as a treatment of adult miscellaneous solid tumors, including but not limited to the following:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Cancer of the bile duct",
                  "conditions": null
                },
                {
                  "desc": "Cancer of the fallopian tubes",
                  "conditions": null
                },
                {
                  "desc": "Cervical cancer",
                  "conditions": null
                },
                {
                  "desc": "Colon cancer",
                  "conditions": null
                },
                {
                  "desc": "Esophageal cancer",
                  "conditions": null
                },
                {
                  "desc": "Gallbladder cancer",
                  "conditions": null
                },
                {
                  "desc": "Lung cancer, any histology",
                  "conditions": null
                },
                {
                  "desc": "Malignant melanoma",
                  "conditions": null
                },
                {
                  "desc": "Neuroendocrine tumors",
                  "conditions": null
                },
                {
                  "desc": "Nasopharyngeal cancer",
                  "conditions": null
                },
                {
                  "desc": "Pancreas cancer",
                  "conditions": null
                },
                {
                  "desc": "Paranasal sinus cancer",
                  "conditions": null
                },
                {
                  "desc": "Prostate cancer",
                  "conditions": null
                },
                {
                  "desc": "Rectal cancer",
                  "conditions": null
                },
                {
                  "desc": "Renal cell cancer",
                  "conditions": null
                },
                {
                  "desc": "Soft tissue sarcoma",
                  "conditions": null
                },
                {
                  "desc": "Stomach cancer",
                  "conditions": null
                },
                {
                  "desc": "Thyroid tumors",
                  "conditions": null
                },
                {
                  "desc": "Tumors of the thymus",
                  "conditions": null
                },
                {
                  "desc": "Uterine cancer",
                  "conditions": null
                },
                {
                  "desc": "Undifferentiated tumors and tumors of unknown primary origin",
                  "conditions": null
                }
              ]
            }
          }
        ],
        "usage": {
          "total_tokens": 4705,
          "prompt_tokens": 2830,
          "completion_tokens": 1875,
          "total_cost": 0.042275,
          "processing_time": 27.32541799545288
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a070096.html",
    "subject": "Hematopoietic Stem Cell Transplantation for Diabetes Mellitus",
    "document_number": "TRANS.00034",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Autologous or allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation is considered <strong>investigational and not medically necessary</strong> as a treatment of diabetes mellitus.</p>",
    "content": "Investigational and Not Medically Necessary:\nAutologous or allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of diabetes mellitus.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Autologous or allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous or allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of diabetes mellitus.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 971,
          "prompt_tokens": 860,
          "completion_tokens": 111,
          "total_cost": 0.005965,
          "processing_time": 2.234600067138672
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a053525.html",
    "subject": "Liver Transplantation",
    "document_number": "TRANS.00008",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p class=\"MsoAcetate\"><em>Note: Members must meet the disease specific criteria as well as the general Individual Selection Criteria below for the transplantation to be considered medically necessary.</em></p>\n<p><strong>Medically Necessary:</strong></p>\n<p>A whole or partial liver transplant using a deceased or living donor is considered <strong>medically necessary</strong> for selected individuals with end-stage organ failure due to irreversible liver damage that includes, but is not limited to, the following conditions:</p>\n<li class=\"MsoBodyTextIndent\">Cholestatic liver diseases:\t<ol>\t\t<li>Primary biliary cirrhosis</li>\t\t<li>Primary sclerosing cholangitis</li>\t\t<li>Biliary atresia</li>\t\t<li>Caroli's disease</li>\t\t<li>Familial cholestasis</li>\t\t<li>Arteriohepatic dysplasia (Alagaille's disease)</li>\t\t<li class=\"MsoBodyTextIndent\">Cystic Fibrosis</li>\t</ol>\t</li>\n<li>Primary biliary cirrhosis</li>\n<li>Primary sclerosing cholangitis</li>\n<li>Biliary atresia</li>\n<li>Caroli's disease</li>\n<li>Familial cholestasis</li>\n<li>Arteriohepatic dysplasia (Alagaille's disease)</li>\n<li class=\"MsoBodyTextIndent\">Cystic Fibrosis</li>\n<li class=\"MsoBodyTextIndent\">Hepatocellular injury:\t<ol>\t\t<li>Viral-induced Hepatitis</li>\t\t<li>Drug induced\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Acetaminophen</li>\t\t\t<li>Associated with halothane, gold, disulfram, others</li>\t\t</ol>\t\t</li>\t\t<li>Alcohol induced</li>\t\t<li>Toxin exposure: Amanita mushroom poisoning</li>\t\t<li>Autoimmune hepatitis</li>\t</ol>\t</li>\n<li>Viral-induced Hepatitis</li>\n<li>Drug induced\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Acetaminophen</li>\t\t\t<li>Associated with halothane, gold, disulfram, others</li>\t\t</ol>\t\t</li>\n<li>Acetaminophen</li>\n<li>Associated with halothane, gold, disulfram, others</li>\n<li>Alcohol induced</li>\n<li>Toxin exposure: Amanita mushroom poisoning</li>\n<li>Autoimmune hepatitis</li>\n<li>Inborn errors of metabolism:\t<ol>\t\t<li>Wilson's disease</li>\t\t<li>Organic acidurias</li>\t\t<li>Hemochromatosis</li>\t\t<li>Alpha-1 antitrypsin deficiency</li>\t\t<li>Homozygous type II hyperlipoproteinemia</li>\t\t<li>Crigler-Najjar Syndrome type I</li>\t\t<li>Protoporphyria</li>\t\t<li>Some urea cycle deficiencies</li>\t\t<li>Glycogen storage diseases types I and IV</li>\t\t<li>Tyrosine deficiency</li>\t\t<li>Citrullinemia</li>\t\t<li>Ornithine transcarboxylase deficiency</li>\t\t<li>Familial amyloid polyneuropathy (requires transplantation - polyneuropathy and cardiac amyloidosis development due to the production of a variant transthyretin molecule by the liver)</li>\t\t<li>Oxalosis (primary)</li>\t</ol>\t</li>\n<li>Wilson's disease</li>\n<li>Organic acidurias</li>\n<li>Hemochromatosis</li>\n<li>Alpha-1 antitrypsin deficiency</li>\n<li>Homozygous type II hyperlipoproteinemia</li>\n<li>Crigler-Najjar Syndrome type I</li>\n<li>Protoporphyria</li>\n<li>Some urea cycle deficiencies</li>\n<li>Glycogen storage diseases types I and IV</li>\n<li>Tyrosine deficiency</li>\n<li>Citrullinemia</li>\n<li>Ornithine transcarboxylase deficiency</li>\n<li>Familial amyloid polyneuropathy (requires transplantation - polyneuropathy and cardiac amyloidosis development due to the production of a variant transthyretin molecule by the liver)</li>\n<li>Oxalosis (primary)</li>\n<li>Acute Diseases:\t<ol>\t\t<li>Fulminant hepatic failure</li>\t</ol>\t</li>\n<li>Fulminant hepatic failure</li>\n<li>Mass Occupying Lesions:\t<ol>\t\t<li>Polycystic disease of the liver (requiring transplantation due to the anatomic complications of a hugely enlarged liver)</li>\t\t<li>Hepatoblastoma confined to the liver</li>\t\t<li>Primary hepatocellular carcinoma confined to the liver</li>\t\t<li>Hemangioendothelioma</li>\t\t<li>Hilar cholangiocarcinoma (CCA) with a cross-sectional diameter 3 cm or less in conjunction with neoadjuvant chemoradiation therapy and the tumor is unresectable or there is underlying liver disease such that the individual is not a candidate for resection</li>\t</ol>\t</li>\n<li>Polycystic disease of the liver (requiring transplantation due to the anatomic complications of a hugely enlarged liver)</li>\n<li>Hepatoblastoma confined to the liver</li>\n<li>Primary hepatocellular carcinoma confined to the liver</li>\n<li>Hemangioendothelioma</li>\n<li>Hilar cholangiocarcinoma (CCA) with a cross-sectional diameter 3 cm or less in conjunction with neoadjuvant chemoradiation therapy and the tumor is unresectable or there is underlying liver disease such that the individual is not a candidate for resection</li>\n<li>Vascular disease:\t<ol>\t\t<li>Budd-Chiari Syndrome</li>\t</ol>\t</li>\n<li>Budd-Chiari Syndrome</li>\n<li>Other:\t<ol>\t\t<li>Cryptogenic cirrhosis</li>\t</ol>\t</li>\n<li>Cryptogenic cirrhosis</li>\n<p><strong><em>Liver Retransplantation</em></strong></p>\n<p>Retransplantation in individuals with graft failure of an initial liver transplant, due to either technical reasons or hyperacute rejection<strong> </strong>is considered <strong>medically necessary.</strong></p>\n<p>Retransplantation in individuals due to either chronic rejection or recurrent disease is considered <strong>medically necessary</strong> when the individual meets general selection criteria as defined below.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Liver transplants in individuals with extrahepatic malignancy, including, but not limited to non-hilar extrahepatic cholangiocarcinoma, intrahepatic cholangiocarcinoma or hepatocellular carcinoma when either condition extends beyond the liver, are considered <strong>investigational and not medically necessary. </strong></p>\n<p>Liver transplants for all other conditions that do not lead to end-stage organ failure due to irreversible liver damage<strong> </strong>are considered <strong>investigational and not medically necessary.</strong></p>\n<p style=\"text-align:justify\">Xenotransplantation is considered<strong> investigational and not medically necessary.</strong></p>\n<p style=\"text-align:justify\">Bioartificial liver devices are considered <strong>investigational and not medically necessary.</strong></p>\n<p style=\"text-align:justify\"><strong>Note:</strong> For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, a member may present with concurrent medical conditions which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the additional organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member's candidacy for transplantation.</p>\n<p align=\"center\" style=\"text-align:center\"><strong>General Individual Selection Criteria</strong></p>\n<p>In addition to having end stage liver disease, the member must not have a contraindication as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001) listed below.</p>\n<p><strong>Absolute Contraindications- for Transplant <em>Recipients</em></strong> include, but are not limited to, the following:</p>\n<li>Metastatic cancer</li>\n<li>Ongoing or recurring infections that are not effectively treated</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm<sup>3</sup>) unless the following are noted:\t<ol>\t\t<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months</li>\t\t<li>HIV-1 RNA undetectable</li>\t\t<li>On stable anti-retroviral therapy greater than 3 months</li>\t\t<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li>\t\t<li>Meeting all other criteria for liver transplantation*</li>\t</ol>\t</li>\n<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months</li>\n<li>HIV-1 RNA undetectable</li>\n<li>On stable anti-retroviral therapy greater than 3 months</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li>\n<li>Meeting all other criteria for liver transplantation*</li>\n<p style=\"text-align:justify\">*Steinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. Vol. 71, 1189-1204, No. 9, May 15, 2001.</p>",
    "content": "Note: Members must meet the disease specific criteria as well as the general Individual Selection Criteria below for the transplantation to be considered medically necessary.\nMedically Necessary:\nA whole or partial liver transplant using a deceased or living donor is considered medically necessary for selected individuals with end-stage organ failure due to irreversible liver damage that includes, but is not limited to, the following conditions:\n<li class=\"MsoBodyTextIndent\">Cholestatic liver diseases:\t<ol> <li>Primary biliary cirrhosis</li> <li>Primary sclerosing cholangitis</li> <li>Biliary atresia</li> <li>Caroli's disease</li> <li>Familial cholestasis</li> <li>Arteriohepatic dysplasia (Alagaille's disease)</li> <li class=\"MsoBodyTextIndent\">Cystic Fibrosis</li> </ol> </li>\n<li>Primary biliary cirrhosis</li>\n<li>Primary sclerosing cholangitis</li>\n<li>Biliary atresia</li>\n<li>Caroli's disease</li>\n<li>Familial cholestasis</li>\n<li>Arteriohepatic dysplasia (Alagaille's disease)</li>\n<li class=\"MsoBodyTextIndent\">Cystic Fibrosis</li>\n<li class=\"MsoBodyTextIndent\">Hepatocellular injury:\t<ol> <li>Viral-induced Hepatitis</li> <li>Drug induced\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Acetaminophen</li> <li>Associated with halothane, gold, disulfram, others</li> </ol> </li> <li>Alcohol induced</li> <li>Toxin exposure: Amanita mushroom poisoning</li> <li>Autoimmune hepatitis</li> </ol> </li>\n<li>Viral-induced Hepatitis</li>\n<li>Drug induced\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Acetaminophen</li> <li>Associated with halothane, gold, disulfram, others</li> </ol> </li>\n<li>Acetaminophen</li>\n<li>Associated with halothane, gold, disulfram, others</li>\n<li>Alcohol induced</li>\n<li>Toxin exposure: Amanita mushroom poisoning</li>\n<li>Autoimmune hepatitis</li>\n<li>Inborn errors of metabolism:\t<ol> <li>Wilson's disease</li> <li>Organic acidurias</li> <li>Hemochromatosis</li> <li>Alpha-1 antitrypsin deficiency</li> <li>Homozygous type II hyperlipoproteinemia</li> <li>Crigler-Najjar Syndrome type I</li> <li>Protoporphyria</li> <li>Some urea cycle deficiencies</li> <li>Glycogen storage diseases types I and IV</li> <li>Tyrosine deficiency</li> <li>Citrullinemia</li> <li>Ornithine transcarboxylase deficiency</li> <li>Familial amyloid polyneuropathy (requires transplantation - polyneuropathy and cardiac amyloidosis development due to the production of a variant transthyretin molecule by the liver)</li> <li>Oxalosis (primary)</li> </ol> </li>\n<li>Wilson's disease</li>\n<li>Organic acidurias</li>\n<li>Hemochromatosis</li>\n<li>Alpha-1 antitrypsin deficiency</li>\n<li>Homozygous type II hyperlipoproteinemia</li>\n<li>Crigler-Najjar Syndrome type I</li>\n<li>Protoporphyria</li>\n<li>Some urea cycle deficiencies</li>\n<li>Glycogen storage diseases types I and IV</li>\n<li>Tyrosine deficiency</li>\n<li>Citrullinemia</li>\n<li>Ornithine transcarboxylase deficiency</li>\n<li>Familial amyloid polyneuropathy (requires transplantation - polyneuropathy and cardiac amyloidosis development due to the production of a variant transthyretin molecule by the liver)</li>\n<li>Oxalosis (primary)</li>\n<li>Acute Diseases:\t<ol> <li>Fulminant hepatic failure</li> </ol> </li>\n<li>Fulminant hepatic failure</li>\n<li>Mass Occupying Lesions:\t<ol> <li>Polycystic disease of the liver (requiring transplantation due to the anatomic complications of a hugely enlarged liver)</li> <li>Hepatoblastoma confined to the liver</li> <li>Primary hepatocellular carcinoma confined to the liver</li> <li>Hemangioendothelioma</li> <li>Hilar cholangiocarcinoma (CCA) with a cross-sectional diameter 3 cm or less in conjunction with neoadjuvant chemoradiation therapy and the tumor is unresectable or there is underlying liver disease such that the individual is not a candidate for resection</li> </ol> </li>\n<li>Polycystic disease of the liver (requiring transplantation due to the anatomic complications of a hugely enlarged liver)</li>\n<li>Hepatoblastoma confined to the liver</li>\n<li>Primary hepatocellular carcinoma confined to the liver</li>\n<li>Hemangioendothelioma</li>\n<li>Hilar cholangiocarcinoma (CCA) with a cross-sectional diameter 3 cm or less in conjunction with neoadjuvant chemoradiation therapy and the tumor is unresectable or there is underlying liver disease such that the individual is not a candidate for resection</li>\n<li>Vascular disease:\t<ol> <li>Budd-Chiari Syndrome</li> </ol> </li>\n<li>Budd-Chiari Syndrome</li>\n<li>Other:\t<ol> <li>Cryptogenic cirrhosis</li> </ol> </li>\n<li>Cryptogenic cirrhosis</li>\nLiver Retransplantation\nRetransplantation in individuals with graft failure of an initial liver transplant, due to either technical reasons or hyperacute rejection is considered medically necessary.\nRetransplantation in individuals due to either chronic rejection or recurrent disease is considered medically necessary when the individual meets general selection criteria as defined below.\nInvestigational and Not Medically Necessary:\nLiver transplants in individuals with extrahepatic malignancy, including, but not limited to non-hilar extrahepatic cholangiocarcinoma, intrahepatic cholangiocarcinoma or hepatocellular carcinoma when either condition extends beyond the liver, are considered investigational and not medically necessary. \nLiver transplants for all other conditions that do not lead to end-stage organ failure due to irreversible liver damage are considered investigational and not medically necessary.\nXenotransplantation is considered investigational and not medically necessary.\nBioartificial liver devices are considered investigational and not medically necessary.\nNote: For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, a member may present with concurrent medical conditions which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the additional organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member's candidacy for transplantation.\nGeneral Individual Selection Criteria\nIn addition to having end stage liver disease, the member must not have a contraindication as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001) listed below.\nAbsolute Contraindications- for Transplant Recipients include, but are not limited to, the following:\n<li>Metastatic cancer</li>\n<li>Ongoing or recurring infections that are not effectively treated</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm<sup>3</sup>) unless the following are noted:\t<ol> <li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months</li> <li>HIV-1 RNA undetectable</li> <li>On stable anti-retroviral therapy greater than 3 months</li> <li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li> <li>Meeting all other criteria for liver transplantation*</li> </ol> </li>\n<li>CD4 count greater than 200 cells/mm<sup>3</sup> for greater than 6 months</li>\n<li>HIV-1 RNA undetectable</li>\n<li>On stable anti-retroviral therapy greater than 3 months</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li>\n<li>Meeting all other criteria for liver transplantation*</li>\n*Steinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. Vol. 71, 1189-1204, No. 9, May 15, 2001.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Liver Transplant",
            "sub_medical_act": "Whole or Partial Liver Transplant",
            "necessity_type": "Medically Necessary",
            "description": "A whole or partial liver transplant using a deceased or living donor is considered medically necessary for selected individuals with end-stage organ failure due to irreversible liver damage that includes, but is not limited to, the following conditions:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Cholestatic liver diseases",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Primary biliary cirrhosis",
                        "conditions": null
                      },
                      {
                        "desc": "Primary sclerosing cholangitis",
                        "conditions": null
                      },
                      {
                        "desc": "Biliary atresia",
                        "conditions": null
                      },
                      {
                        "desc": "Caroli's disease",
                        "conditions": null
                      },
                      {
                        "desc": "Familial cholestasis",
                        "conditions": null
                      },
                      {
                        "desc": "Arteriohepatic dysplasia (Alagaille's disease)",
                        "conditions": null
                      },
                      {
                        "desc": "Cystic Fibrosis",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Primary biliary cirrhosis",
                  "conditions": null
                },
                {
                  "desc": "Primary sclerosing cholangitis",
                  "conditions": null
                },
                {
                  "desc": "Biliary atresia",
                  "conditions": null
                },
                {
                  "desc": "Caroli's disease",
                  "conditions": null
                },
                {
                  "desc": "Familial cholestasis",
                  "conditions": null
                },
                {
                  "desc": "Arteriohepatic dysplasia (Alagaille's disease)",
                  "conditions": null
                },
                {
                  "desc": "Cystic Fibrosis",
                  "conditions": null
                },
                {
                  "desc": "Hepatocellular injury",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Viral-induced Hepatitis",
                        "conditions": null
                      },
                      {
                        "desc": "Drug induced",
                        "conditions": {
                          "ANY": [
                            {
                              "desc": "Acetaminophen",
                              "conditions": null
                            },
                            {
                              "desc": "Associated with halothane, gold, disulfram, others",
                              "conditions": null
                            }
                          ]
                        }
                      },
                      {
                        "desc": "Alcohol induced",
                        "conditions": null
                      },
                      {
                        "desc": "Toxin exposure: Amanita mushroom poisoning",
                        "conditions": null
                      },
                      {
                        "desc": "Autoimmune hepatitis",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Viral-induced Hepatitis",
                  "conditions": null
                },
                {
                  "desc": "Drug induced",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Acetaminophen",
                        "conditions": null
                      },
                      {
                        "desc": "Associated with halothane, gold, disulfram, others",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Alcohol induced",
                  "conditions": null
                },
                {
                  "desc": "Toxin exposure: Amanita mushroom poisoning",
                  "conditions": null
                },
                {
                  "desc": "Autoimmune hepatitis",
                  "conditions": null
                },
                {
                  "desc": "Inborn errors of metabolism",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Wilson's disease",
                        "conditions": null
                      },
                      {
                        "desc": "Organic acidurias",
                        "conditions": null
                      },
                      {
                        "desc": "Hemochromatosis",
                        "conditions": null
                      },
                      {
                        "desc": "Alpha-1 antitrypsin deficiency",
                        "conditions": null
                      },
                      {
                        "desc": "Homozygous type II hyperlipoproteinemia",
                        "conditions": null
                      },
                      {
                        "desc": "Crigler-Najjar Syndrome type I",
                        "conditions": null
                      },
                      {
                        "desc": "Protoporphyria",
                        "conditions": null
                      },
                      {
                        "desc": "Some urea cycle deficiencies",
                        "conditions": null
                      },
                      {
                        "desc": "Glycogen storage diseases types I and IV",
                        "conditions": null
                      },
                      {
                        "desc": "Tyrosine deficiency",
                        "conditions": null
                      },
                      {
                        "desc": "Citrullinemia",
                        "conditions": null
                      },
                      {
                        "desc": "Ornithine transcarboxylase deficiency",
                        "conditions": null
                      },
                      {
                        "desc": "Familial amyloid polyneuropathy (requires transplantation - polyneuropathy and cardiac amyloidosis development due to the production of a variant transthyretin molecule by the liver)",
                        "conditions": null
                      },
                      {
                        "desc": "Oxalosis (primary)",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Wilson's disease",
                  "conditions": null
                },
                {
                  "desc": "Organic acidurias",
                  "conditions": null
                },
                {
                  "desc": "Hemochromatosis",
                  "conditions": null
                },
                {
                  "desc": "Alpha-1 antitrypsin deficiency",
                  "conditions": null
                },
                {
                  "desc": "Homozygous type II hyperlipoproteinemia",
                  "conditions": null
                },
                {
                  "desc": "Crigler-Najjar Syndrome type I",
                  "conditions": null
                },
                {
                  "desc": "Protoporphyria",
                  "conditions": null
                },
                {
                  "desc": "Some urea cycle deficiencies",
                  "conditions": null
                },
                {
                  "desc": "Glycogen storage diseases types I and IV",
                  "conditions": null
                },
                {
                  "desc": "Tyrosine deficiency",
                  "conditions": null
                },
                {
                  "desc": "Citrullinemia",
                  "conditions": null
                },
                {
                  "desc": "Ornithine transcarboxylase deficiency",
                  "conditions": null
                },
                {
                  "desc": "Familial amyloid polyneuropathy (requires transplantation - polyneuropathy and cardiac amyloidosis development due to the production of a variant transthyretin molecule by the liver)",
                  "conditions": null
                },
                {
                  "desc": "Oxalosis (primary)",
                  "conditions": null
                },
                {
                  "desc": "Acute Diseases",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Fulminant hepatic failure",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Fulminant hepatic failure",
                  "conditions": null
                },
                {
                  "desc": "Mass Occupying Lesions",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Polycystic disease of the liver (requiring transplantation due to the anatomic complications of a hugely enlarged liver)",
                        "conditions": null
                      },
                      {
                        "desc": "Hepatoblastoma confined to the liver",
                        "conditions": null
                      },
                      {
                        "desc": "Primary hepatocellular carcinoma confined to the liver",
                        "conditions": null
                      },
                      {
                        "desc": "Hemangioendothelioma",
                        "conditions": null
                      },
                      {
                        "desc": "Hilar cholangiocarcinoma (CCA) with a cross-sectional diameter 3 cm or less in conjunction with neoadjuvant chemoradiation therapy and the tumor is unresectable or there is underlying liver disease such that the individual is not a candidate for resection",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Polycystic disease of the liver (requiring transplantation due to the anatomic complications of a hugely enlarged liver)",
                  "conditions": null
                },
                {
                  "desc": "Hepatoblastoma confined to the liver",
                  "conditions": null
                },
                {
                  "desc": "Primary hepatocellular carcinoma confined to the liver",
                  "conditions": null
                },
                {
                  "desc": "Hemangioendothelioma",
                  "conditions": null
                },
                {
                  "desc": "Hilar cholangiocarcinoma (CCA) with a cross-sectional diameter 3 cm or less in conjunction with neoadjuvant chemoradiation therapy and the tumor is unresectable or there is underlying liver disease such that the individual is not a candidate for resection",
                  "conditions": null
                },
                {
                  "desc": "Vascular disease",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Budd-Chiari Syndrome",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Budd-Chiari Syndrome",
                  "conditions": null
                },
                {
                  "desc": "Other",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Cryptogenic cirrhosis",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Cryptogenic cirrhosis",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Liver Retransplantation",
            "sub_medical_act": "Graft Failure",
            "necessity_type": "Medically Necessary",
            "description": "Retransplantation in individuals with graft failure of an initial liver transplant, due to either technical reasons or hyperacute rejection is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Liver Retransplantation",
            "sub_medical_act": "Chronic Rejection or Recurrent Disease",
            "necessity_type": "Medically Necessary",
            "description": "Retransplantation in individuals due to either chronic rejection or recurrent disease is considered medically necessary when the individual meets general selection criteria as defined below.",
            "conditions": null
          },
          {
            "medical_act": "Liver Transplant",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Liver transplants in individuals with extrahepatic malignancy, including, but not limited to non-hilar extrahepatic cholangiocarcinoma, intrahepatic cholangiocarcinoma or hepatocellular carcinoma when either condition extends beyond the liver, are considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Liver Transplant",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Liver transplants for all other conditions that do not lead to end-stage organ failure due to irreversible liver damage are considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Xenotransplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Xenotransplantation is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Bioartificial Liver Devices",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Bioartificial liver devices are considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "General Individual Selection Criteria",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "In addition to having end stage liver disease, the member must not have a contraindication as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001) listed below.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Absolute Contraindications",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Metastatic cancer",
                        "conditions": null
                      },
                      {
                        "desc": "Ongoing or recurring infections that are not effectively treated",
                        "conditions": null
                      },
                      {
                        "desc": "Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery",
                        "conditions": null
                      },
                      {
                        "desc": "Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured",
                        "conditions": null
                      },
                      {
                        "desc": "Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations",
                        "conditions": null
                      },
                      {
                        "desc": "Potential complications from immunosuppressive medications are unacceptable to the patient",
                        "conditions": null
                      },
                      {
                        "desc": "Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm3) unless the following are noted:",
                        "conditions": {
                          "ALL": [
                            {
                              "desc": "CD4 count greater than 200 cells/mm3 for greater than 6 months",
                              "conditions": null
                            },
                            {
                              "desc": "HIV-1 RNA undetectable",
                              "conditions": null
                            },
                            {
                              "desc": "On stable anti-retroviral therapy greater than 3 months",
                              "conditions": null
                            },
                            {
                              "desc": "No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)",
                              "conditions": null
                            },
                            {
                              "desc": "Meeting all other criteria for liver transplantation",
                              "conditions": null
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ],
        "usage": {
          "total_tokens": 5765,
          "prompt_tokens": 2945,
          "completion_tokens": 2820,
          "total_cost": 0.057025,
          "processing_time": 60.70245695114136
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a053821.html",
    "subject": "Lung and Lobar Transplantation",
    "document_number": "TRANS.00009",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>Lung or lobar transplantation is considered <strong>medically necessary</strong> for individuals who meet the general individual selection criteria <strong>and</strong> have irreversible, progressively disabling, end-stage pulmonary disease including, but not limited to, one or more of the conditions listed below.</p>\n<li>Restrictive lung disease, examples of which include, but are not limited to:\t<ol>\t\t<li>Idiopathic pulmonary fibrosis (IPF);</li>\t\t<li>Interstitial pulmonary fibrosis;</li>\t\t<li>Scleroderma;</li>\t\t<li>Sarcoidosis;</li>\t\t<li>Extrinsic allergic alveolitis;</li>\t\t<li>Post-chemotherapy disease;</li>\t\t<li>Asbestosis.</li>\t</ol>\t</li>\n<li>Idiopathic pulmonary fibrosis (IPF);</li>\n<li>Interstitial pulmonary fibrosis;</li>\n<li>Scleroderma;</li>\n<li>Sarcoidosis;</li>\n<li>Extrinsic allergic alveolitis;</li>\n<li>Post-chemotherapy disease;</li>\n<li>Asbestosis.</li>\n<li>Chronic lung disease, examples of which include, but are not limited to:\t<ol>\t\t<li>Alpha-1 antitrypsin deficiency;</li>\t\t<li>Eosinophilic granuloma (Langerhans cell histiocytosis or histiocytosis X);</li>\t\t<li>Chronic Obstructive Pulmonary Disease (COPD) (emphysema, chronic bronchitis);</li>\t\t<li>Bronchiolitis obliterans;</li>\t\t<li>Bronchopulmonary dysplasia;</li>\t\t<li>Recurrent pulmonary embolus;</li>\t\t<li>Lymphangiomyomatosis (LAM).</li>\t</ol>\t</li>\n<li>Alpha-1 antitrypsin deficiency;</li>\n<li>Eosinophilic granuloma (Langerhans cell histiocytosis or histiocytosis X);</li>\n<li>Chronic Obstructive Pulmonary Disease (COPD) (emphysema, chronic bronchitis);</li>\n<li>Bronchiolitis obliterans;</li>\n<li>Bronchopulmonary dysplasia;</li>\n<li>Recurrent pulmonary embolus;</li>\n<li>Lymphangiomyomatosis (LAM).</li>\n<li>Pulmonary hypertension, examples of which include, but are not limited to:\t<ol>\t\t<li>Primary pulmonary hypertension;</li>\t\t<li>Pulmonary hypertension due to cardiac diseases and interstitial pulmonary fibrosis;</li>\t\t<li>Eisenmenger's syndrome;</li>\t\t<li>Fibrosing mediastinitis.</li>\t</ol>\t</li>\n<li>Primary pulmonary hypertension;</li>\n<li>Pulmonary hypertension due to cardiac diseases and interstitial pulmonary fibrosis;</li>\n<li>Eisenmenger's syndrome;</li>\n<li>Fibrosing mediastinitis.</li>\n<li>Septic lung disease, examples of which include, but are not limited to:\t<ol>\t\t<li>Cystic fibrosis;</li>\t\t<li>Bronchiectasis.</li>\t</ol>\t</li>\n<li>Cystic fibrosis;</li>\n<li>Bronchiectasis.</li>\n<p><strong>Lung or Lobar Retransplantation</strong></p>\n<p>Retransplantation in individuals with graft failure of an initial lung or lobar transplant, due to either technical reasons or hyperacute rejection is considered <strong>medically necessary.</strong></p>\n<p>Retransplantation in individuals with chronic rejection or recurrent disease is considered <strong>medically necessary</strong> when the individual meets general selection criteria as defined below.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Lobar or lung transplantation in individuals for all other diagnoses is considered <strong>investigational and not medically necessary.</strong></p>\n<p><strong>Note:</strong> For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with a concurrent medical condition which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member's candidacy for transplantation.</p>\n<p><strong>General Individual Selection Criteria</strong></p>\n<p>In addition to having end stage pulmonary disease, the individual must not have a contraindication, as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001)* listed below.</p>\n<p><strong>Absolute Contraindications- for Transplant <em>Recipients </em></strong>include, but are not limited to, the following:</p>\n<li>Metastatic cancer;</li>\n<li>Ongoing or recurring infections that are not effectively treated;</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery;</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured;</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations;</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient;</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm<sup>3</sup>) unless the following are noted:\t<ol>\t\t<li>CD4 count greater than 200 cells/mm\u00b3 for greater than 6 months;</li>\t\t<li>HIV-1 RNA undetectable;</li>\t\t<li>On stable anti-retroviral therapy greater than 3 months;</li>\t\t<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li>\t\t<li>Meeting all other criteria for lung transplantation.</li>\t</ol>\t</li>\n<li>CD4 count greater than 200 cells/mm\u00b3 for greater than 6 months;</li>\n<li>HIV-1 RNA undetectable;</li>\n<li>On stable anti-retroviral therapy greater than 3 months;</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li>\n<li>Meeting all other criteria for lung transplantation.</li>\n<p>* Steinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. 2002; 71(9):1189-1204.</p>",
    "content": "Medically Necessary:\nLung or lobar transplantation is considered medically necessary for individuals who meet the general individual selection criteria and have irreversible, progressively disabling, end-stage pulmonary disease including, but not limited to, one or more of the conditions listed below.\n<li>Restrictive lung disease, examples of which include, but are not limited to:\t<ol> <li>Idiopathic pulmonary fibrosis (IPF);</li> <li>Interstitial pulmonary fibrosis;</li> <li>Scleroderma;</li> <li>Sarcoidosis;</li> <li>Extrinsic allergic alveolitis;</li> <li>Post-chemotherapy disease;</li> <li>Asbestosis.</li> </ol> </li>\n<li>Idiopathic pulmonary fibrosis (IPF);</li>\n<li>Interstitial pulmonary fibrosis;</li>\n<li>Scleroderma;</li>\n<li>Sarcoidosis;</li>\n<li>Extrinsic allergic alveolitis;</li>\n<li>Post-chemotherapy disease;</li>\n<li>Asbestosis.</li>\n<li>Chronic lung disease, examples of which include, but are not limited to:\t<ol> <li>Alpha-1 antitrypsin deficiency;</li> <li>Eosinophilic granuloma (Langerhans cell histiocytosis or histiocytosis X);</li> <li>Chronic Obstructive Pulmonary Disease (COPD) (emphysema, chronic bronchitis);</li> <li>Bronchiolitis obliterans;</li> <li>Bronchopulmonary dysplasia;</li> <li>Recurrent pulmonary embolus;</li> <li>Lymphangiomyomatosis (LAM).</li> </ol> </li>\n<li>Alpha-1 antitrypsin deficiency;</li>\n<li>Eosinophilic granuloma (Langerhans cell histiocytosis or histiocytosis X);</li>\n<li>Chronic Obstructive Pulmonary Disease (COPD) (emphysema, chronic bronchitis);</li>\n<li>Bronchiolitis obliterans;</li>\n<li>Bronchopulmonary dysplasia;</li>\n<li>Recurrent pulmonary embolus;</li>\n<li>Lymphangiomyomatosis (LAM).</li>\n<li>Pulmonary hypertension, examples of which include, but are not limited to:\t<ol> <li>Primary pulmonary hypertension;</li> <li>Pulmonary hypertension due to cardiac diseases and interstitial pulmonary fibrosis;</li> <li>Eisenmenger's syndrome;</li> <li>Fibrosing mediastinitis.</li> </ol> </li>\n<li>Primary pulmonary hypertension;</li>\n<li>Pulmonary hypertension due to cardiac diseases and interstitial pulmonary fibrosis;</li>\n<li>Eisenmenger's syndrome;</li>\n<li>Fibrosing mediastinitis.</li>\n<li>Septic lung disease, examples of which include, but are not limited to:\t<ol> <li>Cystic fibrosis;</li> <li>Bronchiectasis.</li> </ol> </li>\n<li>Cystic fibrosis;</li>\n<li>Bronchiectasis.</li>\nLung or Lobar Retransplantation\nRetransplantation in individuals with graft failure of an initial lung or lobar transplant, due to either technical reasons or hyperacute rejection is considered medically necessary.\nRetransplantation in individuals with chronic rejection or recurrent disease is considered medically necessary when the individual meets general selection criteria as defined below.\nInvestigational and Not Medically Necessary:\nLobar or lung transplantation in individuals for all other diagnoses is considered investigational and not medically necessary.\nNote: For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with a concurrent medical condition which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member's candidacy for transplantation.\nGeneral Individual Selection Criteria\nIn addition to having end stage pulmonary disease, the individual must not have a contraindication, as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001)* listed below.\nAbsolute Contraindications- for Transplant Recipients include, but are not limited to, the following:\n<li>Metastatic cancer;</li>\n<li>Ongoing or recurring infections that are not effectively treated;</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery;</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured;</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations;</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient;</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm<sup>3</sup>) unless the following are noted:\t<ol> <li>CD4 count greater than 200 cells/mm\u00b3 for greater than 6 months;</li> <li>HIV-1 RNA undetectable;</li> <li>On stable anti-retroviral therapy greater than 3 months;</li> <li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li> <li>Meeting all other criteria for lung transplantation.</li> </ol> </li>\n<li>CD4 count greater than 200 cells/mm\u00b3 for greater than 6 months;</li>\n<li>HIV-1 RNA undetectable;</li>\n<li>On stable anti-retroviral therapy greater than 3 months;</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm);</li>\n<li>Meeting all other criteria for lung transplantation.</li>\n* Steinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. 2002; 71(9):1189-1204.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Lung or lobar transplantation",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Lung or lobar transplantation is considered medically necessary for individuals who meet the general individual selection criteria and have irreversible, progressively disabling, end-stage pulmonary disease including, but not limited to, one or more of the conditions listed below.",
            "conditions": {
              "ANY": [
                {
                  "desc": "Restrictive lung disease",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Idiopathic pulmonary fibrosis (IPF)",
                        "conditions": null
                      },
                      {
                        "desc": "Interstitial pulmonary fibrosis",
                        "conditions": null
                      },
                      {
                        "desc": "Scleroderma",
                        "conditions": null
                      },
                      {
                        "desc": "Sarcoidosis",
                        "conditions": null
                      },
                      {
                        "desc": "Extrinsic allergic alveolitis",
                        "conditions": null
                      },
                      {
                        "desc": "Post-chemotherapy disease",
                        "conditions": null
                      },
                      {
                        "desc": "Asbestosis",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Idiopathic pulmonary fibrosis (IPF)",
                  "conditions": null
                },
                {
                  "desc": "Interstitial pulmonary fibrosis",
                  "conditions": null
                },
                {
                  "desc": "Scleroderma",
                  "conditions": null
                },
                {
                  "desc": "Sarcoidosis",
                  "conditions": null
                },
                {
                  "desc": "Extrinsic allergic alveolitis",
                  "conditions": null
                },
                {
                  "desc": "Post-chemotherapy disease",
                  "conditions": null
                },
                {
                  "desc": "Asbestosis",
                  "conditions": null
                },
                {
                  "desc": "Chronic lung disease",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Alpha-1 antitrypsin deficiency",
                        "conditions": null
                      },
                      {
                        "desc": "Eosinophilic granuloma (Langerhans cell histiocytosis or histiocytosis X)",
                        "conditions": null
                      },
                      {
                        "desc": "Chronic Obstructive Pulmonary Disease (COPD) (emphysema, chronic bronchitis)",
                        "conditions": null
                      },
                      {
                        "desc": "Bronchiolitis obliterans",
                        "conditions": null
                      },
                      {
                        "desc": "Bronchopulmonary dysplasia",
                        "conditions": null
                      },
                      {
                        "desc": "Recurrent pulmonary embolus",
                        "conditions": null
                      },
                      {
                        "desc": "Lymphangiomyomatosis (LAM)",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Alpha-1 antitrypsin deficiency",
                  "conditions": null
                },
                {
                  "desc": "Eosinophilic granuloma (Langerhans cell histiocytosis or histiocytosis X)",
                  "conditions": null
                },
                {
                  "desc": "Chronic Obstructive Pulmonary Disease (COPD) (emphysema, chronic bronchitis)",
                  "conditions": null
                },
                {
                  "desc": "Bronchiolitis obliterans",
                  "conditions": null
                },
                {
                  "desc": "Bronchopulmonary dysplasia",
                  "conditions": null
                },
                {
                  "desc": "Recurrent pulmonary embolus",
                  "conditions": null
                },
                {
                  "desc": "Lymphangiomyomatosis (LAM)",
                  "conditions": null
                },
                {
                  "desc": "Pulmonary hypertension",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Primary pulmonary hypertension",
                        "conditions": null
                      },
                      {
                        "desc": "Pulmonary hypertension due to cardiac diseases and interstitial pulmonary fibrosis",
                        "conditions": null
                      },
                      {
                        "desc": "Eisenmenger's syndrome",
                        "conditions": null
                      },
                      {
                        "desc": "Fibrosing mediastinitis",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Primary pulmonary hypertension",
                  "conditions": null
                },
                {
                  "desc": "Pulmonary hypertension due to cardiac diseases and interstitial pulmonary fibrosis",
                  "conditions": null
                },
                {
                  "desc": "Eisenmenger's syndrome",
                  "conditions": null
                },
                {
                  "desc": "Fibrosing mediastinitis",
                  "conditions": null
                },
                {
                  "desc": "Septic lung disease",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Cystic fibrosis",
                        "conditions": null
                      },
                      {
                        "desc": "Bronchiectasis",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Cystic fibrosis",
                  "conditions": null
                },
                {
                  "desc": "Bronchiectasis",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Lung or Lobar Retransplantation",
            "sub_medical_act": "Graft failure",
            "necessity_type": "Medically Necessary",
            "description": "Retransplantation in individuals with graft failure of an initial lung or lobar transplant, due to either technical reasons or hyperacute rejection is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Lung or Lobar Retransplantation",
            "sub_medical_act": "Chronic rejection or recurrent disease",
            "necessity_type": "Medically Necessary",
            "description": "Retransplantation in individuals with chronic rejection or recurrent disease is considered medically necessary when the individual meets general selection criteria as defined below.",
            "conditions": null
          },
          {
            "medical_act": "Lobar or lung transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Lobar or lung transplantation in individuals for all other diagnoses is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "General Individual Selection Criteria",
            "sub_medical_act": null,
            "necessity_type": "Absolute Contraindications",
            "description": "In addition to having end stage pulmonary disease, the individual must not have a contraindication, as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001)* listed below.",
            "conditions": {
              "ANY": [
                {
                  "desc": "Metastatic cancer",
                  "conditions": null
                },
                {
                  "desc": "Ongoing or recurring infections that are not effectively treated",
                  "conditions": null
                },
                {
                  "desc": "Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery",
                  "conditions": null
                },
                {
                  "desc": "Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured",
                  "conditions": null
                },
                {
                  "desc": "Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations",
                  "conditions": null
                },
                {
                  "desc": "Potential complications from immunosuppressive medications are unacceptable to the patient",
                  "conditions": null
                },
                {
                  "desc": "Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention [CDC] definition of CD4 count, 200 cells/mm\u00b3) unless the following are noted:",
                  "conditions": {
                    "ALL": [
                      {
                        "desc": "CD4 count greater than 200 cells/mm\u00b3 for greater than 6 months",
                        "conditions": null
                      },
                      {
                        "desc": "HIV-1 RNA undetectable",
                        "conditions": null
                      },
                      {
                        "desc": "On stable anti-retroviral therapy greater than 3 months",
                        "conditions": null
                      },
                      {
                        "desc": "No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)",
                        "conditions": null
                      },
                      {
                        "desc": "Meeting all other criteria for lung transplantation",
                        "conditions": null
                      }
                    ]
                  }
                }
              ]
            }
          }
        ],
        "usage": {
          "total_tokens": 3874,
          "prompt_tokens": 2174,
          "completion_tokens": 1700,
          "total_cost": 0.03637,
          "processing_time": 26.936880111694336
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a053824.html",
    "subject": "Small Bowel, Small Bowel/Liver and Multivisceral Transplantation",
    "document_number": "TRANS.00013",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p style=\"text-align:justify\"><strong>Medically Necessary:</strong></p>\n<p>A small bowel transplant using cadaveric intestine is considered <strong>medically necessary </strong>for adults and children with short bowel syndrome or irreversible intestinal failure who have failed total parenteral nutrition (TPN) <strong>and</strong> meet the general individual selection criteria listed below.</p>\n<p style=\"text-align:justify\">TPN failure is defined when any <strong>one</strong> of the following is met:</p>\n<li>Impending or overt liver failure due to TPN induced liver injury. (Clinical indicators include: increased serum bilirubin or liver enzyme levels, splenomegaly, thrombocytopenia, gastroesophageal varices, coagulopathy, stomal bleeding, hepatic fibrosis, or cirrhosis); <strong>or</strong></li>\n<li>Thrombosis of two or more major central venous channels (subclavian, jugular, or femoral veins). Thrombosis of two or more of these vessels is considered a life-threatening complication and TPN failure; <strong>or</strong></li>\n<li>Frequent central line-related sepsis. Two or more episodes of line-induced systemic sepsis per year that require hospitalization are considered TPN failure. A single episode of line-related fungemia, septic shock, or acute respiratory distress syndrome is considered TPN failure; <strong>or </strong></li>\n<li>Frequent episodes of severe dehydration despite TPN and intravenous fluid supplement. Under certain medical conditions such as secretory diarrhea and non-constructable gastrointestinal tract, the loss of combined gastrointestinal and pancreatobiliary secretions exceed the maximum intravenous infusion rates that can be tolerated by the cardiopulmonary system.</li>\n<p>A small bowel transplant using a living donor may be considered <strong>medically necessary</strong> only when a cadaveric intestine is not available for transplantation in an individual who meets the criteria noted above for a cadaveric intestinal transplant.</p>\n<p>Combined small bowel/liver transplants from deceased donors are considered <strong>medically necessary</strong> for adults and children who meet criteria for intestinal transplant <strong>and</strong> have overt or imminent liver failure or anatomical abnormalities which preclude an isolated small bowel transplant.</p>\n<p>Multivisceral transplants from deceased donors are considered <strong>medically necessary</strong> for adults and children who meet criteria for the combined small bowel/liver transplant <strong>and</strong> require one or more abdominal visceral organs to be transplanted due to concomitant organ failure or anatomical abnormalities which preclude a small bowel/liver transplant.</p>\n<p>Retransplantation in individuals with graft failure of an initial small bowel, small bowel/liver, or multivisceral transplant, due to either technical reasons or hyperacute rejection is considered <strong>medically necessary.</strong></p>\n<p>Retransplantation in individuals with chronic rejection or recurrent disease is considered <strong>medically necessary</strong> when the individual meets general selection criteria as defined below.</p>\n<p style=\"text-align:justify\"><strong>Not Medically Necessary:</strong></p>\n<p>A small bowel transplant in adults or children is considered <strong>not medically necessary </strong>for those who can tolerate TPN.</p>\n<p>A small bowel transplant using a living donor in adults or children is considered <strong>not medically necessary</strong> when a cadaveric intestine is available for transplantation.</p>\n<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>All other indications for small bowel or multivisceral transplants in adults or children, including but not limited to treatment of pseudotumor peritonei, are considered <strong>investigational and not medically necessary.</strong></p>\n<p>Living donor multivisceral transplants in adults or children are considered <strong>investigational and not medically necessary.</strong></p>\n<p><strong>General Individual Selection Criteria</strong></p>\n<p>In addition to having one of the clinical indications above, the individual must not have a contraindication as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001) listed below.</p>\n<p style=\"text-align:justify\"><strong>Absolute Contraindications for Transplant <em>Recipients</em></strong> include, but are not limited to, the following:</p>\n<li>Metastatic cancer</li>\n<li>Ongoing or recurring infections that are not effectively treated</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention (CDC) definition of CD4 count, 200cells/mm<sup>3</sup>) unless the following are noted:\t<ol>\t\t<li>CD4 count greater than 200cells/mm<sup>3</sup> for greater than 6 months</li>\t\t<li>HIV-1 RNA undetectable</li>\t\t<li>On stable anti-retroviral therapy greater than 3 months</li>\t\t<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioide-mycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li>\t\t<li>Meeting all other criteria for small bowel or multivisceral transplantation</li>\t</ol>\t</li>\n<li>CD4 count greater than 200cells/mm<sup>3</sup> for greater than 6 months</li>\n<li>HIV-1 RNA undetectable</li>\n<li>On stable anti-retroviral therapy greater than 3 months</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioide-mycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li>\n<li>Meeting all other criteria for small bowel or multivisceral transplantation</li>\n<p>Steinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. Vol. 71, 1189-1204, No. 9, May 15, 2001.</p>",
    "content": "Medically Necessary:\nA small bowel transplant using cadaveric intestine is considered medically necessary for adults and children with short bowel syndrome or irreversible intestinal failure who have failed total parenteral nutrition (TPN) and meet the general individual selection criteria listed below.\nTPN failure is defined when any one of the following is met:\n<li>Impending or overt liver failure due to TPN induced liver injury. (Clinical indicators include: increased serum bilirubin or liver enzyme levels, splenomegaly, thrombocytopenia, gastroesophageal varices, coagulopathy, stomal bleeding, hepatic fibrosis, or cirrhosis); or</li>\n<li>Thrombosis of two or more major central venous channels (subclavian, jugular, or femoral veins). Thrombosis of two or more of these vessels is considered a life-threatening complication and TPN failure; or</li>\n<li>Frequent central line-related sepsis. Two or more episodes of line-induced systemic sepsis per year that require hospitalization are considered TPN failure. A single episode of line-related fungemia, septic shock, or acute respiratory distress syndrome is considered TPN failure; or </li>\n<li>Frequent episodes of severe dehydration despite TPN and intravenous fluid supplement. Under certain medical conditions such as secretory diarrhea and non-constructable gastrointestinal tract, the loss of combined gastrointestinal and pancreatobiliary secretions exceed the maximum intravenous infusion rates that can be tolerated by the cardiopulmonary system.</li>\nA small bowel transplant using a living donor may be considered medically necessary only when a cadaveric intestine is not available for transplantation in an individual who meets the criteria noted above for a cadaveric intestinal transplant.\nCombined small bowel/liver transplants from deceased donors are considered medically necessary for adults and children who meet criteria for intestinal transplant and have overt or imminent liver failure or anatomical abnormalities which preclude an isolated small bowel transplant.\nMultivisceral transplants from deceased donors are considered medically necessary for adults and children who meet criteria for the combined small bowel/liver transplant and require one or more abdominal visceral organs to be transplanted due to concomitant organ failure or anatomical abnormalities which preclude a small bowel/liver transplant.\nRetransplantation in individuals with graft failure of an initial small bowel, small bowel/liver, or multivisceral transplant, due to either technical reasons or hyperacute rejection is considered medically necessary.\nRetransplantation in individuals with chronic rejection or recurrent disease is considered medically necessary when the individual meets general selection criteria as defined below.\nNot Medically Necessary:\nA small bowel transplant in adults or children is considered not medically necessary for those who can tolerate TPN.\nA small bowel transplant using a living donor in adults or children is considered not medically necessary when a cadaveric intestine is available for transplantation.\nInvestigational and Not Medically Necessary:\nAll other indications for small bowel or multivisceral transplants in adults or children, including but not limited to treatment of pseudotumor peritonei, are considered investigational and not medically necessary.\nLiving donor multivisceral transplants in adults or children are considered investigational and not medically necessary.\nGeneral Individual Selection Criteria\nIn addition to having one of the clinical indications above, the individual must not have a contraindication as defined by the American Society of Transplantation in Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation (2001) listed below.\nAbsolute Contraindications for Transplant Recipients include, but are not limited to, the following:\n<li>Metastatic cancer</li>\n<li>Ongoing or recurring infections that are not effectively treated</li>\n<li>Serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery</li>\n<li>Serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured</li>\n<li>Demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations</li>\n<li>Potential complications from immunosuppressive medications are unacceptable to the patient</li>\n<li>Acquired immune deficiency syndrome (AIDS) (diagnosis based on Centers for Disease Control and Prevention (CDC) definition of CD4 count, 200cells/mm<sup>3</sup>) unless the following are noted:\t<ol> <li>CD4 count greater than 200cells/mm<sup>3</sup> for greater than 6 months</li> <li>HIV-1 RNA undetectable</li> <li>On stable anti-retroviral therapy greater than 3 months</li> <li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioide-mycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li> <li>Meeting all other criteria for small bowel or multivisceral transplantation</li> </ol> </li>\n<li>CD4 count greater than 200cells/mm<sup>3</sup> for greater than 6 months</li>\n<li>HIV-1 RNA undetectable</li>\n<li>On stable anti-retroviral therapy greater than 3 months</li>\n<li>No other complications from AIDS (for example, opportunistic infection, including aspergillus, tuberculosis, coccidioide-mycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)</li>\n<li>Meeting all other criteria for small bowel or multivisceral transplantation</li>\nSteinman, Theodore, et al. Guidelines for the Referral and Management of Patients Eligible for Solid Organ Transplantation. Transplantation. Vol. 71, 1189-1204, No. 9, May 15, 2001.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Small Bowel Transplant using Cadaveric Intestine",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A small bowel transplant using cadaveric intestine is considered medically necessary for adults and children with short bowel syndrome or irreversible intestinal failure who have failed total parenteral nutrition (TPN) and meet the general individual selection criteria listed below.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Short bowel syndrome or irreversible intestinal failure",
                  "conditions": null
                },
                {
                  "desc": "Failed total parenteral nutrition (TPN)",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Impending or overt liver failure due to TPN induced liver injury",
                        "conditions": null
                      },
                      {
                        "desc": "Thrombosis of two or more major central venous channels (subclavian, jugular, or femoral veins)",
                        "conditions": null
                      },
                      {
                        "desc": "Frequent central line-related sepsis",
                        "conditions": null
                      },
                      {
                        "desc": "Frequent episodes of severe dehydration despite TPN and intravenous fluid supplement",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Meet the general individual selection criteria",
                  "conditions": {
                    "ALL": [
                      {
                        "desc": "No metastatic cancer",
                        "conditions": null
                      },
                      {
                        "desc": "No ongoing or recurring infections that are not effectively treated",
                        "conditions": null
                      },
                      {
                        "desc": "No serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery",
                        "conditions": null
                      },
                      {
                        "desc": "No serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured",
                        "conditions": null
                      },
                      {
                        "desc": "No demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations",
                        "conditions": null
                      },
                      {
                        "desc": "No potential complications from immunosuppressive medications are unacceptable to the patient",
                        "conditions": null
                      },
                      {
                        "desc": "No acquired immune deficiency syndrome (AIDS) unless the following are noted",
                        "conditions": {
                          "ALL": [
                            {
                              "desc": "CD4 count greater than 200cells/mm\u00b3 for greater than 6 months",
                              "conditions": null
                            },
                            {
                              "desc": "HIV-1 RNA undetectable",
                              "conditions": null
                            },
                            {
                              "desc": "On stable anti-retroviral therapy greater than 3 months",
                              "conditions": null
                            },
                            {
                              "desc": "No other complications from AIDS (e.g., opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)",
                              "conditions": null
                            },
                            {
                              "desc": "Meeting all other criteria for small bowel or multivisceral transplantation",
                              "conditions": null
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Small Bowel Transplant using Living Donor",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A small bowel transplant using a living donor may be considered medically necessary only when a cadaveric intestine is not available for transplantation in an individual who meets the criteria noted above for a cadaveric intestinal transplant.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Cadaveric intestine is not available for transplantation",
                  "conditions": null
                },
                {
                  "desc": "Meets the criteria noted above for a cadaveric intestinal transplant",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Combined Small Bowel/Liver Transplants from Deceased Donors",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Combined small bowel/liver transplants from deceased donors are considered medically necessary for adults and children who meet criteria for intestinal transplant and have overt or imminent liver failure or anatomical abnormalities which preclude an isolated small bowel transplant.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Meets criteria for intestinal transplant",
                  "conditions": null
                },
                {
                  "desc": "Overt or imminent liver failure or anatomical abnormalities which preclude an isolated small bowel transplant",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Multivisceral Transplants from Deceased Donors",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Multivisceral transplants from deceased donors are considered medically necessary for adults and children who meet criteria for the combined small bowel/liver transplant and require one or more abdominal visceral organs to be transplanted due to concomitant organ failure or anatomical abnormalities which preclude a small bowel/liver transplant.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Meets criteria for the combined small bowel/liver transplant",
                  "conditions": null
                },
                {
                  "desc": "Require one or more abdominal visceral organs to be transplanted due to concomitant organ failure or anatomical abnormalities which preclude a small bowel/liver transplant",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Retransplantation in Individuals with Graft Failure",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Retransplantation in individuals with graft failure of an initial small bowel, small bowel/liver, or multivisceral transplant, due to either technical reasons or hyperacute rejection is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Retransplantation in Individuals with Chronic Rejection or Recurrent Disease",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Retransplantation in individuals with chronic rejection or recurrent disease is considered medically necessary when the individual meets general selection criteria as defined below.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Meets general selection criteria",
                  "conditions": {
                    "ALL": [
                      {
                        "desc": "No metastatic cancer",
                        "conditions": null
                      },
                      {
                        "desc": "No ongoing or recurring infections that are not effectively treated",
                        "conditions": null
                      },
                      {
                        "desc": "No serious cardiac or other ongoing insufficiencies that create an inability to tolerate transplant surgery",
                        "conditions": null
                      },
                      {
                        "desc": "No serious conditions that are unlikely to be improved by transplantation as life expectancy can be finitely measured",
                        "conditions": null
                      },
                      {
                        "desc": "No demonstrated patient noncompliance, which places the organ at risk by not adhering to medical recommendations",
                        "conditions": null
                      },
                      {
                        "desc": "No potential complications from immunosuppressive medications are unacceptable to the patient",
                        "conditions": null
                      },
                      {
                        "desc": "No acquired immune deficiency syndrome (AIDS) unless the following are noted",
                        "conditions": {
                          "ALL": [
                            {
                              "desc": "CD4 count greater than 200cells/mm\u00b3 for greater than 6 months",
                              "conditions": null
                            },
                            {
                              "desc": "HIV-1 RNA undetectable",
                              "conditions": null
                            },
                            {
                              "desc": "On stable anti-retroviral therapy greater than 3 months",
                              "conditions": null
                            },
                            {
                              "desc": "No other complications from AIDS (e.g., opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis, resistant fungal infections, Kaposi\u2019s sarcoma or other neoplasm)",
                              "conditions": null
                            },
                            {
                              "desc": "Meeting all other criteria for small bowel or multivisceral transplantation",
                              "conditions": null
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Small Bowel Transplant in Adults or Children",
            "sub_medical_act": null,
            "necessity_type": "Not Medically Necessary",
            "description": "A small bowel transplant in adults or children is considered not medically necessary for those who can tolerate TPN.",
            "conditions": null
          },
          {
            "medical_act": "Small Bowel Transplant using a Living Donor in Adults or Children",
            "sub_medical_act": null,
            "necessity_type": "Not Medically Necessary",
            "description": "A small bowel transplant using a living donor in adults or children is considered not medically necessary when a cadaveric intestine is available for transplantation.",
            "conditions": null
          },
          {
            "medical_act": "Small Bowel or Multivisceral Transplants in Adults or Children",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "All other indications for small bowel or multivisceral transplants in adults or children, including but not limited to treatment of pseudotumor peritonei, are considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Living Donor Multivisceral Transplants in Adults or Children",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Living donor multivisceral transplants in adults or children are considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 4157,
          "prompt_tokens": 2004,
          "completion_tokens": 2153,
          "total_cost": 0.042315,
          "processing_time": 40.22065091133118
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a047560.html",
    "subject": "Hematopoietic Stem Cell Transplantation for Genetic Diseases and Aplastic Anemias",
    "document_number": "TRANS.00029",
    "publish_date": "01/03/2024",
    "status": "Reviewed",
    "last_review_date": "11/09/2023",
    "html_content": "<p><strong>Medically Necessary: </strong></p>\n<p><em>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation</em> is considered<strong> medically necessary </strong>for individuals with the following disorders. In addition, individuals with Aplastic Anemia, Sickle Cell Disease or Thalassemia should meet the Disease Specific Criteria below.</p>\n<li>Bone Marrow Failure Syndromes\t<ol>\t\t<li>Acquired aplastic anemia (drug, idiopathic, immune disorder, toxin or viral infection)</li>\t\t<li>Heritable bone marrow syndromes:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Congenital amegakaryocytic thrombocytopenia (CAMT)</li>\t\t\t<li>Diamond-Blackfan anemia (DBA)</li>\t\t\t<li>Dyskeratosis congenita</li>\t\t\t<li>Fanconi\u2019s anemia (FA)</li>\t\t\t<li>Schwachman-Diamond syndrome (SDS)</li>\t\t</ol>\t\t</li>\t\t<li>Paroxysmal nocturnal hemoglobinuria (PNH)</li>\t</ol>\t</li>\n<li>Acquired aplastic anemia (drug, idiopathic, immune disorder, toxin or viral infection)</li>\n<li>Heritable bone marrow syndromes:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Congenital amegakaryocytic thrombocytopenia (CAMT)</li>\t\t\t<li>Diamond-Blackfan anemia (DBA)</li>\t\t\t<li>Dyskeratosis congenita</li>\t\t\t<li>Fanconi\u2019s anemia (FA)</li>\t\t\t<li>Schwachman-Diamond syndrome (SDS)</li>\t\t</ol>\t\t</li>\n<li>Congenital amegakaryocytic thrombocytopenia (CAMT)</li>\n<li>Diamond-Blackfan anemia (DBA)</li>\n<li>Dyskeratosis congenita</li>\n<li>Fanconi\u2019s anemia (FA)</li>\n<li>Schwachman-Diamond syndrome (SDS)</li>\n<li>Paroxysmal nocturnal hemoglobinuria (PNH)</li>\n<li>Immunodeficiencies\t<ol>\t\t<li>Hemophagocytic Lymphohistiocytosis (HLH)</li>\t\t<li>Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome</li>\t\t<li>Severe Combined Immunodeficiency (SCID)</li>\t\t<li>Wiskott-Aldrich Syndrome (WAS)</li>\t\t<li>X-linked lymphoproliferative syndrome</li>\t\t<li>Chediak-Higashi syndrome</li>\t\t<li>Primary granulocyte dysfunction</li>\t\t<li>Chronic granulomatous disease</li>\t</ol>\t</li>\n<li>Hemophagocytic Lymphohistiocytosis (HLH)</li>\n<li>Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome</li>\n<li>Severe Combined Immunodeficiency (SCID)</li>\n<li>Wiskott-Aldrich Syndrome (WAS)</li>\n<li>X-linked lymphoproliferative syndrome</li>\n<li>Chediak-Higashi syndrome</li>\n<li>Primary granulocyte dysfunction</li>\n<li>Chronic granulomatous disease</li>\n<li>Storage disorders\t<ol>\t\t<li>Hurler Syndrome (MPS I)</li>\t\t<li>Hunter Syndrome (MPS II)</li>\t\t<li>Maroteaux-Lamy Syndrome (MPS VI)</li>\t\t<li>SanFilippo\u2019s (MPS III)</li>\t\t<li>Gaucher disease</li>\t</ol>\t</li>\n<li>Hurler Syndrome (MPS I)</li>\n<li>Hunter Syndrome (MPS II)</li>\n<li>Maroteaux-Lamy Syndrome (MPS VI)</li>\n<li>SanFilippo\u2019s (MPS III)</li>\n<li>Gaucher disease</li>\n<li>Leukodystrophies\t<ol>\t\t<li>Adrenoleukodystrophy (ALD)</li>\t\t<li>Globoid Cell Leukodystrophy (GBL; Krabbe's disease)</li>\t\t<li>Metachromatic Leukodystrophy (MLD)</li>\t</ol>\t</li>\n<li>Adrenoleukodystrophy (ALD)</li>\n<li>Globoid Cell Leukodystrophy (GBL; Krabbe's disease)</li>\n<li>Metachromatic Leukodystrophy (MLD)</li>\n<li>Hemoglobinopathies\t<ol>\t\t<li>Sickle Cell Disease</li>\t\t<li>Thalassemia (homozygous beta-thalassemia)</li>\t</ol>\t</li>\n<li>Sickle Cell Disease</li>\n<li>Thalassemia (homozygous beta-thalassemia)</li>\n<li>Infantile malignant osteopetrosis (Albers-Schonberg disease or marble bone disease)</li>\n<li>Other autosomal recessive disorders\t<ol>\t\t<li>Leukocyte adhesion deficiencies</li>\t\t<li>Kostmann\u2019s syndrome (severe congenital neutropenia, infantile genetic agranulocytosis)</li>\t</ol>\t</li>\n<li>Leukocyte adhesion deficiencies</li>\n<li>Kostmann\u2019s syndrome (severe congenital neutropenia, infantile genetic agranulocytosis)</li>\n<p><em>A repeat allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation </em>due to primary graft failure or failure to engraft is considered <strong>medically necessary.</strong></p>\n<p><em>Autologous hematopoietic stem cell mobilization and pheresis </em>is considered <strong>medically necessary </strong>for the treatment of a genetic disease as part of the development of an FDA-approved ex vivo gene therapy (for example, betibeglogene autotemcel or elivaldogene autotemcel).</p>\n<p style=\"text-align:justify\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<p><em>Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary </strong>for the treatment of all genetic diseases not listed above including, but not limited to cystic fibrosis, and all acquired anemias not specifically identified above as medically necessary.</p>\n<p><em>Autologous hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary </strong>for the treatment of all genetic diseases including, but not limited to cystic fibrosis, and all acquired anemias.</p>\n<p><em>A planned tandem allogeneic hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation</em> is considered <strong>investigational and not medically necessary </strong>for all genetic diseases and for all acquired anemias.</p>\n<p class=\"MsoBodyTextIndent3\"><em>A second or repeat allogeneic (ablative or non-myeloablative) </em><em>hematopoietic stem cell transplant </em>due to persistent, progressive or<em> </em>relapsed disease is considered<strong> investigational and not medically necessary.</strong></p>\n<p><em>Hematopoietic stem cell harvesting for a future but unscheduled transplant</em> is considered <strong>investigational and not medically necessary.</strong></p>\n<p><em>Autologous hematopoietic stem cell mobilization and pheresis </em>is considered <strong>investigational and</strong> <strong>not medically necessary </strong>for the treatment of a genetic disease when the medically necessary criteria above are not met.</p>\n<p align=\"center\" style=\"text-align:center\"><strong><u>Disease Specific Criteria</u></strong></p>\n<p style=\"margin-right:-64px; text-align:justify\"><strong><em>Aplastic Anemia Criteria:</em></strong></p>\n<ul>\t<li>One of the following:\t<ul>\t\t<li>55 years of age or younger do not need to have failed immunosuppressive therapy</li>\t\t<li>Older than 55 years of age, or non-HLA identical donor, have to have failed immunosuppressive therapy</li>\t</ul>\t</li></ul>\n<li>One of the following:\t<ul>\t\t<li>55 years of age or younger do not need to have failed immunosuppressive therapy</li>\t\t<li>Older than 55 years of age, or non-HLA identical donor, have to have failed immunosuppressive therapy</li>\t</ul>\t</li>\n<ul>\t\t<li>55 years of age or younger do not need to have failed immunosuppressive therapy</li>\t\t<li>Older than 55 years of age, or non-HLA identical donor, have to have failed immunosuppressive therapy</li>\t</ul>\n<li>55 years of age or younger do not need to have failed immunosuppressive therapy</li>\n<li>Older than 55 years of age, or non-HLA identical donor, have to have failed immunosuppressive therapy</li>\n<p style=\"margin-right:-64px\"><strong><em>Sickle Cell Criteria:</em></strong></p>\n<ul>\t<li>Children less than 16 years of age with homozygous SS disease or S-B thalassemia and who have had at least one of the following complications:\t<ul style=\"list-style-type:circle\">\t\t<li>Stroke or CNS hemorrhage</li>\t\t<li>Clinical evidence of progressive neurologic deterioration, for example, abnormal cerebral MRI and arteriogram and impaired neuropsychiatric testing</li>\t\t<li>Sickle cell lung disease, recurrent acute chest syndrome or a combination of both requiring hospitalization and exchange transfusions</li>\t\t<li>Sickle cell nephropathy</li>\t</ul>\t</li></ul>\n<li>Children less than 16 years of age with homozygous SS disease or S-B thalassemia and who have had at least one of the following complications:\t<ul style=\"list-style-type:circle\">\t\t<li>Stroke or CNS hemorrhage</li>\t\t<li>Clinical evidence of progressive neurologic deterioration, for example, abnormal cerebral MRI and arteriogram and impaired neuropsychiatric testing</li>\t\t<li>Sickle cell lung disease, recurrent acute chest syndrome or a combination of both requiring hospitalization and exchange transfusions</li>\t\t<li>Sickle cell nephropathy</li>\t</ul>\t</li>\n<ul style=\"list-style-type:circle\">\t\t<li>Stroke or CNS hemorrhage</li>\t\t<li>Clinical evidence of progressive neurologic deterioration, for example, abnormal cerebral MRI and arteriogram and impaired neuropsychiatric testing</li>\t\t<li>Sickle cell lung disease, recurrent acute chest syndrome or a combination of both requiring hospitalization and exchange transfusions</li>\t\t<li>Sickle cell nephropathy</li>\t</ul>\n<li>Stroke or CNS hemorrhage</li>\n<li>Clinical evidence of progressive neurologic deterioration, for example, abnormal cerebral MRI and arteriogram and impaired neuropsychiatric testing</li>\n<li>Sickle cell lung disease, recurrent acute chest syndrome or a combination of both requiring hospitalization and exchange transfusions</li>\n<li>Sickle cell nephropathy</li>\n<p style=\"margin-right:-64px\"><strong><em>Thalassemia Criteria:</em></strong></p>\n<ul>\t<li>Thalassemia major only <strong>and</strong></li>\t<li>Individuals less than or equal to 30 years of age <strong>and</strong></li>\t<li>The presence of minimal or no portal fibrous or active hepatitis</li></ul>\n<li>Thalassemia major only <strong>and</strong></li>\n<li>Individuals less than or equal to 30 years of age <strong>and</strong></li>\n<li>The presence of minimal or no portal fibrous or active hepatitis</li>",
    "content": "Medically Necessary: \nAllogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation is considered medically necessary for individuals with the following disorders. In addition, individuals with Aplastic Anemia, Sickle Cell Disease or Thalassemia should meet the Disease Specific Criteria below.\n<li>Bone Marrow Failure Syndromes\t<ol> <li>Acquired aplastic anemia (drug, idiopathic, immune disorder, toxin or viral infection)</li> <li>Heritable bone marrow syndromes:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Congenital amegakaryocytic thrombocytopenia (CAMT)</li> <li>Diamond-Blackfan anemia (DBA)</li> <li>Dyskeratosis congenita</li> <li>Fanconi\u2019s anemia (FA)</li> <li>Schwachman-Diamond syndrome (SDS)</li> </ol> </li> <li>Paroxysmal nocturnal hemoglobinuria (PNH)</li> </ol> </li>\n<li>Acquired aplastic anemia (drug, idiopathic, immune disorder, toxin or viral infection)</li>\n<li>Heritable bone marrow syndromes:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Congenital amegakaryocytic thrombocytopenia (CAMT)</li> <li>Diamond-Blackfan anemia (DBA)</li> <li>Dyskeratosis congenita</li> <li>Fanconi\u2019s anemia (FA)</li> <li>Schwachman-Diamond syndrome (SDS)</li> </ol> </li>\n<li>Congenital amegakaryocytic thrombocytopenia (CAMT)</li>\n<li>Diamond-Blackfan anemia (DBA)</li>\n<li>Dyskeratosis congenita</li>\n<li>Fanconi\u2019s anemia (FA)</li>\n<li>Schwachman-Diamond syndrome (SDS)</li>\n<li>Paroxysmal nocturnal hemoglobinuria (PNH)</li>\n<li>Immunodeficiencies\t<ol> <li>Hemophagocytic Lymphohistiocytosis (HLH)</li> <li>Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome</li> <li>Severe Combined Immunodeficiency (SCID)</li> <li>Wiskott-Aldrich Syndrome (WAS)</li> <li>X-linked lymphoproliferative syndrome</li> <li>Chediak-Higashi syndrome</li> <li>Primary granulocyte dysfunction</li> <li>Chronic granulomatous disease</li> </ol> </li>\n<li>Hemophagocytic Lymphohistiocytosis (HLH)</li>\n<li>Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome</li>\n<li>Severe Combined Immunodeficiency (SCID)</li>\n<li>Wiskott-Aldrich Syndrome (WAS)</li>\n<li>X-linked lymphoproliferative syndrome</li>\n<li>Chediak-Higashi syndrome</li>\n<li>Primary granulocyte dysfunction</li>\n<li>Chronic granulomatous disease</li>\n<li>Storage disorders\t<ol> <li>Hurler Syndrome (MPS I)</li> <li>Hunter Syndrome (MPS II)</li> <li>Maroteaux-Lamy Syndrome (MPS VI)</li> <li>SanFilippo\u2019s (MPS III)</li> <li>Gaucher disease</li> </ol> </li>\n<li>Hurler Syndrome (MPS I)</li>\n<li>Hunter Syndrome (MPS II)</li>\n<li>Maroteaux-Lamy Syndrome (MPS VI)</li>\n<li>SanFilippo\u2019s (MPS III)</li>\n<li>Gaucher disease</li>\n<li>Leukodystrophies\t<ol> <li>Adrenoleukodystrophy (ALD)</li> <li>Globoid Cell Leukodystrophy (GBL; Krabbe's disease)</li> <li>Metachromatic Leukodystrophy (MLD)</li> </ol> </li>\n<li>Adrenoleukodystrophy (ALD)</li>\n<li>Globoid Cell Leukodystrophy (GBL; Krabbe's disease)</li>\n<li>Metachromatic Leukodystrophy (MLD)</li>\n<li>Hemoglobinopathies\t<ol> <li>Sickle Cell Disease</li> <li>Thalassemia (homozygous beta-thalassemia)</li> </ol> </li>\n<li>Sickle Cell Disease</li>\n<li>Thalassemia (homozygous beta-thalassemia)</li>\n<li>Infantile malignant osteopetrosis (Albers-Schonberg disease or marble bone disease)</li>\n<li>Other autosomal recessive disorders\t<ol> <li>Leukocyte adhesion deficiencies</li> <li>Kostmann\u2019s syndrome (severe congenital neutropenia, infantile genetic agranulocytosis)</li> </ol> </li>\n<li>Leukocyte adhesion deficiencies</li>\n<li>Kostmann\u2019s syndrome (severe congenital neutropenia, infantile genetic agranulocytosis)</li>\nA repeat allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.\nAutologous hematopoietic stem cell mobilization and pheresis is considered medically necessary for the treatment of a genetic disease as part of the development of an FDA-approved ex vivo gene therapy (for example, betibeglogene autotemcel or elivaldogene autotemcel).\nInvestigational and Not Medically Necessary:\nAllogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation is considered investigational and not medically necessary for the treatment of all genetic diseases not listed above including, but not limited to cystic fibrosis, and all acquired anemias not specifically identified above as medically necessary.\nAutologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for the treatment of all genetic diseases including, but not limited to cystic fibrosis, and all acquired anemias.\nA planned tandem allogeneic hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for all genetic diseases and for all acquired anemias.\nA second or repeat allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.\nHematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.\nAutologous hematopoietic stem cell mobilization and pheresis is considered investigational and not medically necessary for the treatment of a genetic disease when the medically necessary criteria above are not met.\n<u>Disease Specific Criteria</u>\nAplastic Anemia Criteria:\n<ul> <li>One of the following:\t<ul> <li>55 years of age or younger do not need to have failed immunosuppressive therapy</li> <li>Older than 55 years of age, or non-HLA identical donor, have to have failed immunosuppressive therapy</li> </ul> </li></ul>\n<li>One of the following:\t<ul> <li>55 years of age or younger do not need to have failed immunosuppressive therapy</li> <li>Older than 55 years of age, or non-HLA identical donor, have to have failed immunosuppressive therapy</li> </ul> </li>\n<ul> <li>55 years of age or younger do not need to have failed immunosuppressive therapy</li> <li>Older than 55 years of age, or non-HLA identical donor, have to have failed immunosuppressive therapy</li> </ul>\n<li>55 years of age or younger do not need to have failed immunosuppressive therapy</li>\n<li>Older than 55 years of age, or non-HLA identical donor, have to have failed immunosuppressive therapy</li>\nSickle Cell Criteria:\n<ul> <li>Children less than 16 years of age with homozygous SS disease or S-B thalassemia and who have had at least one of the following complications:\t<ul style=\"list-style-type:circle\"> <li>Stroke or CNS hemorrhage</li> <li>Clinical evidence of progressive neurologic deterioration, for example, abnormal cerebral MRI and arteriogram and impaired neuropsychiatric testing</li> <li>Sickle cell lung disease, recurrent acute chest syndrome or a combination of both requiring hospitalization and exchange transfusions</li> <li>Sickle cell nephropathy</li> </ul> </li></ul>\n<li>Children less than 16 years of age with homozygous SS disease or S-B thalassemia and who have had at least one of the following complications:\t<ul style=\"list-style-type:circle\"> <li>Stroke or CNS hemorrhage</li> <li>Clinical evidence of progressive neurologic deterioration, for example, abnormal cerebral MRI and arteriogram and impaired neuropsychiatric testing</li> <li>Sickle cell lung disease, recurrent acute chest syndrome or a combination of both requiring hospitalization and exchange transfusions</li> <li>Sickle cell nephropathy</li> </ul> </li>\n<ul style=\"list-style-type:circle\"> <li>Stroke or CNS hemorrhage</li> <li>Clinical evidence of progressive neurologic deterioration, for example, abnormal cerebral MRI and arteriogram and impaired neuropsychiatric testing</li> <li>Sickle cell lung disease, recurrent acute chest syndrome or a combination of both requiring hospitalization and exchange transfusions</li> <li>Sickle cell nephropathy</li> </ul>\n<li>Stroke or CNS hemorrhage</li>\n<li>Clinical evidence of progressive neurologic deterioration, for example, abnormal cerebral MRI and arteriogram and impaired neuropsychiatric testing</li>\n<li>Sickle cell lung disease, recurrent acute chest syndrome or a combination of both requiring hospitalization and exchange transfusions</li>\n<li>Sickle cell nephropathy</li>\nThalassemia Criteria:\n<ul> <li>Thalassemia major only and</li> <li>Individuals less than or equal to 30 years of age and</li> <li>The presence of minimal or no portal fibrous or active hepatitis</li></ul>\n<li>Thalassemia major only and</li>\n<li>Individuals less than or equal to 30 years of age and</li>\n<li>The presence of minimal or no portal fibrous or active hepatitis</li>",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation is considered medically necessary for individuals with the following disorders. In addition, individuals with Aplastic Anemia, Sickle Cell Disease or Thalassemia should meet the Disease Specific Criteria below.",
            "conditions": {
              "ANY": [
                {
                  "desc": "Bone Marrow Failure Syndromes",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Acquired aplastic anemia (drug, idiopathic, immune disorder, toxin or viral infection)",
                        "conditions": null
                      },
                      {
                        "desc": "Heritable bone marrow syndromes",
                        "conditions": {
                          "ANY": [
                            {
                              "desc": "Congenital amegakaryocytic thrombocytopenia (CAMT)",
                              "conditions": null
                            },
                            {
                              "desc": "Diamond-Blackfan anemia (DBA)",
                              "conditions": null
                            },
                            {
                              "desc": "Dyskeratosis congenita",
                              "conditions": null
                            },
                            {
                              "desc": "Fanconi\u2019s anemia (FA)",
                              "conditions": null
                            },
                            {
                              "desc": "Schwachman-Diamond syndrome (SDS)",
                              "conditions": null
                            }
                          ]
                        }
                      },
                      {
                        "desc": "Paroxysmal nocturnal hemoglobinuria (PNH)",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Acquired aplastic anemia (drug, idiopathic, immune disorder, toxin or viral infection)",
                  "conditions": null
                },
                {
                  "desc": "Heritable bone marrow syndromes",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Congenital amegakaryocytic thrombocytopenia (CAMT)",
                        "conditions": null
                      },
                      {
                        "desc": "Diamond-Blackfan anemia (DBA)",
                        "conditions": null
                      },
                      {
                        "desc": "Dyskeratosis congenita",
                        "conditions": null
                      },
                      {
                        "desc": "Fanconi\u2019s anemia (FA)",
                        "conditions": null
                      },
                      {
                        "desc": "Schwachman-Diamond syndrome (SDS)",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Congenital amegakaryocytic thrombocytopenia (CAMT)",
                  "conditions": null
                },
                {
                  "desc": "Diamond-Blackfan anemia (DBA)",
                  "conditions": null
                },
                {
                  "desc": "Dyskeratosis congenita",
                  "conditions": null
                },
                {
                  "desc": "Fanconi\u2019s anemia (FA)",
                  "conditions": null
                },
                {
                  "desc": "Schwachman-Diamond syndrome (SDS)",
                  "conditions": null
                },
                {
                  "desc": "Paroxysmal nocturnal hemoglobinuria (PNH)",
                  "conditions": null
                },
                {
                  "desc": "Immunodeficiencies",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Hemophagocytic Lymphohistiocytosis (HLH)",
                        "conditions": null
                      },
                      {
                        "desc": "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome",
                        "conditions": null
                      },
                      {
                        "desc": "Severe Combined Immunodeficiency (SCID)",
                        "conditions": null
                      },
                      {
                        "desc": "Wiskott-Aldrich Syndrome (WAS)",
                        "conditions": null
                      },
                      {
                        "desc": "X-linked lymphoproliferative syndrome",
                        "conditions": null
                      },
                      {
                        "desc": "Chediak-Higashi syndrome",
                        "conditions": null
                      },
                      {
                        "desc": "Primary granulocyte dysfunction",
                        "conditions": null
                      },
                      {
                        "desc": "Chronic granulomatous disease",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Hemophagocytic Lymphohistiocytosis (HLH)",
                  "conditions": null
                },
                {
                  "desc": "Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome",
                  "conditions": null
                },
                {
                  "desc": "Severe Combined Immunodeficiency (SCID)",
                  "conditions": null
                },
                {
                  "desc": "Wiskott-Aldrich Syndrome (WAS)",
                  "conditions": null
                },
                {
                  "desc": "X-linked lymphoproliferative syndrome",
                  "conditions": null
                },
                {
                  "desc": "Chediak-Higashi syndrome",
                  "conditions": null
                },
                {
                  "desc": "Primary granulocyte dysfunction",
                  "conditions": null
                },
                {
                  "desc": "Chronic granulomatous disease",
                  "conditions": null
                },
                {
                  "desc": "Storage disorders",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Hurler Syndrome (MPS I)",
                        "conditions": null
                      },
                      {
                        "desc": "Hunter Syndrome (MPS II)",
                        "conditions": null
                      },
                      {
                        "desc": "Maroteaux-Lamy Syndrome (MPS VI)",
                        "conditions": null
                      },
                      {
                        "desc": "SanFilippo\u2019s (MPS III)",
                        "conditions": null
                      },
                      {
                        "desc": "Gaucher disease",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Hurler Syndrome (MPS I)",
                  "conditions": null
                },
                {
                  "desc": "Hunter Syndrome (MPS II)",
                  "conditions": null
                },
                {
                  "desc": "Maroteaux-Lamy Syndrome (MPS VI)",
                  "conditions": null
                },
                {
                  "desc": "SanFilippo\u2019s (MPS III)",
                  "conditions": null
                },
                {
                  "desc": "Gaucher disease",
                  "conditions": null
                },
                {
                  "desc": "Leukodystrophies",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Adrenoleukodystrophy (ALD)",
                        "conditions": null
                      },
                      {
                        "desc": "Globoid Cell Leukodystrophy (GBL; Krabbe's disease)",
                        "conditions": null
                      },
                      {
                        "desc": "Metachromatic Leukodystrophy (MLD)",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Adrenoleukodystrophy (ALD)",
                  "conditions": null
                },
                {
                  "desc": "Globoid Cell Leukodystrophy (GBL; Krabbe's disease)",
                  "conditions": null
                },
                {
                  "desc": "Metachromatic Leukodystrophy (MLD)",
                  "conditions": null
                },
                {
                  "desc": "Hemoglobinopathies",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Sickle Cell Disease",
                        "conditions": null
                      },
                      {
                        "desc": "Thalassemia (homozygous beta-thalassemia)",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Sickle Cell Disease",
                  "conditions": null
                },
                {
                  "desc": "Thalassemia (homozygous beta-thalassemia)",
                  "conditions": null
                },
                {
                  "desc": "Infantile malignant osteopetrosis (Albers-Schonberg disease or marble bone disease)",
                  "conditions": null
                },
                {
                  "desc": "Other autosomal recessive disorders",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Leukocyte adhesion deficiencies",
                        "conditions": null
                      },
                      {
                        "desc": "Kostmann\u2019s syndrome (severe congenital neutropenia, infantile genetic agranulocytosis)",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Leukocyte adhesion deficiencies",
                  "conditions": null
                },
                {
                  "desc": "Kostmann\u2019s syndrome (severe congenital neutropenia, infantile genetic agranulocytosis)",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Repeat allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "A repeat allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplantation due to primary graft failure or failure to engraft is considered medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Autologous hematopoietic stem cell mobilization and pheresis",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Autologous hematopoietic stem cell mobilization and pheresis is considered medically necessary for the treatment of a genetic disease as part of the development of an FDA-approved ex vivo gene therapy (for example, betibeglogene autotemcel or elivaldogene autotemcel).",
            "conditions": null
          },
          {
            "medical_act": "Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation is considered investigational and not medically necessary for the treatment of all genetic diseases not listed above including, but not limited to cystic fibrosis, and all acquired anemias not specifically identified above as medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Autologous hematopoietic stem cell transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for the treatment of all genetic diseases including, but not limited to cystic fibrosis, and all acquired anemias.",
            "conditions": null
          },
          {
            "medical_act": "Planned tandem allogeneic hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A planned tandem allogeneic hematopoietic stem cell transplantation or autologous hematopoietic stem cell transplantation is considered investigational and not medically necessary for all genetic diseases and for all acquired anemias.",
            "conditions": null
          },
          {
            "medical_act": "Second or repeat allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplant",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "A second or repeat allogeneic (ablative or non-myeloablative) hematopoietic stem cell transplant due to persistent, progressive or relapsed disease is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Hematopoietic stem cell harvesting for a future but unscheduled transplant",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hematopoietic stem cell harvesting for a future but unscheduled transplant is considered investigational and not medically necessary.",
            "conditions": null
          },
          {
            "medical_act": "Autologous hematopoietic stem cell mobilization and pheresis",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous hematopoietic stem cell mobilization and pheresis is considered investigational and not medically necessary for the treatment of a genetic disease when the medically necessary criteria above are not met.",
            "conditions": null
          },
          {
            "medical_act": "Aplastic Anemia Criteria",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Aplastic Anemia Criteria:",
            "conditions": {
              "ANY": [
                {
                  "desc": "55 years of age or younger do not need to have failed immunosuppressive therapy",
                  "conditions": null
                },
                {
                  "desc": "Older than 55 years of age, or non-HLA identical donor, have to have failed immunosuppressive therapy",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Sickle Cell Criteria",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Sickle Cell Criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Children less than 16 years of age with homozygous SS disease or S-B thalassemia and who have had at least one of the following complications:",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Stroke or CNS hemorrhage",
                        "conditions": null
                      },
                      {
                        "desc": "Clinical evidence of progressive neurologic deterioration, for example, abnormal cerebral MRI and arteriogram and impaired neuropsychiatric testing",
                        "conditions": null
                      },
                      {
                        "desc": "Sickle cell lung disease, recurrent acute chest syndrome or a combination of both requiring hospitalization and exchange transfusions",
                        "conditions": null
                      },
                      {
                        "desc": "Sickle cell nephropathy",
                        "conditions": null
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Thalassemia Criteria",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Thalassemia Criteria:",
            "conditions": {
              "ALL": [
                {
                  "desc": "Thalassemia major only",
                  "conditions": null
                },
                {
                  "desc": "Individuals less than or equal to 30 years of age",
                  "conditions": null
                },
                {
                  "desc": "The presence of minimal or no portal fibrous or active hepatitis",
                  "conditions": null
                }
              ]
            }
          }
        ],
        "usage": {
          "total_tokens": 6163,
          "prompt_tokens": 3135,
          "completion_tokens": 3028,
          "total_cost": 0.061095,
          "processing_time": 50.34462213516235
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e001867.html",
    "subject": "Hand Transplantation",
    "document_number": "TRANS.00040",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p style=\"margin-right:-61px\"><strong>Investigational and Not Medically Necessary:</strong></p>\n<p style=\"margin-right:-61px\">Hand transplantation is considered <strong>investigational and not medically necessary.</strong></p>",
    "content": "Investigational and Not Medically Necessary:\nHand transplantation is considered investigational and not medically necessary.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Hand transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Hand transplantation is considered investigational and not medically necessary.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 893,
          "prompt_tokens": 832,
          "completion_tokens": 61,
          "total_cost": 0.005075,
          "processing_time": 1.2947251796722412
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_a053822.html",
    "subject": "Autologous and Allogeneic Pancreatic Islet Cell Transplantation",
    "document_number": "TRANS.00010",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>Autologous pancreatic islet cell transplantation is considered <strong>medically necessary</strong> as an adjunct to a total or near total pancreatectomy for individuals with chronic pancreatitis.</p>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Autologous pancreatic islet cell transplantation is considered <strong>investigational and not medically necessary </strong>when the above criteria are not met and<strong> </strong>for all other indications.</p>\n<p>Allogeneic pancreatic islet cell transplantation is considered <strong>investigational and not medically necessary </strong>for all indications.</p>\n<p><strong>Note:</strong> For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with a concurrent medical condition which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member's candidacy for transplantation.</p>",
    "content": "Medically Necessary:\nAutologous pancreatic islet cell transplantation is considered medically necessary as an adjunct to a total or near total pancreatectomy for individuals with chronic pancreatitis.\nInvestigational and Not Medically Necessary:\nAutologous pancreatic islet cell transplantation is considered investigational and not medically necessary when the above criteria are not met and for all other indications.\nAllogeneic pancreatic islet cell transplantation is considered investigational and not medically necessary for all indications.\nNote: For multi-organ transplant requests, criteria must be met for each organ requested. In those situations, an individual may present with a concurrent medical condition which would be considered an exclusion or a comorbidity that would preclude a successful outcome, but would be treated with the other organ transplant. Such cases will be reviewed on an individual basis for coverage determination to assess the member's candidacy for transplantation.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Autologous pancreatic islet cell transplantation",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Autologous pancreatic islet cell transplantation is considered medically necessary as an adjunct to a total or near total pancreatectomy for individuals with chronic pancreatitis.",
            "conditions": {
              "ALL": [
                {
                  "desc": "Adjunct to a total or near total pancreatectomy",
                  "conditions": null
                },
                {
                  "desc": "Individuals with chronic pancreatitis",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Autologous pancreatic islet cell transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous pancreatic islet cell transplantation is considered investigational and not medically necessary when the above criteria are not met and for all other indications.",
            "conditions": null
          },
          {
            "medical_act": "Allogeneic pancreatic islet cell transplantation",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Allogeneic pancreatic islet cell transplantation is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 1282,
          "prompt_tokens": 986,
          "completion_tokens": 296,
          "total_cost": 0.00937,
          "processing_time": 5.645832300186157
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_e001734.html",
    "subject": "Portable Normothermic Organ Perfusion Systems",
    "document_number": "TRANS.00039",
    "publish_date": "09/27/2023",
    "status": "Revised",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Medically Necessary:</strong></p>\n<p>Portable normothermic organ perfusion systems are considered <strong>medically necessary</strong> when the following criteria are met (both criteria set A <em>and </em>criteria set B):</p>\n<li><em>General Criteria </em>(both 1 <em>and</em> 2 below):\t<ol>\t\t<li>Used as part of the acquisition, collection and storage of a covered and medically necessary organ transplant; <strong>and</strong></li>\t\t<li>Involving donor organ(s) initially deemed unacceptable for procurement and transplantation based on limitations of cold storage preservation;&nbsp;<br>\t\t<strong>and</strong></li>\t</ol>\t</li>\n<li>Used as part of the acquisition, collection and storage of a covered and medically necessary organ transplant; <strong>and</strong></li>\n<li>Involving donor organ(s) initially deemed unacceptable for procurement and transplantation based on limitations of cold storage preservation;&nbsp;<br>\t\t<strong>and</strong></li>\n<li><em>Organ-Specific Criteria </em>(1 <em>or</em> 2 <em>or</em> 3 below)<em>:</em>\t<ol>\t\t<li><strong>Lung </strong>perfusion (for example, Organ Care System Lung<sup>\u2122</sup>) involving donor lung pairs with <em>one or more</em> of the following risk factors:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Donor after circulatory death (DCD);<strong> or</strong></li>\t\t\t<li>Age greater than 55 years;<strong> or</strong></li>\t\t\t<li>PaO2/FiO2 less than 300 mmHg;<strong> or</strong></li>\t\t\t<li>Ischemic time greater than 6 hours;&nbsp;<br>\t\t\t<strong>or</strong></li>\t\t</ol>\t\t</li>\t\t<li><strong>Liver </strong>perfusion when criteria are met (a <em>or</em> b below):\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li><em>Organ Care System Liver</em>: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\">\t\t\t\t<li>From DCD less than or equal to 55 years old; <strong>and</strong></li>\t\t\t\t<li>With less than or equal to 30 minutes of warm ischemic time; <strong>and</strong></li>\t\t\t\t<li>Macrosteatosis less than or equal to 15%.</li>\t\t\t</ol>\t\t\t</li>\t\t\t<li><em>OrganOx<sup>\u00ae</sup> metra<sup>\u00ae</sup> System</em>: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\">\t\t\t\t<li>From DCD less than or equal to 40 years of age; <strong>and</strong></li>\t\t\t\t<li>With less than or equal to 20 minutes of functional warm ischemic time; <strong>and</strong></li>\t\t\t\t<li>Macrosteatosis less than or equal to 15%;&nbsp;<br>\t\t\t\t<strong>or</strong></li>\t\t\t</ol>\t\t\t</li>\t\t</ol>\t\t</li>\t\t<li><strong>Heart</strong> perfusion (for example, Organ Care System Heart<sup>\u2122</sup>) when criteria are met:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>From DCD 18 to 49 years of age; <strong>and</strong></li>\t\t\t<li>Classified as Maastricht category III (persons who became donors after controlled withdrawal of life support and subsequent cardiac arrest and cardiocirculatory death); <strong>and</strong></li>\t\t\t<li>Functional warm ischemic time (defined as time from mean systolic arterial blood pressure less than 50 mm Hg or peripheral oxygen saturation less than 70% to aortic cross-clamp and administration of cold cardioplegia) is 30 minutes or less.&nbsp;</li>\t\t</ol>\t\t</li>\t</ol>\t</li>\n<li><strong>Lung </strong>perfusion (for example, Organ Care System Lung<sup>\u2122</sup>) involving donor lung pairs with <em>one or more</em> of the following risk factors:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>Donor after circulatory death (DCD);<strong> or</strong></li>\t\t\t<li>Age greater than 55 years;<strong> or</strong></li>\t\t\t<li>PaO2/FiO2 less than 300 mmHg;<strong> or</strong></li>\t\t\t<li>Ischemic time greater than 6 hours;&nbsp;<br>\t\t\t<strong>or</strong></li>\t\t</ol>\t\t</li>\n<li>Donor after circulatory death (DCD);<strong> or</strong></li>\n<li>Age greater than 55 years;<strong> or</strong></li>\n<li>PaO2/FiO2 less than 300 mmHg;<strong> or</strong></li>\n<li>Ischemic time greater than 6 hours;&nbsp;<br>\t\t\t<strong>or</strong></li>\n<li><strong>Liver </strong>perfusion when criteria are met (a <em>or</em> b below):\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li><em>Organ Care System Liver</em>: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\">\t\t\t\t<li>From DCD less than or equal to 55 years old; <strong>and</strong></li>\t\t\t\t<li>With less than or equal to 30 minutes of warm ischemic time; <strong>and</strong></li>\t\t\t\t<li>Macrosteatosis less than or equal to 15%.</li>\t\t\t</ol>\t\t\t</li>\t\t\t<li><em>OrganOx<sup>\u00ae</sup> metra<sup>\u00ae</sup> System</em>: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\">\t\t\t\t<li>From DCD less than or equal to 40 years of age; <strong>and</strong></li>\t\t\t\t<li>With less than or equal to 20 minutes of functional warm ischemic time; <strong>and</strong></li>\t\t\t\t<li>Macrosteatosis less than or equal to 15%;&nbsp;<br>\t\t\t\t<strong>or</strong></li>\t\t\t</ol>\t\t\t</li>\t\t</ol>\t\t</li>\n<li><em>Organ Care System Liver</em>: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\">\t\t\t\t<li>From DCD less than or equal to 55 years old; <strong>and</strong></li>\t\t\t\t<li>With less than or equal to 30 minutes of warm ischemic time; <strong>and</strong></li>\t\t\t\t<li>Macrosteatosis less than or equal to 15%.</li>\t\t\t</ol>\t\t\t</li>\n<li>From DCD less than or equal to 55 years old; <strong>and</strong></li>\n<li>With less than or equal to 30 minutes of warm ischemic time; <strong>and</strong></li>\n<li>Macrosteatosis less than or equal to 15%.</li>\n<li><em>OrganOx<sup>\u00ae</sup> metra<sup>\u00ae</sup> System</em>: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\">\t\t\t\t<li>From DCD less than or equal to 40 years of age; <strong>and</strong></li>\t\t\t\t<li>With less than or equal to 20 minutes of functional warm ischemic time; <strong>and</strong></li>\t\t\t\t<li>Macrosteatosis less than or equal to 15%;&nbsp;<br>\t\t\t\t<strong>or</strong></li>\t\t\t</ol>\t\t\t</li>\n<li>From DCD less than or equal to 40 years of age; <strong>and</strong></li>\n<li>With less than or equal to 20 minutes of functional warm ischemic time; <strong>and</strong></li>\n<li>Macrosteatosis less than or equal to 15%;&nbsp;<br>\t\t\t\t<strong>or</strong></li>\n<li><strong>Heart</strong> perfusion (for example, Organ Care System Heart<sup>\u2122</sup>) when criteria are met:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\">\t\t\t<li>From DCD 18 to 49 years of age; <strong>and</strong></li>\t\t\t<li>Classified as Maastricht category III (persons who became donors after controlled withdrawal of life support and subsequent cardiac arrest and cardiocirculatory death); <strong>and</strong></li>\t\t\t<li>Functional warm ischemic time (defined as time from mean systolic arterial blood pressure less than 50 mm Hg or peripheral oxygen saturation less than 70% to aortic cross-clamp and administration of cold cardioplegia) is 30 minutes or less.&nbsp;</li>\t\t</ol>\t\t</li>\n<li>From DCD 18 to 49 years of age; <strong>and</strong></li>\n<li>Classified as Maastricht category III (persons who became donors after controlled withdrawal of life support and subsequent cardiac arrest and cardiocirculatory death); <strong>and</strong></li>\n<li>Functional warm ischemic time (defined as time from mean systolic arterial blood pressure less than 50 mm Hg or peripheral oxygen saturation less than 70% to aortic cross-clamp and administration of cold cardioplegia) is 30 minutes or less.&nbsp;</li>\n<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<p>Portable normothermic organ machine perfusion is considered <strong>investigational and not medically necessary </strong>when the above criteria are not met, including but not limited to use as part of the acquisition, collection and storage of a covered and medically necessary organ transplant involving other solid donor organs or donor organs deemed acceptable for transplant according to standard criteria.</p>",
    "content": "Medically Necessary:\nPortable normothermic organ perfusion systems are considered medically necessary when the following criteria are met (both criteria set A and criteria set B):\n<li>General Criteria (both 1 and 2 below):\t<ol> <li>Used as part of the acquisition, collection and storage of a covered and medically necessary organ transplant; and</li> <li>Involving donor organ(s) initially deemed unacceptable for procurement and transplantation based on limitations of cold storage preservation;\u00a0<br/> and</li> </ol> </li>\n<li>Used as part of the acquisition, collection and storage of a covered and medically necessary organ transplant; and</li>\n<li>Involving donor organ(s) initially deemed unacceptable for procurement and transplantation based on limitations of cold storage preservation;\u00a0<br/> and</li>\n<li>Organ-Specific Criteria (1 or 2 or 3 below): <ol> <li>Lung perfusion (for example, Organ Care System Lung<sup>\u2122</sup>) involving donor lung pairs with one or more of the following risk factors:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Donor after circulatory death (DCD); or</li> <li>Age greater than 55 years; or</li> <li>PaO2/FiO2 less than 300 mmHg; or</li> <li>Ischemic time greater than 6 hours;\u00a0<br/> or</li> </ol> </li> <li>Liver perfusion when criteria are met (a or b below):\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Organ Care System Liver: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\"> <li>From DCD less than or equal to 55 years old; and</li> <li>With less than or equal to 30 minutes of warm ischemic time; and</li> <li>Macrosteatosis less than or equal to 15%.</li> </ol> </li> <li>OrganOx<sup>\u00ae</sup> metra<sup>\u00ae</sup> System: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\"> <li>From DCD less than or equal to 40 years of age; and</li> <li>With less than or equal to 20 minutes of functional warm ischemic time; and</li> <li>Macrosteatosis less than or equal to 15%;\u00a0<br/> or</li> </ol> </li> </ol> </li> <li>Heart perfusion (for example, Organ Care System Heart<sup>\u2122</sup>) when criteria are met:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>From DCD 18 to 49 years of age; and</li> <li>Classified as Maastricht category III (persons who became donors after controlled withdrawal of life support and subsequent cardiac arrest and cardiocirculatory death); and</li> <li>Functional warm ischemic time (defined as time from mean systolic arterial blood pressure less than 50 mm Hg or peripheral oxygen saturation less than 70% to aortic cross-clamp and administration of cold cardioplegia) is 30 minutes or less.\u00a0</li> </ol> </li> </ol> </li>\n<li>Lung perfusion (for example, Organ Care System Lung<sup>\u2122</sup>) involving donor lung pairs with one or more of the following risk factors:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Donor after circulatory death (DCD); or</li> <li>Age greater than 55 years; or</li> <li>PaO2/FiO2 less than 300 mmHg; or</li> <li>Ischemic time greater than 6 hours;\u00a0<br/> or</li> </ol> </li>\n<li>Donor after circulatory death (DCD); or</li>\n<li>Age greater than 55 years; or</li>\n<li>PaO2/FiO2 less than 300 mmHg; or</li>\n<li>Ischemic time greater than 6 hours;\u00a0<br/> or</li>\n<li>Liver perfusion when criteria are met (a or b below):\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>Organ Care System Liver: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\"> <li>From DCD less than or equal to 55 years old; and</li> <li>With less than or equal to 30 minutes of warm ischemic time; and</li> <li>Macrosteatosis less than or equal to 15%.</li> </ol> </li> <li>OrganOx<sup>\u00ae</sup> metra<sup>\u00ae</sup> System: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\"> <li>From DCD less than or equal to 40 years of age; and</li> <li>With less than or equal to 20 minutes of functional warm ischemic time; and</li> <li>Macrosteatosis less than or equal to 15%;\u00a0<br/> or</li> </ol> </li> </ol> </li>\n<li>Organ Care System Liver: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\"> <li>From DCD less than or equal to 55 years old; and</li> <li>With less than or equal to 30 minutes of warm ischemic time; and</li> <li>Macrosteatosis less than or equal to 15%.</li> </ol> </li>\n<li>From DCD less than or equal to 55 years old; and</li>\n<li>With less than or equal to 30 minutes of warm ischemic time; and</li>\n<li>Macrosteatosis less than or equal to 15%.</li>\n<li>OrganOx<sup>\u00ae</sup> metra<sup>\u00ae</sup> System: liver allografts\t\t\t<ol start=\"1\" style=\"list-style-type:lower-roman\"> <li>From DCD less than or equal to 40 years of age; and</li> <li>With less than or equal to 20 minutes of functional warm ischemic time; and</li> <li>Macrosteatosis less than or equal to 15%;\u00a0<br/> or</li> </ol> </li>\n<li>From DCD less than or equal to 40 years of age; and</li>\n<li>With less than or equal to 20 minutes of functional warm ischemic time; and</li>\n<li>Macrosteatosis less than or equal to 15%;\u00a0<br/> or</li>\n<li>Heart perfusion (for example, Organ Care System Heart<sup>\u2122</sup>) when criteria are met:\t\t<ol start=\"1\" style=\"list-style-type:lower-alpha\"> <li>From DCD 18 to 49 years of age; and</li> <li>Classified as Maastricht category III (persons who became donors after controlled withdrawal of life support and subsequent cardiac arrest and cardiocirculatory death); and</li> <li>Functional warm ischemic time (defined as time from mean systolic arterial blood pressure less than 50 mm Hg or peripheral oxygen saturation less than 70% to aortic cross-clamp and administration of cold cardioplegia) is 30 minutes or less.\u00a0</li> </ol> </li>\n<li>From DCD 18 to 49 years of age; and</li>\n<li>Classified as Maastricht category III (persons who became donors after controlled withdrawal of life support and subsequent cardiac arrest and cardiocirculatory death); and</li>\n<li>Functional warm ischemic time (defined as time from mean systolic arterial blood pressure less than 50 mm Hg or peripheral oxygen saturation less than 70% to aortic cross-clamp and administration of cold cardioplegia) is 30 minutes or less.\u00a0</li>\nInvestigational and Not Medically Necessary:\nPortable normothermic organ machine perfusion is considered investigational and not medically necessary when the above criteria are not met, including but not limited to use as part of the acquisition, collection and storage of a covered and medically necessary organ transplant involving other solid donor organs or donor organs deemed acceptable for transplant according to standard criteria.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Portable normothermic organ perfusion systems",
            "sub_medical_act": null,
            "necessity_type": "Medically Necessary",
            "description": "Portable normothermic organ perfusion systems are considered medically necessary when the following criteria are met (both criteria set A and criteria set B):",
            "conditions": {
              "ALL": [
                {
                  "desc": "General Criteria (both 1 and 2 below):",
                  "conditions": {
                    "ALL": [
                      {
                        "desc": "Used as part of the acquisition, collection and storage of a covered and medically necessary organ transplant",
                        "conditions": null
                      },
                      {
                        "desc": "Involving donor organ(s) initially deemed unacceptable for procurement and transplantation based on limitations of cold storage preservation",
                        "conditions": null
                      }
                    ]
                  }
                },
                {
                  "desc": "Organ-Specific Criteria (1 or 2 or 3 below):",
                  "conditions": {
                    "ANY": [
                      {
                        "desc": "Lung perfusion (for example, Organ Care System Lung\u2122) involving donor lung pairs with one or more of the following risk factors:",
                        "conditions": {
                          "ANY": [
                            {
                              "desc": "Donor after circulatory death (DCD)",
                              "conditions": null
                            },
                            {
                              "desc": "Age greater than 55 years",
                              "conditions": null
                            },
                            {
                              "desc": "PaO2/FiO2 less than 300 mmHg",
                              "conditions": null
                            },
                            {
                              "desc": "Ischemic time greater than 6 hours",
                              "conditions": null
                            }
                          ]
                        }
                      },
                      {
                        "desc": "Liver perfusion when criteria are met (a or b below):",
                        "conditions": {
                          "ANY": [
                            {
                              "desc": "Organ Care System Liver: liver allografts",
                              "conditions": {
                                "ALL": [
                                  {
                                    "desc": "From DCD less than or equal to 55 years old",
                                    "conditions": null
                                  },
                                  {
                                    "desc": "With less than or equal to 30 minutes of warm ischemic time",
                                    "conditions": null
                                  },
                                  {
                                    "desc": "Macrosteatosis less than or equal to 15%",
                                    "conditions": null
                                  }
                                ]
                              }
                            },
                            {
                              "desc": "OrganOx\u00ae metra\u00ae System: liver allografts",
                              "conditions": {
                                "ALL": [
                                  {
                                    "desc": "From DCD less than or equal to 40 years of age",
                                    "conditions": null
                                  },
                                  {
                                    "desc": "With less than or equal to 20 minutes of functional warm ischemic time",
                                    "conditions": null
                                  },
                                  {
                                    "desc": "Macrosteatosis less than or equal to 15%",
                                    "conditions": null
                                  }
                                ]
                              }
                            }
                          ]
                        }
                      },
                      {
                        "desc": "Heart perfusion (for example, Organ Care System Heart\u2122) when criteria are met:",
                        "conditions": {
                          "ALL": [
                            {
                              "desc": "From DCD 18 to 49 years of age",
                              "conditions": null
                            },
                            {
                              "desc": "Classified as Maastricht category III (persons who became donors after controlled withdrawal of life support and subsequent cardiac arrest and cardiocirculatory death)",
                              "conditions": null
                            },
                            {
                              "desc": "Functional warm ischemic time (defined as time from mean systolic arterial blood pressure less than 50 mm Hg or peripheral oxygen saturation less than 70% to aortic cross-clamp and administration of cold cardioplegia) is 30 minutes or less",
                              "conditions": null
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "medical_act": "Portable normothermic organ machine perfusion",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Portable normothermic organ machine perfusion is considered investigational and not medically necessary when the above criteria are not met, including but not limited to use as part of the acquisition, collection and storage of a covered and medically necessary organ transplant involving other solid donor organs or donor organs deemed acceptable for transplant according to standard criteria.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 3638,
          "prompt_tokens": 2674,
          "completion_tokens": 964,
          "total_cost": 0.02783,
          "processing_time": 14.790852069854736
        }
      }
    ]
  },
  {
    "url": "https://www.anthem.com/dam/medpolicies/abc/active/policies/mp_pw_b094276.html",
    "subject": "Therapeutic use of Stem Cells, Blood and Bone Marrow Products",
    "document_number": "TRANS.00035",
    "publish_date": "09/27/2023",
    "status": "Reviewed",
    "last_review_date": "08/10/2023",
    "html_content": "<p><strong>Investigational and Not Medically Necessary:</strong></p>\n<li>Stem cell therapy, including but not limited to mesenchymal stem cell therapy is considered <strong>investigational and not medically necessary</strong> for the prevention and treatment of all conditions, including but not limited to:\t<ol start=\"1\" style=\"list-style-type:upper-alpha\">\t\t<li>Peripheral vascular disease; <strong>or</strong></li>\t\t<li>Orthopedic conditions; <strong>or</strong></li>\t\t<li>Autoimmune conditions; <strong>or</strong></li>\t\t<li>Inflammatory conditions; <strong>or</strong></li>\t\t<li>Degenerative conditions.</li>\t</ol>\t</li>\n<li>Peripheral vascular disease; <strong>or</strong></li>\n<li>Orthopedic conditions; <strong>or</strong></li>\n<li>Autoimmune conditions; <strong>or</strong></li>\n<li>Inflammatory conditions; <strong>or</strong></li>\n<li>Degenerative conditions.</li>\n<li>Autologous cell therapy, including but not limited to, skeletal myoblasts, mesenchymal stem cells, endothelial progenitor cells (EPCs) or bone marrow mononuclear cells (BMMC), is considered <strong>investigational</strong><strong> and not medically necessary</strong> for all indications, including but not limited to treatment of damaged myocardium<strong>.</strong></li>\n<li>Autologous blood-derived wound products (for example, Aurix [formerly Autologel], Vitagel) are considered <strong>investigational and not medically necessary</strong> for all applications.</li>\n<li>Use of platelet rich plasma (PRP), including autologous conditioned plasma (ACP), is considered <strong>investigational and not medically necessary</strong> for all indications, including the treatment of any of the following:\t<ol style=\"list-style-type:upper-alpha\">\t\t<li>Cutaneous wounds; <strong>or</strong></li>\t\t<li>Soft tissue injuries (including epicondylitis and sinus surgery); <strong>or</strong></li>\t\t<li>Bone injuries (including surgically created wounds and non-unions).</li>\t</ol>\t</li>\n<li>Cutaneous wounds; <strong>or</strong></li>\n<li>Soft tissue injuries (including epicondylitis and sinus surgery); <strong>or</strong></li>\n<li>Bone injuries (including surgically created wounds and non-unions).</li>\n<li>Use of bone marrow aspirate concentrate (BMAC) is considered <strong>investigational and not medically necessary</strong> for all indications, including for the treatment of critical limb ischemia.</li>\n<li>Use of autologous protein solution (for example, nSTRIDE<sup>\u00ae</sup>), also known as autologous white blood cell concentrate, is considered <strong>investigational and not medically necessary</strong> for all indications.</li>\n<p><strong>Note:</strong> This document <em>does not</em> address stem cell therapy used for disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment, or hematopoietic stem cell transplantation.</p>",
    "content": "Investigational and Not Medically Necessary:\n<li>Stem cell therapy, including but not limited to mesenchymal stem cell therapy is considered investigational and not medically necessary for the prevention and treatment of all conditions, including but not limited to:\t<ol start=\"1\" style=\"list-style-type:upper-alpha\"> <li>Peripheral vascular disease; or</li> <li>Orthopedic conditions; or</li> <li>Autoimmune conditions; or</li> <li>Inflammatory conditions; or</li> <li>Degenerative conditions.</li> </ol> </li>\n<li>Peripheral vascular disease; or</li>\n<li>Orthopedic conditions; or</li>\n<li>Autoimmune conditions; or</li>\n<li>Inflammatory conditions; or</li>\n<li>Degenerative conditions.</li>\n<li>Autologous cell therapy, including but not limited to, skeletal myoblasts, mesenchymal stem cells, endothelial progenitor cells (EPCs) or bone marrow mononuclear cells (BMMC), is considered investigational and not medically necessary for all indications, including but not limited to treatment of damaged myocardium.</li>\n<li>Autologous blood-derived wound products (for example, Aurix [formerly Autologel], Vitagel) are considered investigational and not medically necessary for all applications.</li>\n<li>Use of platelet rich plasma (PRP), including autologous conditioned plasma (ACP), is considered investigational and not medically necessary for all indications, including the treatment of any of the following:\t<ol style=\"list-style-type:upper-alpha\"> <li>Cutaneous wounds; or</li> <li>Soft tissue injuries (including epicondylitis and sinus surgery); or</li> <li>Bone injuries (including surgically created wounds and non-unions).</li> </ol> </li>\n<li>Cutaneous wounds; or</li>\n<li>Soft tissue injuries (including epicondylitis and sinus surgery); or</li>\n<li>Bone injuries (including surgically created wounds and non-unions).</li>\n<li>Use of bone marrow aspirate concentrate (BMAC) is considered investigational and not medically necessary for all indications, including for the treatment of critical limb ischemia.</li>\n<li>Use of autologous protein solution (for example, nSTRIDE<sup>\u00ae</sup>), also known as autologous white blood cell concentrate, is considered investigational and not medically necessary for all indications.</li>\nNote: This document does not address stem cell therapy used for disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment, or hematopoietic stem cell transplantation.",
    "criteria": [
      {
        "model": "gpt-4o",
        "criteria": [
          {
            "medical_act": "Stem cell therapy",
            "sub_medical_act": "Mesenchymal stem cell therapy",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Stem cell therapy, including but not limited to mesenchymal stem cell therapy is considered investigational and not medically necessary for the prevention and treatment of all conditions, including but not limited to:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Peripheral vascular disease",
                  "conditions": null
                },
                {
                  "desc": "Orthopedic conditions",
                  "conditions": null
                },
                {
                  "desc": "Autoimmune conditions",
                  "conditions": null
                },
                {
                  "desc": "Inflammatory conditions",
                  "conditions": null
                },
                {
                  "desc": "Degenerative conditions",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Autologous cell therapy",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous cell therapy, including but not limited to, skeletal myoblasts, mesenchymal stem cells, endothelial progenitor cells (EPCs) or bone marrow mononuclear cells (BMMC), is considered investigational and not medically necessary for all indications, including but not limited to treatment of damaged myocardium.",
            "conditions": null
          },
          {
            "medical_act": "Autologous blood-derived wound products",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Autologous blood-derived wound products (for example, Aurix [formerly Autologel], Vitagel) are considered investigational and not medically necessary for all applications.",
            "conditions": null
          },
          {
            "medical_act": "Platelet rich plasma (PRP)",
            "sub_medical_act": "Autologous conditioned plasma (ACP)",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Use of platelet rich plasma (PRP), including autologous conditioned plasma (ACP), is considered investigational and not medically necessary for all indications, including the treatment of any of the following:",
            "conditions": {
              "ANY": [
                {
                  "desc": "Cutaneous wounds",
                  "conditions": null
                },
                {
                  "desc": "Soft tissue injuries (including epicondylitis and sinus surgery)",
                  "conditions": null
                },
                {
                  "desc": "Bone injuries (including surgically created wounds and non-unions)",
                  "conditions": null
                }
              ]
            }
          },
          {
            "medical_act": "Bone marrow aspirate concentrate (BMAC)",
            "sub_medical_act": null,
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Use of bone marrow aspirate concentrate (BMAC) is considered investigational and not medically necessary for all indications, including for the treatment of critical limb ischemia.",
            "conditions": null
          },
          {
            "medical_act": "Autologous protein solution",
            "sub_medical_act": "Autologous white blood cell concentrate",
            "necessity_type": "Investigational and Not Medically Necessary",
            "description": "Use of autologous protein solution (for example, nSTRIDE\u00ae), also known as autologous white blood cell concentrate, is considered investigational and not medically necessary for all indications.",
            "conditions": null
          }
        ],
        "usage": {
          "total_tokens": 2121,
          "prompt_tokens": 1379,
          "completion_tokens": 742,
          "total_cost": 0.018025,
          "processing_time": 12.477761030197144
        }
      }
    ]
  }
]